Electronic Supplementary Material (ESI) for Chemical Science. This journal is © The Royal Society of Chemistry 2019

Supporting Information

Sulfamides Direct Radical-Mediated Chlorination of Aliphatic C–H Bonds

M. A. Short, M. F. Shehata, M. A. Sanders, and J. L. Roizen*

Department of Chemistry, Duke University, Durham, NC 27708-0354

Table of Contents:

I.	General considerations.	S2
II.	Reaction optimization.	S5
III.	Experimental procedures.	S6
IV.	Preparation and characterization of sulfamides.	S13
V.	Preparation and characterization of diversified sulfamides.	S16
VI.	Preparation and characterization of N-chlorosulfamides.	S27
VII.	Preparation and characterization of γ-chlorinated sulfamides.	S37
VIII.	Preparation and characterization of non-γ-chlorinated sulfamides.	S49
IX.	Preparation and characterization of sulfamate ester derivatives.	S52
Х.	Sulfamide cleavage to access 3-chloroalkylamines.	S58
XI.	Preparation and characterization of compounds related to the radical clock experiment.	S59
XII.	Description of quantum yield experiment.	S61
XIII.	UV-Vis spectra.	S64
XIV.	S–N bond lengths in related sulfamides.	S66
XV.	Computational calculations.	S68
XVI.	References.	S122
XVII.	NMR spectra.	S125

I. General considerations.

Reagents.

All reagents and chemicals were obtained commercially and used without further purification unless otherwise noted.

Acros	sulfur trioxide pyridine complex, 1,10-phenanthroline, potassium oxalate monohydrate trimethylacetyl chloride 1-hexanol <i>tert</i> -				
	butylamine				
Alfa Aesar	oxone, triphenylphosphine				
Ark Pharm	4-(trifluoromethyl)hydrocinnamic acid				
BDH	ammonium hydroxide solution (28% w/w NH ₃ in H ₂ O)				
BTC Chemicals	trimethylacetonitrile				
Chem Impex	di <i>tert</i> -butyl pyrocarbonate, iron(III) chloride hexahydrate, 2- iodobenzoic acid				
Clorox	aqueous sodium hypochlorite solution (bleach, 8.25%)				
EMD Millipore	benzene (anhydrous, PhH)				
Fisher Scientific	acetonitrile (ACS grade), hexanes, sodium sulfate (anhydrous), magnesium sulfate (anhydrous)				
Fluka	hydrogen bromides solution (32% in acetic acid)				
Oakwood Chemical	2,2,2-trifluoroethylamine, triethylamine, trifluoroacetic anhydride, trifluoromethanesulfonic anhydride, trifluoroacetic acid, triphenylphosphine oxide, trichloroisocyanuric acid (TCICA), phthalimide, chlorosulfonyl isocyanate, 1,1'-carbonyldiimidazole (CDI), hexylamine, 2-cyclohexylethanol				
Sigma-Aldrich	hydrochloric acid (concentrated), lithium aluminium hydride, 4- dimethylaminopyridine (DMAP), <i>tert</i> -butylamine, 4-aminobutyric acid, 3,7-dimethyloctan-1-ol, <i>tert</i> -butanol, 1,1'-carbonyldiimidazole (CDI), ethyl acetate (EtOAc), diethyl azidocarboxylate, acetic anhydride				
TCI	amylamine, isopentylamine (isoamylamine)				
Soap Goods	sodium acetate (anhydrous), sodium hydroxide (pellets)				

Anhydrous 1,4-dioxane, tetrahydrofuran (THF), dichloromethane (CH₂Cl₂), and diethyl ether (Et₂O) were obtained from Sigma Aldrich and were purified, dried, and degassed by passage through two columns of neutral, activated alumina under N_2 using an Innovative Technologies solvent purification system. Anhydrous toluene was purified, dried, and degassed by passage through a column containing copper followed by a column of neutral, activated alumina under N_2 using an Innovative Technologies solvent purification system. Triethylamine (Et₃N) was distilled from CaH₂ and stored in a Schlenk flask for future use.

Preparation of Known Reagents.

Tert-butyl hypochlorite,¹ potassium ferrioxalate trihydrate,² triethylammonium sulfamate salts,³ neopentylamine,⁴ methyl 6-aminohexanoate hydrochloride,⁵ 4-chloropentanol, ⁶ *tert*-butyl 4-aminobutyrate, ⁷ (*R*)-methyl-2-amino-4-methylpentanoate hydrochloride, ⁸ (*S*)-2-(1-hydroxy-3-methylbutan-2-yl)isoindoline-1,3-dione, ⁹ 2-chloro-4-methylpentanol, ¹⁰ *N*-(*tert*-butyl)-*N*⁻(2,2,2-trifluoroethyl)sulfamide, ¹¹ and 3-(2,2,-dimethylcyclopropyl)propan-1-ol ¹² were prepared according to the literature and stored at -20 °C.

Procedures.

Moisture-sensitive reactions were performed using flame-dried glassware under an atmosphere of dry nitrogen (N₂). Where noted, air- and water-sensitive reactions were performed in an MBraun MB200 glovebox held under an atmosphere of nitrogen gas (working pressure 2–6 mbar). Flame-dried equipment was stored in a 130 °C oven before use and either allowed to cool in a cabinet dessicator or assembled hot and allowed to cool under an inert atmosphere. Air- and moisture-sensitive liquids and solutions were transferred *via* plastic or glass syringe. Chromatographic purification of products was accomplished using Silicycle Silica flash F60 (particle size 40–63 μ m, 230–400 mesh), Teledyne Isco CombiFlashRf system using 12–220 g Redi Sep Rf normal phase silica columns (particle size 40–63 μ m irregular, 230–400 mesh), or Alfa Aesar Florisil (100–200 mesh). Thin layer chromatography was performed on EMD Millipore silica gel 60 F254 glass-backed plates (layer thickness 250 μ m, particle size 10–12 μ m, impregnated with a fluorescent indicator). Visualization of the developed chromatogram was accomplished by fluorescence quenching under shortwave UV light and/or by staining with *p*-anisaldehyde or KMnO₄ stains. Unless otherwise noted, room temperature is 22 °C.

Instrumentation.

NMR Spectrometry

NMR spectra were obtained on Varian iNOVA spectrometers operating at 400 or 500 MHz for ¹H NMR, 101 or 126 MHz for ¹³C NMR, and 376 MHz for ¹⁹F NMR at 23–25 °C, and are reported as chemical shifts (δ) in parts per million (ppm). Spectra were referenced internally according to residual solvent signals (¹H: CDCl₃, 7.26 ppm; C₆D₆, 7.16 ppm; CD₃CN, 1.94; ¹³C: CDCl₃, 77.0 ppm; C₆D₆, 128.0; CD₃CN, 1.3, 118.3 ppm). Data for NMR spectra use the following abbreviations to describe multiplicity: s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; td, triplet of doublets; ddd, doublet of doublet of doublet s; ABq, AB system quartet; m, multiplet. Coupling constant (*J*) are reported in units of Hertz (Hz).

IR Spectroscopy

IR spectra were obtained on a Nicolet 6700 FT-IR system. Peaks are reported in cm^{-1} with indicated relative intensities: s (strong, 0–33% T); m (medium, 34–66% T); w (weak, 67–100% T); and br (broad).

Mass Spectrometry

High resolution mass spectra (HRMS, m/z) were recorded on an Agilent LCMS-TOF-DART spectrometer using electrospray ionization (ESI, Duke University Department of Chemistry Instrumentation Center).

UV-Vis Spectroscopy UV-vis spectra were obtained on an Agilent Cary 50 UV-Vis Spectrophotometer.

Light Source

 Southern New England Ultraviolet Co. RPR-100 Photochemical Reactor Lamp: 35W RPR-2537A
Emission wavelength: 254 nm
Reactor Barrel Dimensions: 10" diameter, 15" depth
Power supply: 110/120V AC (Input), 50/60 Hz Cycle
Power usage: ~400W
https://rayonet.org/reactors.php?part=RPR-100

II. Optimization of Sulfamide-Guided Chlorine-Transfer.

General Procedure for Optimization.

 $\stackrel{0,0}{\stackrel{'Bu}{\underset{l}{N}}} \stackrel{N}{\underset{l}{N}} \stackrel{N}{\underset{l}{N}} \stackrel{Me}{\xrightarrow{}} \stackrel{hv}{\underset{solvent}{}} \stackrel{iBu}{\underset{l}{N}} \stackrel{N}{\underset{Boc}{}} \stackrel{CI}{\underset{l}{N}} \stackrel{0,0}{\underset{N}{}} \stackrel{O}{\underset{N}{}} \stackrel{O}{\underset{N}{} \stackrel{O}{\underset{N}{}} \stackrel{O}{\underset{N}{}} \stackrel{O}{\underset{N}{}} \stackrel{O}{\underset{N}{} \stackrel{O}{\underset{N}{}} \stackrel{O}{\underset{N}{} \stackrel{O}{\underset{N}{}} \stackrel{O}{\underset{N}{} } \stackrel{O}{\underset{N}{} \stackrel{O}{\underset{N}{}} \stackrel{O}{\underset{N}{} } \stackrel{O}{\underset{N}{} } \stackrel{O}{\underset{N}{} } \stackrel{O}{\underset{N}{} } \stackrel{O}{\underset{N}{} \stackrel{O}{\underset{N}{} } \stackrel{O}{\underset{N}{} }$

A flame-dried 1 dram vial equipped with a stir bar was charged with chlorosulfamide **1i** (11 mg, 0.03 mmol, 1.0 equiv). The vial was transferred to a nitrogen-filled glovebox where it was charged with anhydrous solvent (0.75 mL, 0.04 M or 0.3 mL, 0.1 M). The vial was sealed with a Teflon lined screw cap and removed from the glovebox. The vial was placed on a stir plate and irradiated for the reported time by the light source as described below.

Upon completion of the reaction, the solution was concentrated under reduced pressure and 1,2,4,5-tetrachloro-3-nitrobenzene (0.6 mL, 7.8 mg, 0.03 mmol, 1.0 equiv) was added from a stock solution (0.05 M). The crude was analyzed by ¹H NMR with 25 second relaxation delay and the yields were calculated.

^t Bu	, 0 .s.,	∧Me h∖	, 0,0 ™BU: 1\$:	CI	0 0 Bu S	∧ ^δ ,Me ^t Bu		Me
N I	Boc	solv	ent H Boc	γ γ ν ^{ind}	H Boc	Ϋ́,	H Boc	\sim
CI	1 <i>i</i>		4	i	5i	CI	S7i	
,					1			
	entry	solvent	light source	time	yield 4i ^b	yield 5i ^b	yield S7i ^b	
	1^c	PhH	CFL lamps	2 h	55%	20%	23%	
	2	PhH	CFL lamps	2 h	65%	13%	17%	
	3 ^c	PhH	Kessil lamps	1 h	60%	16%	20%	
	4	PhH	Kessil lamps	1 h	56%	16%	20%	
	5^c	PhH	UV reactor	15 min	65%	12%	15%	
	6 ^{<i>d</i>}	PhH	UV reactor	15 min	88%	10%	4%	
	7	MeCN	UV reactor	15 min	85%	9%	7%	
	8	^{<i>i</i>} PrOAc	UV reactor	15 min	85%	9%	8%	
	9	PhCl	UV reactor	15 min	61%	14%	19%	
	10	PhCF ₃	UV reactor	15 min	78%	9%	6%	

Table S1. Optimization of reaction solvent and light source.

^{*a*}Reactions performed on 0.03 mmol scale at 0.04 M in the listed solvent unless otherwise noted. ^{*b*}Yields from ¹H NMR of crude reaction mixture with 1,2,4,5-tetrachloro-3-nitrobenzene (1.0 equiv) added as an internal standard. ^{*c*}Performed at 0.1 M. ^{*d*}Reported as an average of two runs.

III. Experimental Procedures.

Preparation of 4-Chlorohexanol (S1)



Inspired by a procedure reported by Alexanian and coworkers,⁶ a flame-dried round bottom flask was charged with γ -valerolactone (2.2 mL, 20.0 mmol, 1.0 equiv) and hydrogen bromide solution (32% in acetic acid, 5 mL, 27 mmol, 1.4 equiv). The flask was fitted with a reflux condenser with rubber septum and nitrogen inlet and heated in an oil bath set at 75 °C for 4 h. After this time, the flask was removed from the heat and allowed to cool to room temperature. Once cooled, freshly distilled methanol (8.0 mL, 2.5 M) was added and the reaction was stirred at 22 °C for 16 h. After 16 h, the reaction was partially concentrated under reduced pressure (to remove methanol) and taken up in EtOAc (10 mL). The mixture was then transferred to a separatory funnel, rinsing the flask with EtOAc to achieve quantitative transfer. The organic phase was washed three times with saturated aqueous NaHCO₃ (3 x 25 mL) and once with brine (25 mL). The organic phase was dried with MgSO₄, filtered, and concentrated under reduced pressure.

The crude bromoester was taken up in anhydrous DMF (13 mL) and LiCl (1.67 g, 39.3 mmol, 2.0 equiv) was added in a single portion. The flask was fitted with a Vigreux column with rubber septum and nitrogen inlet and heated in an oil bath set at 90 °C for 18 h. After 18 h, the reaction flask was removed from the heat and allowed to cool to room temperature. Once cool, the reaction was diluted with Et₂O (30 mL) and 1 M HCl (30 mL). The biphasic mixture was transferred to a separatory funnel, rinsing the flask with Et₂O to achieve quantitative transfer. The aqueous phase was removed and the organic phase was washed twice more with 1 M HCl (2 x 30 mL) and once with brine (30 mL). The organic phase was dried with MgSO₄, filtered, and concentrated under reduced pressure. The crude chloroester was used in the next step without purification.

The crude chloroester was added dropwise to a suspension of lithium aluminum hydride (797 mg, 21.0 mmol, 1.1 equiv) in Et₂O (45 mL, 2.3 M) that had been cooled at 0 °C in an ice water bath. The reaction was left to stir at 0 °C for 30 minutes and then heated to reflux overnight. After refluxing overnight, the flask was again cooled to 0 °C, and the reaction was carefully quenched by sequential dropwise addition of H₂O (0.8 mL), 15% aqueous NaOH (0.8 mL), and H₂O (0.8 mL). The resulting suspension was filtered by vacuum filtration through a pad of celite in a glass fritted funnel. The filtrate was concentrated under reduced pressure and then purified by silica gel flash chromatography by dry loading the sample and eluting with hexanes:EtOAc (Gradient: 100% hexanes \rightarrow 9:1 hexanes/EtOAc) to yield the desired product as a colorless oil (390 mg, 14% yield over 3 steps).

¹H NMR (400 MHz, CDCl₃) δ 3.88 (tt, *J* = 4.4 Hz, 8.3 Hz, 1H), 3.69 (t, *J* = 6.0 Hz, 2H), 1.91– 1.66 (m, 6H), 1.44 (br s, 1H), 1.03 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 65.5, 62.2, 34.3, 31.5, 29.6, 10.9. IR (neat) v 3326 (br), 2940 (m), 2877 (m), 1456 (m), 1381 (m), 1310 (m), 1236 (m), 1173 (w), 1059 (s), 921 (s), 896 (m), 803 (m), 734 (m), 658 (m), 603 (s) cm⁻¹. TLC $R_f = 0.21$ in 4:1 hexanes:EtOAc HRMS (ESI) m/z: $[M + H - H_2O]^+$ Calcd for C₆H₁₃ClO 119.0622; Found 119.0621.

Preparation of 3,7-Dimethyloctanoic acid (S2h).



Following a modified literature procedure,¹³ a round-bottom flask with stir bar was charged with 3,7-dimethyloctanol (6.0 mL, 31.4 mmol, 1.0 equiv) without taking any precautions to exclude air or moisture. The flask was charged with acetonitrile (285 mL, 0.11 M) and deionized water (143 mL, 0.22 M), followed by 2-iodobenzoic acid (2.34 g, 9.4 mmol, 0.3 equiv) and then oxone (25.13 g, 40.8 mmol, 1.3 equiv), each in single portions. The reaction flask was fitted with a reflux condenser and heated in an oil bath at 70 °C overnight (16 h) open to air.

After heating overnight, the flask was removed from the oil bath and allowed to cool to room temperature. Once cool, the solid material was removed by vacuum filtration using a Büchner funnel, and the filter cake was rinsed with additional acetonitrile (ca. 100 mL). The filtrate was concentrated under reduced pressure to remove acetonitrile. The remaining aqueous phase was extracted with CH₂Cl₂ (3 x ca. 200 mL). The combined organic phases were dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified by silica gel flash chromatography by dry loading the sample and eluting with hexanes:EtOAc (9:1 hexanes/EtOAc) to yield the desired product as a colorless oil (3.78 g, 70% yield).

*The characterization data for this compound were in agreement with previously published information.*¹⁴

¹H NMR (400 MHz, CDCl₃) δ 2.36 (dd, J = 14.9 Hz, 5.9 Hz, 1H), 2.14 (dd, J =14.9 Hz, 8.2 Hz, 1H), 2.00–1.92 (m, 1H), 1.53 (heptet, J = 6.6 Hz, 1H), 1.33–1.13 (m, 6H), 0.97 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz, 6H). TLC R_f = 0.27 in 9:1 hexanes:EtOAc

General Procedure A: Preparation of amides from carboxylic acids.



A flame-dried flask with stir bar was charged with carboxylic acid (1.0 equiv) and fitted with a rubber septum. The flask was evacuated and backfilled with N₂. ACS grade CH_2Cl_2 (0.3 M) was added via syringe. Carbonyl diimidazole (CDI, 1.25 equiv) was then added by briefly removing the septum and adding the solid as a single portion. The reaction was left to stir at 22 °C for 1 h. After 1 h, the reaction flask was cooled at 0 °C in an ice water bath and aqueous NH₄OH (30%) (3.6 equiv) was added via syringe. Following NH₄OH addition, the reaction was allowed to slowly warm to room temperature by not removing the ice bath and stirred overnight.

After stirring overnight, the biphasic suspension was transferred to a separatory funnel and diluted with deionized H_2O (ca. amount of CH_2Cl_2). The reaction flask was rinsed with an additional 5 mL CH_2Cl_2 to ensure quantitative transfer. The organic phase was removed and the aqueous was extracted twice more with CH_2Cl_2 . The combined organic phases were dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude material was purified by silica gel flash chromatography eluting with a CH_2Cl_2 :EtOAc solvent system as noted below.

2-Cyclopentylacetamide (S3d)

Prepared from cyclopentylacetic acid (0.96 g, 7.5 mmol, 1.0 equiv), CDI (1.52 g, 9.4 mmol, 1.25 equiv), and aq NH₄OH (3.5 mL, 26.0 mmol, 3.6 equiv) following general procedure A. The product was obtained as a white solid (763 mg, 80%

yield) following silica gel column chromatography (1:1 CH₂Cl₂:EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.85 (br s, 1H), 5.53 (br s, 1H), 2.24–2.15 (m, 3H), 1.87–1.82 (m, 2H), 1.64–1.50 (m, 4H), 1.19–1.11 (m, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 175.7, 42.1, 36.9, 32.5, 24.9.

IR (neat) v 3346 (br m), 3168 (br m), 2951 (m), 2867 (m), 1661 (s), 1629 (s), 1412 (s), 1353 (m), 1308 (m), 1250 (m), 1156 (m), 952 (w), 882 (w), 809 (w), 672 (s) cm⁻¹. TLC $R_f = 0.19$ in 1:1 CH₂Cl₂:EtOAc.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₇H₁₃NO 128.1070; Found 128.1068.

3,7-Dimethyloctylamide (S3h)

Prepared from 3,7-dimethyloctanoic acid (S2h) (5.17 g, 30.0 mmol, 1.0 equiv), CDI (6.1 g, 37.6 mmol, 1.25 equiv), and aq NH4OH (14 mL, 108 mmol, 3.6 equiv) following general procedure A. The product was

obtained as a white solid (4.38 g, 85% yield) following silica gel column chromatography (1:1 $CH_2Cl_2:EtOAc$).

*The characterization data for this compound were in agreement with previously published information.*¹⁵

¹H NMR (400 MHz, CDCl₃) δ 5.57 (br s, 1H), 5.42 (br s, 1H), 2.26–2.19 (m, 1H), 2.00–1.90 (m, 2H), 1.52 (heptet, J = 6.6 Hz, 1H), 1.36–1.10 (m, 6H), 0.95 (d, J = 6.2 Hz, 3H), 0.86 (d, J = 6.6 Hz, 6H).

TLC $R_f = 0.39$ in 1:1 CH₂Cl₂:EtOAc

H₂N

3-(4-Trifluoromethylphenyl)propamide (S3u)

Prepared from 4-(trifluoromethyl)hydrocinnamic acid (2.2 g, 10.0 mmol, 1.0 equiv), CDI (2.03 g, 12.5 mmol, 1.25 equiv), and aq NH₄OH (4.7 mL, 36.2 mmol, 3.6 equiv) following general procedure A. The product was obtained as a white solid (1.78 g, 82% yield) following silica gel

column chromatography (1:1 CH₂Cl₂:EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 5.50 (br s, 1H), 5.37 (br s, 1H), 3.03 (t, *J* = 7.6 Hz, 2H), 2.54 (t, *J* = 7.6 Hz, 2H).

¹³C NMR (126 MHz, CDCl₃, ¹H and ¹⁹F decoupled) δ 173.9, 144.8, 128.7, 125.4, 124.2, 36.9, 31.0. ¹⁹F NMR (376 MHz, CDCl₃) δ –62.45.

IR (neat) v 3399 (br w), 3199 (br w), 2947 (w), 1652 (m), 1615 (m), 1453 (w), 1418 (m), 1320 (s), 1246 (w), 1167 (s), 1108 (s), 1066 (s), 1018 (m), 954 (w), 912 (w), 896 (w), 837 (s), 825 (s), 733 (w), 592 (s) cm⁻¹.

TLC $R_f = 0.22$ in 1:1 CH₂Cl₂:EtOAc.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₀H₁₀F₃NO 218.0787; Found 218.0783.

General Procedure B: Preparation of amines from amides.

$$H_2N \stackrel{O}{\longleftarrow}_R \xrightarrow{\text{LiAIH}_4} H_2N \stackrel{C}{\longrightarrow} H_2N \stackrel{C}{\frown}_R$$

A flame-dried flask with stir bar and fitted with a reflux condenser was charged with lithium aluminum hydride (LiAlH₄) (2.1 equiv). The flask was fitted with a rubber septum and evacuated and back-filled with N₂. Anhydrous Et₂O (0.2 M) was added and the reaction flask was cooled at 0 °C in an ice/water bath. Amide (1.0 equiv) was carefully added portion-wise as a solid (ca. 3 portions) by briefly removing the reflux condenser and then replacing it. Once all amide had been added, the ice/water bath was replaced with an oil bath and the reaction flask was heated at reflux and stirred overnight.

After refluxing overnight, the reaction was removed from the heat and allowed to cool to room temperature and then further cooled at 0 °C in an ice/water bath. The reaction was then carefully quenched by careful, sequential addition of deionized H₂O (1 mL/g LiAlH₄), 15% w/v aq. NaOH (1 mL/g LiAlH₄), and deionized H₂O (1 mL/g LiAlH₄). The quenched reaction was left stirring at 0 °C for ca. 30 minutes to ensure complete quenching of remaining LiAlH₄. Once fully quenched, the reaction was filtered through a pad of celite in a glass-fritted funnel by vacuum filtration eluting with Et₂O (ca. $\frac{1}{2}$ reaction volume). The filtrate was then concentrated under reduced pressure. The concentrated crude material was generally pure without need for further purification.

3,7-Dimethyloctylamine (S4h)

 $\begin{array}{c|c} & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ &$

The characterization data for this compound were in agreement with previously published information. $^{\rm 16}$

¹H NMR (400 MHz, CDCl₃) δ 2.76–2.63 (m, 2H), 1.55–1.40 (m, 3H), 1.33–1.20 (m, 5H), 1.17–1.08 (m, 2H), 0.87–0.85 (m, 9H).

3-(4-(Trifluoromethyl)phenyl)propylamine (S4u)



Prepared from 3-(4-trifluoromethylphenyl)propamide (S3u) (1.3 g, 62.0 mmol, 1.0 equiv) and LiAlH₄ (478 mg, 12.6 mmol, 2.1 equiv) in anhydrous Et_2O (30 mL) following general procedure B. The product was obtained as a colorless oil (1.18 g, 97% yield).

¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, *J* = 8.0 Hz, 2H), 7.29 (d, *J* = 8.0 Hz, 2H), 2.76–2.70 (m, 4H), 1.79 (dt, *J* = 7.1, 14.8 Hz, 2H), 1.50 (br s, 2H).

 ^{13}C NMR (126 MHz, CDCl₃, ^{1}H and ^{19}F decoupled) δ 146.2, 128.6, 128.1, 125.2, 124.3, 41.5, 34.8, 33.0.

¹⁹F NMR (376 MHz, CDCl₃) δ –62.35.

IR (neat) v 2932 (br w), 2860 (br w), 1618 (w), 1418 (w), 1321 (s), 1159 (m), 1111 (s), 1065 (s), 1018 (m), 840 (m), 814 (m), 731 (w), 631 (w), 614 (w), 594 (m) cm⁻¹. HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₀H₁₂F₃N 204.0995; Found 204.0995.

General Procedure C: Preparation of N-Boc free sulfamides



Following a modified literature procedure,¹⁷ to a flame-dried round bottom flask fitted with a rubber septum and under an atmosphere of N_2 was added anhydrous THF (0.5 M) and chlorosulfonyl isocyanate (1.0 equiv). The solution was cooled at 0 °C in an ice water bath and 'BuOH (1.0 equiv) was added dropwise via syringe. Upon complete addition of 'BuOH, the solution was allowed to slowly warm to room temperature by not removing the ice water bath or adding any additional ice and was stirred for 1 h.

After 1 hour, the solution was cooled at -78 °C in a dry ice/ⁱPrOH bath and pyridine (5.0 equiv) and amine (R¹–NH₂, 2.0 equiv) were added dropwise via syringe. Upon complete addition of amine, the cloudy mixture was allowed to slowly warm to room temperature by not removing the cooling bath or adding any additional dry ice and was stirred overnight. After stirring overnight, the suspension was cooled at 0 °C in an ice water bath and the pH was adjusted to 1 by dropwise addition of a 6 M HCl solution. Once reaching pH = 1, the solution was diluted with H₂O (ca. 1 M) and transferred to a separatory funnel rinsing the flask with EtOAc (ca. 5 mL) to ensure quantitative transfer. The aqueous phase was extracted with EtOAc (3 x ca. 1 mL) The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford a white solid. The crude solid was either used without further purification or recrystallized as noted below.

N-tert-Butoxycarbonyl-*N'-tert*-butylsulfamide (S5a)

¹H NMR (500 MHz, CD₃CN) δ 8.44 (br s, 1H), 5.56 (br s, 1H), 1.46 (s, 9H), 1.29 (s, 9H). ¹³C NMR (126 MHz, CD₃CN) δ 151.5, 83.1, 55.2, 29.6, 28.2.

IR (neat) v 3277 (br), 2973 (w), 1709 (m), 1477 (w), 1454 (w), 1421 (w), 1393 (m), 1369 (m), 1348 (m), 1250 (m), 1206 (w), 1167 (m), 1138 (m), 1041 (w), 1000 (m), 914 (m), 862 (w), 817 (m), 780 (w), 720 (m), 606 (m), 575 (m) cm^{-1} .

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₉H₁₉N₂O₄S 251.1065; Found 251.1063.

N-tert-Butoxycarbonyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (S5b)

 \circ \circ \circ Prepared from chlorosulfonyl isocyanate (1.7 mL, 19.8 mmol), 'BuOH (1.9 mL, 19.8 mmol), pyridine (8.0 mL, 99.3 mmol), and 2,2,2-trifluoroethylamine (3.1 mL, 39.4 mmol) following general procedure C. The product was obtained as a white solid (5.28 g, 96% yield) following workup.

¹H NMR (400 MHz, CD₃CN) δ 8.60 (br s, 1H), 6.44 (br s, 1H), 3.76 (qd, J = 9.2, 6.9 Hz, 2H), 1.46 (s, 9H).

¹³C NMR (126 MHz, CD₃CN) δ 151.2, 125.1 (q, J = 277.7 Hz), 83.9, 45.3 (q, J = 35.2 Hz), 28.1. ¹⁹F NMR (376 MHz, CD₃CN) δ –73.16 (t, J = 9.2 Hz).

IR (neat) v 3290 (br), 2999 (w), 1713 (m), 1478 (w), 1468 (w), 1427 (m), 1396 (w), 1371 (w), 1356 (m), 1299 (w), 1282 (w), 1252 (m), 1141 (m), 1111 (m), 1069 (w), 1032 (w), 970 (m), 921 (w), 848 (w), 835 (m), 820 (m), 778 (w), 761 (w), 731 (m), 667 (m), 589 (m), 545 (m) cm⁻¹. HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₇H₁₂F₃N₂O₄S 277.0469; Found 277.0457.

N-tert-Butoxycarbonyl-*N*'-ethylsulfamide (S5c)

Me N S N Boc Prepared from chlorosulfonyl isocyanate (1.7 mL, 19.8 mmol), 'BuOH (1.9 mL, 19.8 mmol), pyridine (8.0 mL, 99.3 mmol), and ethylamine (20 mL of 2 M solution in THE 40.0 M solution in THF, 40.0 mmol) following general procedure C. The product was obtained as a white solid (2.40 g, 54% yield) following recrystallization performed by dissolving the crude solid in a minimal amount of a warm solution of hexanes:EtOAc (1:4) and allowing the solution to slowly cool to room temperature before further cooling at -20 °C.

¹H NMR (500 MHz, CD₃CN) δ 8.37 (br s, 1H), 5.65 (br s, 1H), 3.03 (qd, J = 7.3, 6.0 Hz, 2H), 1.46 (s, 9H), 1.13 (t, J = 7.2 Hz, 3H).

¹³C NMR (126 MHz, CD₃CN) δ 151.5, 83.4, 39.4, 28.2, 14.8.

IR (neat) v 3286 (br), 3212 (m), 2993 (w), 2938 (w), 2873 (w), 1698 (s), 1427 (s), 1394 (m), 1371 (m), 1341 (s), 1250 (m), 1153 (m), 1128 (s), 1102 (s), 1063 (w), 952 (s), 912 (m), 858 (m), 816 (s), 780 (s), 717 (s), 583 (s) cm⁻¹.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₇H₁₅N₂O₄S 223.0752; Found 223.0752.

N-tert-Butoxycarbonyl-*N*'-hexylsulfamide (S5d)

Prepared from chlorosulfonyl isocyanate (1.7 mL, 19.8 mmol), BuOH (1.9 mL, 19.8 mmol), pyridine (8.0 mL, 99.3 mmol), and hexylamine (5.2 mL, 39.4 mmol) following general procedure C. The

product was obtained as a white solid (3.89 g, 70% yield) following silica gel column chromatography using hexanes: EtOAc (Gradient: 100% hexanes \rightarrow 9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 7.07 (br s, 1H), 5.02 (t, *J* = 6.6 Hz, 1H), 3.06 (dt, *J* = 6.6, 6.6 Hz, 2H), 1.59–1.54 (m, 2H), 1.50 (s, 9H), 1.36–1.27 (m, 6H), 0.89 (t, *J* = 6.8 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 150.2, 83.7, 43.9, 31.2, 29.0, 28.0, 26.2, 22.4, 13.9.

IR (neat) v 3280 (br), 3219 (br), 2959 (w), 2929 (w), 2861 (w), 1696 (s), 1430 (m), 1395 (m), 1371 (m), 1349 (m), 1252 (m), 1176 (m), 1136 (s), 1077 (m), 1002 (w), 931 (m), 818 (m), 784 (m), 720 (s), 583 (s), 516 (m), 458 (m), 434 (m) cm⁻¹.

TLC $R_f = 0.27$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{11}H_{24}N_2O_4S \cdot NH_4$ 298.1795; Found 298.1797.

IV. Preparation and characterization of sulfamides.

General Procedure D: Preparation of sulfamides from sulfamic acid salts with amine nucleophiles.



A flame-dried round bottom flask equipped with magnetic stir bar was charged with triphenylphosphine oxide (1.65 equiv) and fitted with a rubber septum. The flask was evacuated and backfilled with N₂. Anhydrous CH₂Cl₂ (0.22 M with respect to amine) was added and the flask was cooled at 0 °C in an ice water bath. Trifluoromethanesulfonic anhydride (1.5 equiv) that had been freshly removed from the glovebox was then added to the cooled solution dropwise via syringe. The reaction was allowed to stir at 0 °C in an ice water bath for 15 minutes. This suspension was treated with a solution of sulfamate salt (1.5 equiv) in CH₂Cl₂ (1.25 M with respect to amine) via cannula transfer. The flask containing sulfamate salt solution was rinsed with CH₂Cl₂ (ca. 5.0 M with respect to amine) to achieve quantitative transfer. The resulting yellow solution was stirred for 15 minutes at 0 °C. During this time, a clean, flame-dried round bottom flask equipped with stir bar was fitted with a rubber septum and subsequently evacuated and backfilled with N₂. This process was repeated two more times. The flask was then charged with Et₃N (3.0 equiv) and CH₂Cl₂ (0.22 M with respect to amine) and the mixture was cooled at -78 °C in an 'PrOH/dry ice bath. The sulfamate salt solution was transferred dropwise to the Et₃N solution via cannula (during which time a yellow to intense red color often developed), rinsing the flask with CH₂Cl₂ (ca. 2.0 M with respect to amine) to achieve quantitative transfer. The resultant solution was stirred at -78 °C for 15 minutes. The amine ((R²)(R³)–NH, 1.0 equiv) was then added as a solution in CH₂Cl₂ (1.25 M) to the triethylamine solution via cannula. The amine-containing flask was rinsed with CH₂Cl₂ (ca. 5.0 M with respect to amine) to achieve quantitative transfer. Without removing the cooling bath, the reaction was then stirred overnight, during which time no additional dry ice was added to the bath and the mixture gradually warmed to room temperature.

After stirring overnight, the reaction was diluted with 1 M HCl (ca. 5 mL/mmol of sulfamide) and H₂O (ca. 5 mL/mmol of sulfamide). The biphasic mixture was transferred to a separatory funnel, rinsing the flask with CH₂Cl₂ to achieve quantitative transfer. The organic phase was separated and the aqueous phase was extracted twice more with CH_2Cl_2 (ca. $\frac{1}{2}$ reaction volume). The combined organic phases were dried with MgSO₄, filtered, and concentrated under reduced pressure. The crude reaction mixtures were then purified by silica gel flash chromatography by dry loading the samples and eluting with a hexanes:EtOAc solvent system as noted below.

N-tert-Butyl-*N*'-isopentylsulfamide (S6c)

Prepared from triethylammonium *tert*-outylsunamate (0.0 g, 1.0 m) ^tBu, N, N, M, M^tBu, N, N, MThe product was obtained as a white solid (2.06 g, 93% yield) after silica The product was obtained as a white solid (2.06 g, 93% yield) after silica

¹H NMR (400 MHz, CDCl₃) δ 4.26 (br s, 1H), 4.14 (br s, 1H), 3.04 (dt, *J* = 7.0, 7.0 Hz, 2H), 1.70–1.60 (m, 1H), 1.43 (dt, *J* = 7.0, 7.0 Hz, 2H), 1.34 (s, 9H), 0.91 (d, *J* = 6.6 Hz). ¹³C NMP (126 MHz, CDCl₃) δ 53.8 41.5 38.2 20.8 20.7 25.6 22.3

¹³C NMR (126 MHz, CDCl₃) δ 53.8, 41.5, 38.2, 29.8, 29.7, 25.6, 22.3.

IR (neat) v 3295 (m, br), 2956 (w), 2867 (w), 1466 (w), 1431 (m), 1392 (m), 1364 (w), 1307 (s), 1211 (w), 1170 (w), 1135 (s), 1079 (m), 1042 (w), 1006 (m), 918 (m), 898 (m), 860 (w), 821 (w), 761 (w), 622 (m), 590 (m) cm⁻¹.

TLC $R_f = 0.24$ in 4:1 hexanes:EtOAc

HRMS (ESI) m/z: [M – H][–] Calcd for C₉H₂₂N₂O₂S 221.1329; Found 221.1332.

N-tert-Butyl-*N'*-(3,7-dimethyloct-1-yl)sulfamide (S6h)



Prepared from triethylammonium *N-tert*-butylsulfamate (4.19 g, 16.5 mmol, 1.65 equiv) and 3,7-dimethyloctylamine (**S4h**, 1.57 g, 10.0 mmol, 1.00 equiv) according to general procedure D. The product was isolated as a viscous, colorless oil (2.96 g, 51%)

yield) after purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal phase silica gel column (15:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.01 (br s, 1H), 3.92 (t, J = 6.7 Hz, 1H), 3.13–2.99 (m, 2H), 1.61–1.47 (m, 3H), 1.36 (s, 9H), 1.32–1.21 (m, 4H), 1.16–1.09 (m, 3H), 0.90 (d, J = 6.5 Hz, 3H), 0.87 (d, J = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 53.9, 41.4, 39.2, 37.0, 36.5, 30.4, 29.8, 27.9, 24.6, 22.7, 22.6, 19.4.

IR (neat) v 3276 (br), 2954 (w), 2925 (m), 2869 (w), 1464 (w), 1428 (w), 1391 (w), 1367 (w), 1301 (m), 1230 (w), 1137 (s), 1080 (w), 1041 (w), 988 (m), 899 (w), 765 (w), 610 (m) cm⁻¹. TLC $R_f = 0.29$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₄H₃₁N₂O₂S 291.2106; Found 291.2107.

*N-(tert-*Butyl butano-4-yl)-*N'-tert-*butylsulfamide (S6t)

⁶ ^N ^N ^N ^N ^N ^{CO₂'Bu Prepared from triethylammonium *N-tert*-butylsulfamate (1.86 g, 7.30 mmol, 1.65 equiv) and *tert*-butyl 4-aminobutyrate (700.0 mg, 4.40 mmol, 1.00 equiv) according to general procedure D. The product was isolated as a white solid (659.4 mg, 51% yield) after purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal phase silica gel column (7:3 hexanes/EtOAc).}

¹H NMR (400 MHz, CDCl₃) δ 4.26 (t, *J* = 5.3 Hz, 1H), 4.04 (br s, 1H), 3.09 (dt, *J* = 6.7, 6.7 Hz, 2H), 2.32 (t, *J* = 7.0 Hz, 2H), 1.88–1.83 (m, 2H), 1.45 (s, 9H), 1.35 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 172.5, 80.5, 53.8, 42.6, 32.7, 29.7, 28.0, 24.5.

IR (neat) v 3303 (br), 3262 (br), 2976 (m), 1704 (s), 1474 (w), 1438 (m), 1389 (m), 1365 (m), 1310 (s), 1296 (s), 1267 (m), 1234 (m), 1207 (m), 1159 (s), 1127 (s), 1092 (s), 1078 (m), 1039 (m), 993 (s), 957 (s), 929 (m), 872 (m), 846 (m), 785 (m), 774 (m), 613 (s), 573 (s) cm⁻¹. TLC $R_f = 0.07$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₂H₂₅N₂O₄S 293.1535; Found 293.1540.

N-tert-Butyl-*N'*-(3-(4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (S6u)



Prepared from triethylammonium *tert*-butylsulfamate (1.90 g, 7.5 mmol) and 3-(4-(trifluoromethyl)phenyl)propyl amine (**S4u**, 1.02 g, 5.0 mmol) following general procedure D. The product was obtained as a white solid (664 mg, 39% yield) after silica gel

column chromatography (4:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, J = 8.1 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 4.20 (t, J = 5.5 Hz, 1H), 4.13 (br s, 1H), 3.07 (dt, J = 6.8, 6.8 Hz, 2H), 2.75 (dd, J = 7.7, 7.7 Hz, 2H), 1.95–1.87 (m, 2H), 1.33 (s, 9H).

¹³C NMR (126 MHz, CDCl₃, ¹H and ¹⁹F decoupled) δ 145.2, 128.7, 128.4, 125.4, 124.3, 54.0, 42.6, 32.7, 30.8, 29.7.

¹⁹F NMR (376 MHz, CDCl₃) δ –62.41.

IR (neat) v 3292 (br m), 2978 (w), 1672 (w), 1618 (w), 1419 (w), 1395 (w), 1369 (w), 1326 (s), 1300 (m), 1235 (w), 1162 (m), 1141 (s), 1113 (s), 1069 (m), 1047 (w), 1007 (m), 903 (w), 846 (w), 821 (w), 734 (w), 635 (w), 619 (w) cm⁻¹.

TLC $R_f = 0.17$ in 4:1 hexanes:EtOAc

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₄H₂₁F₃N₂S₂S 339.1349; Found 339.1347.

V. Preparation and characterization of Boc-protected sulfamides.

General Procedure E: Preparation of Boc-protected sulfamides.



A flame-dried round bottom flask equipped with a stir bar was charged with sulfamide (1.0 equiv), 4-dimethylaminopyridine (DMAP, 1.1 equiv), and di-tert-butyl dicarbonate (Boc₂O, 1.3 equiv). The flask was fitted with a rubber septum and evacuated and backfilled with N₂, and charged with CH₂Cl₂ (0.2 M). The resulting solution was stirred at 22 °C overnight.

After stirring overnight, the reaction was either concentrated under reduced pressure and purified by silica gel chromatography by dry loading samples and eluting with a hexanes/EtOAc solvent system as noted below, or subjected to an aqueous workup and subsequently purified. When an aqueous workup was performed, the reaction was diluted with deionized H₂O (0.2 M) and the biphasic mixture was transferred to a separatory funnel. The organic phase was removed and the aqueous was extracted twice more with CH₂Cl₂ (2 x 0.2 M). The combined organic layers were dried with MgSO₄, filtered, and concentrated under reduced pressure. The crude mixture was purified by silica gel chromatography by dry loading samples and eluting with a hexanes/EtOAc solvent system as noted below.

General Procedure F: Preparation of Boc-protected sulfamides from alcohol precursors.



Following a procedure reported by Du Bois and co-workers,¹⁸ a flame-dried round bottom flask equipped with stir bar was charged with N-Boc sulfamide S5 (1.3 equiv) and triphenylphosphine (Ph₃P, 1.3 equiv). The flask was fitted with a rubber septum and evacuated and backfilled with N₂. Anhydrous THF (0.2 M with respect to alcohol) was added and the reaction flask was cooled at 0 °C in an ice water bath. Alcohol (1.0 equiv) was added via syringe followed by dropwise addition of diethylazodicarboxylate (DEAD, 1.3 equiv). Following complete addition of all reagents, the reaction was allowed to slowly warm to room temperature by not adding any more ice to the ice water bath and stirred overnight.

After stirring overnight, the reaction was concentrated under reduced pressure and purified by silica gel chromatography by dry loading samples and eluting with a hexanes/EtOAc solvent system as noted below.



N-tert-Butoxycarbonyl-*N*-ethyl-*N*'-hexylsulfamide (S7a) Prepared from sulfamide S5d (925 mg, 3.3 mmol) and ethanol Me Noc H Me (0.15 mL, 2.5 mmol) following general procedure F. The product was obtained as a white solid (711 mg, 92% yield) after silica gel

column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.20 (t, *J* = 6.6 Hz, 1H), 3.72 (q, *J* = 7.0 Hz, 2H), 2.94 (dt, *J* = 6.6, 6.6 Hz, 2H), 1.58–1.54 (m, 2H), 1.53 (s, 9H), 1.35–1.28 (m, 6H), 1.24 (t, *J* = 7.0 Hz, 3H), 0.89 (t, *J* = 6.8 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 151.9, 83.7, 43.8, 42.8, 31.2, 28.8, 28.1, 26.3, 22.4, 15.0, 13.9.

IR (neat) v 3319 (br), 2933 (w), 2860 (w), 1705 (m), 1458 (w), 1424 (w), 1368 (m), 1335 (m), 1280 (m), 1256 (m), 1185 (m), 1138 (s), 1085 (w), 1000 (w), 953 (w), 910 (w), 845 (m), 816 (w), 774 (w), 714 (s), 631 (m), 616 (m), 569 (m), 464 (w) cm⁻¹.

TLC $R_f = 0.27$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{13}H_{28}N_2O_4S\bullet Na$ 331.1662; Found 331.1663.

N-tert-Butoxycarbonyl-*N*'-hexyl-*N*-(2,2,2-trifluoro)ethylsulfamide (S7b)

 F_3C N_{Boc} N_{H} N_{Boc} N_{H} N_{H} N

Prepared from sulfamide **S5d** (925 mg, 3.3 mmol) and (2,2,2trifluoro)ethanol (0.18 mL, 2.5 mmol) following general procedure F. The product was obtained as a white solid (213 mg, 24% yield)

after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.23 (t, J = 6.6 Hz, 1H), 4.31 (q, J = 8.3 Hz, 2H), 3.03 (dt, J = 6.6 Hz, 2H), 1.58–1.54 (m, 2H), 1.54 (s, 9H), 1.36–1.26 (m, 6H), 0.89 (t, J = 6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 151.0, 123.5 (q, J = 280.3 Hz), 85.5, 47.1 (q, J = 35.7 Hz), 43.9,

¹³C NMR (126 MHz, CDCl₃) 8 151.0, 123.5 (q, J = 280.3 Hz), 85.5, 47.1 (q, J = 35.7 H 31.2, 28.8, 27.8, 26.2, 22.4, 13.9.

¹⁹F NMR (376 MHz, CDCl₃) δ –70.85 (t, *J* = 8.4 Hz).

IR (neat) v 3315 (br), 2933 (w), 2861 (w), 1720 (m), 1423 (w), 1397 (w), 1369 (m), 1344 (m), 1298 (w), 1251 (m), 1140 (s), 1082 (w), 1047 (w), 1027 (m), 957 (w), 850 (w), 830 (w), 794 (w), 775 (w), 706 (m), 677 (w), 642 (m), 576 (m), 530 (w), 463 (w) cm⁻¹.

TLC $R_f = 0.25$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{13}H_{25}F_3N_2O_4S \cdot NH_4$ 380.1825; Found 380.1832.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-neopentylsulfamide (S8a)



Prepared from *N-tert*-butyl-*N*'-neopentylsulfamide¹⁹ (445 mg, 2.0 mmol), Boc₂O (567 mg, 2.6 mmol), and DMAP (269 mg, 2.2 mmol) in CH₂Cl₂ (10 mL, 0.2 M) following general procedure E. The product was obtained as a white solid (441 mg, 68% yield) after silica gel column chromatography (9:1

hexanes:EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.44 (br s, 1H), 3.54 (s, 2H), 1.52 (s, 9H), 1.26 (s, 9H), 0.97 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 152.7, 83.4, 57.5, 54.8, 33.4, 29.4, 28.1, 28.0.

IR (neat) v 3312 (br m), 2967 (m), 1703 (s), 1478 (m), 1433 (m), 1392 (m), 1368 (m), 1352 (s), 1285 (m), 1256 (m), 1220 (m), 1156 (s), 1139 (s), 1071 (m), 1041 (w), 1005 (s), 931 (w), 864 (w), 844 (m), 789 (m), 775 (m), 710 (s), 603 (s), 575 (s) cm⁻¹.

TLC $R_f = 0.33$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₄H₃₀N₂O₄S 321.1854; Found 321.1852.

N-tert-Butoxycarbonyl-*N*-butyl-*N'-tert*-butylsulfamide (S8b)

^vBu, N, S, N, M Prepared from sulfamide S5a (820 mg, 3.3 mmol) and 1-butanol (0.23 mL, 2.5 mmol) following general procedure F. The product was obtained as a white solid (741 mg, 96% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.30 (br s, 1H), 3.64 (dd, *J* = 7.5, 7.5 Hz, 2H), 1.70–1.62 (m, 2H), 1.52 (s, 9H), 1.37–1.31 (m, 2H), 1.30 (s, 9H), 0.93 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 152.3, 83.3, 55.0, 47.3, 31.7, 29.4, 28.1, 19.8, 13.7.

IR (neat) v 3282 (m), 2956 (m), 2931 (w), 2872 (w), 1703 (s), 1455 (m), 1441 (m), 1397 (m), 1370 (s), 1339 (s), 1294 (m), 1256 (m), 1230 (m), 1208 (w), 1167 (s), 1137 (s), 1046 (m), 1002 (m), 935 (w), 885 (w), 843 (m), 785 (m), 770 (m), 714 (s), 639 (s), 591 (s), 578 (s), 564 (s)cm⁻¹. TLC $R_f = 0.24$ in 9:1 hexanes:EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₃H₂₈N₂O₄S 307.1697; Found 307.1694.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-isopentylsulfamide (S8c)

⁶Bu N S Noc Me ⁷Bu N S Noc Me ⁷Bu

¹H NMR (500 MHz, CDCl₃) δ 5.31 (br s, 1H), 3.66–3.63 (m, 2H), 1.60–1.56 (m, 3H), 1.52 (s, 9H), 1.30 (s, 9H), 0.92 (d, *J* = 5.8 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 152.2, 83.3, 55.0, 46.0, 38.4, 29.4, 28.1, 25.9, 22.4. IR (neat) v 3308 (br), 2962 (w), 2871 (w), 1710 (m), 1470 (w), 1431 (m), 1392 (w), 1348 (m), 1293 (m), 1253 (m), 1146 (s), 1045 (m), 1009 (m), 964 (w), 932 (m), 847 (m), 798 (w), 772 (m), 754 (w), 711 (m), 629 (m), 579 (m) cm⁻¹.

TLC $R_f = 0.38$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for $C_{14}H_{29}N_2O_4S$ 321.1848; Found 321.1858.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(cyclopentyl)eth-1-yl)sulfamide (S8d)

¹H NMR (400 MHz, CDCl₃) δ 5.31 (br s, 1H), 3.63 (dd, J = 9.7, 7.9 Hz, 2H), 1.81–1.75 (m, 3H), 1.73–1.66 (m, 3H), 1.62–1.57 (m, 3H), 1.52 (s, 9H), 1.29 (s, 9H), 1.16–1.10 (m, 2H). ¹³C NMR (126 MHz, CDCl₃) δ 152.2, 83.3, 55.0, 47.0, 37.4, 35.9, 32.4, 29.4, 28.1, 25.1. IR (neat) v 3332 (br w), 2966 (m), 2861(w), 1715 (s), 1453 (w), 1428 (m), 1392 (m), 1366 (m), 1344 (s), 1289 (m) 1259 (m), 1149 (s), 1123 (s), 1041 (m), 1011 (s), 977 (m), 920 (m), 851 (m), 808 (w), 773 (m), 746 (m), 645 (m), 605 (s), 592 (s), 543 (m) cm⁻¹. TLC R_f = 0.33 in 9:1 hexanes:EtOAc. HRMS (ESI) m/z: [M + Na]⁺ Calcd for C₁₆H₃₂N₂O₄S•Na 371.1975; Found 371.1969.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(cyclohexyl)eth-1-yl)sulfamide (S8e)

Prepared from sulfamide S5a (820 mg, 3.3 mmol) and 2cyclohexylethanol (0.35 mL, 2.5 mmol) following general procedure F. The product was obtained as a colorless oil (696 mg, 77% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1

hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.31 (br s, 1H), 3.68–3.64 (m, 2H), 1.74–1.64 (m, 5H), 1.52 (s, 9H), 1.29 (s, 9H), 1.24–1.13 (m, 6H), 0.98–0.89 (m, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 152.1, 83.2, 54.8, 45.6, 36.9, 35.2, 32.9, 29.3, 28.0, 26.3, 26.0. IR (neat) v 3339 (br), 2979 (w), 2922 (m), 2851 (w), 1707 (m), 1449 (w), 1425 (m), 1392 (m), 1355 (m), 1310 (w), 1292 (m), 1247 (w), 1138 (s), 986 (m), 966 (m), 914 (w), 850 (m), 808 (w), 774 (w), 713 (s), 604 (m), 582 (m), 55 (w) cm⁻¹.

TLC $R_f = 0.51$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₇H₃₄N₂O₄S 361.2167; Found 361.2161.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-((2*R*)-methyl 4-methylpentano-2-yl)sulfamide (S8f)



Prepared from N'-tert-butyl-N-((2R)-methyl 4-methylpentano-2-yl)sulfamide ¹⁹ (200 mg, 0.713 mmol), Boc₂O (202 mg, 0.927 mmol), and DMAP (95.9 mg, 0.7846 mmol) in CH₂Cl₂ (3.5 mL, 0.2 M) following general procedure E. The product was obtained as a colorless oil (92.3 mg,

34% yield) after silica gel column chromatography (9:1 hexanes/EtOAc) and subsequent alumina column chromatography (95:5 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.32 (br s, 1H), 4.85 (dd, J = 7.4, 6.0 Hz, 1H), 3.73 (s, 3H), 2.06 (dd, J = 13.8, 7.6, 5.8 Hz, 1H), 1.86–1.80 (m, 1H), 1.74 (ddd, J = 13.8, 7.6, 5.8, 1H), 1.48 (s, 9H), 1.37 (s, 9H), 0.96 (t, J = 6.4 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 170.8, 151.4, 84.2, 58.0, 55.9, 52.1, 40.3, 29.5, 27.9, 25.0, 22.8, 22.0.

IR (neat) v 3301 (br), 2956 (w), 2871 (w), 1747 (m), 1715 (m), 1435 (w), 1395 (m), 1368 (m), 1351 (m), 1285 (m), 1252 (m), 1232 (m), 1209 (m), 1145 (s), 997 (m), 922 (w), 892 (w), 843 (m), 833 (m), 807 (w), 773 (m), 711 (m), 611 (s), 573 (s) cm⁻¹.

TLC $R_f = 0.39$ in 8:2 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{16}H_{32}N_2O_6S \cdot Na 403.1878$; Found 403.1871.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N-((S)*-2-(1,3-dioxoisoindolin-2-yl)-3-methylbutyl)sulfamide (S8g)



Prepared from sulfamide S5a (820 mg, 3.3 mmol) and (S)-2-(1-hydroxy-3methylbutan-2-yl)isoindoline-1,3-dione (583 mg, 2.5 mmol) following general procedure F. The product was obtained as a white solid (981 mg, 84% yield) after silica gel column chromatography (Gradient: 20:1

hexanes: EtOAc \rightarrow 9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 7.83–7.82 (m, 2H), 7.67 (dd, *J* = 5.6, 2.9 Hz, 2H), 5.19 (br s, 1H), 4.41 (dd, *J* = 10.9, 14.7 Hz, 1H), 4.17 (ddd, *J* = 2.7, 2.7, 10.9 Hz, 1H), 3.93 (dd, *J* = 2.7, 14.7 Hz,

1H), 2.63–2.54 (m, 1H), 1.54 (s, 9H), 1.22 (s, 9H), 1.12 (d, *J* = 6.6 Hz, 3H), 0.85 (d, *J* = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 168.3, 151.3, 133.4, 131.7, 122.9, 122.6, 83.7, 56.8, 54.6, 46.7, 29.0, 27.8, 27.1, 20.3, 19.8.

IR (neat) v 3309 (br), 2975 (w), 1771 (w), 1710 (s), 1615 (w), 1468 (m), 1432 (m), 1392 (m), 1370 (s), 1354 (s), 1322 (s), 1290 (m), 1237 (m), 1162 (m), 1144 (s), 1098 (m), 1068 (m), 1042 (m), 1025 (m), 990 (m), 933 (w), 888 (w), 876 (m), 844 (m), 798 (m),772 (m), 716 (s), 709 (s), 681 (m), 601 (s), 581 (s), 551 (m), 531 (m) cm⁻¹.

TLC $R_f = 0.10$ in 4:1 hexanes:EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₂₂H₃₃N₃O₆S 466.2017; Found 466.2005.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3,7-dimethyloct-1-yl)sulfamide (S8h)

isolated as a colorless oil (635 mg, 95% yield) after purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.30 (br s, 1H), 3.69–3.56 (m, 2H), 1.73–1.66 (m, 1H), 1.50 (s, 9H), 1.48–1.37 (m, 4H), 1.28 (s, 9H), 1.27–1.20 (m, 2H), 1.13–1.08 (m, 3H), 0.88 (d, *J* = 6.4 Hz, 3H), 0.83 (d, *J* = 6.7 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 152.2, 83.3, 54.9, 45.9, 39.1, 37.0, 36.5, 30.7, 29.4, 28.1, 27.9, 24.6, 22.6, 22.5, 19.4.

IR (neat) v 3319 (br), 2955 (w), 2927 (w), 2869 (w), 1707 (m), 1459 (w), 1426 (w), 1392 (m), 1353 (m), 1291 (m), 1255 (w), 1137 (s), 986 (m), 848 (w), 804 (w), 773 (w), 713 (m), 636 (m), 606 (m), 578 (m) cm⁻¹.

TLC $R_f = 0.56$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for $C_{19}H_{39}N_2O_4S$ 391.2630; Found 391.2636.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-pentylsulfamide (S8i)



Prepared from *N-tert*-butyl-*N*'-pentylsulfamide¹⁹ (1.00 g, 4.49 mmol)
Me Boc₂O (1.27 g, 5.84 mmol), and DMAP (602 mg, 4.92 mmol) in CH₂Cl₂
(21 mL, 0.2 M) following general procedure E. The product was

isolated as a white solid (1.17 g, 80% yield) after purification on a Teledyne Isco CombiFlash R_f system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.30 (br s, 1H), 3.63 (dd, J = 7.6, 7.6 Hz, 2H), 1.72–1.64 (m, 2H), 1.53 (s, 9H), 1.36–1.30 (m, 4H), 1.30 (s, 9H), 0.90 (t, J = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 152.3, 83.3, 55.0, 47.5, 29.4, 29.3, 28.8, 28.1, 22.2, 13.9.

IR (neat) v 3293 (br), 2969 (m), 2934 (m), 2861 (w), 1702 (s), 1440 (m), 1396 (m), 1382 (m), 1368 (m), 1342 (s), 1306 (m), 1278 (m), 1246 (m), 1209 (m), 1165 (s), 1136 (s), 1045 (m), 1000 (m), 935 (m), 867 (w), 843 (m), 794 (m), 769 (m), 713 (s), 640 (s), 590 (m), 564 (s) cm⁻¹. TLC $R_f = 0.57$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{14}H_{30}N_2O_4S$ •Na 345.1824; Found 345.1819.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-hexylsulfamide (S8j)



Prepared from *N-tert*-butyl-*N*'-hexylsulfamide¹⁹ (1.18 g, 5.0 mmol), Boc₂O (1.40 g, 6.5 mmol), and DMAP (671 mg, 5.5 mmol) in CH₂Cl₂ (25 mL, 0.2 M) following general procedure E. The product was obtained as a white solid (1.37 g, 82% yield) after silica gel column

chromatography (20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.30 (br s, 1H), 3.63 (dd, J = 7.6, 7.6 Hz, 2H), 1.71–1.64 (m, 2H), 1.52 (s, 9H), 1.30 (s, 9H), 1.33–1.26 (m, 6H), 0.87 (t, J = 6.7 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 152.2, 83.3, 54.9, 47.5, 31.3, 29.5, 29.4, 28.1, 26.2, 22.5, 13.9.

IR (neat) v 3343 (br w), 2960 (w), 2932 (w), 2860 (w), 1705 (m), 1457 (w), 1425 (w), 1392 (m), 1368 (m), 1353 (s), 1294 (m), 1256 (m), 1164 (s), 1138 (s), 1042 (w), 982 (m), 848 (w), 774 (w), 736 (s), 714 (s), 637 (m), 606 (m), 578 (m) cm⁻¹.

TLC $R_f = 0.34$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₅H₃₂N₂O₄S 335.2010; Found 335.2003.

N-tert-Butyoxycarbonyl-*N'-tert*-butyl-*N*-(methyl hexano-6-yl)sulfamide (S7k)

¹H NMR (400 MHz, CDCl₃) δ 5.29 (br s, 1H), 3.66 (s, 3H), 3.66–3.62 (m, 2H), 2.32 (t, J = 7.5 Hz, 2H), 1.74–1.62 (m, 4H), 1.53 (s, 9H), 1.39–1.33 (m, 2H), 1.30 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 173.9, 152.2, 83.5, 55.0, 51.4, 47.2, 33.9, 29.4, 29.2, 28.1, 26.1, 24.5. IR (neat) v 3312 (br), 2974 (w), 1707 (m), 1426 (w), 1392 (m), 1352 (s), 1293 (w), 1253 (w),

In (near) v 5312 (bf), 2974 (w), 1707 (m), 1426 (w), 1592 (m), 1552 (s), 1295 (w), 1255 (w), 1137 (s), 1040 (w), 987 (m), 918 (w), 847 (m), 773 (w), 712 (s), 635 (m), 577 (m) cm⁻¹. TLC $R_f = 0.25$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for $C_{16}H_{31}N_2O_6S$ 379.1902; Found 379.1901.

N-Acetyl-*N*'-*tert*-butyl-*N*-hexylsulfamide (S8I)

After stirring overnight, the reaction was diluted with deionized H_2O (0.2 M) and the biphasic mixture was transferred to a separatory funnel. The organic phase was removed and the aqueous was extracted twice more with CH_2Cl_2 (2 x 0.2 M). The combined organic layers were dried with MgSO₄, filtered, and concentrated under reduced pressure. The product was obtained as a

colorless oil (678 mg, 97% yield) after silica gel column chromatography (20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.41 (br s, 1H), 3.67 (dd, J = 7.9, 7.9 Hz, 2H), 2.28 (s, 3H), 1.76– 1.69 (m, 2H), 1.35-1.30 (m, 6H), 1.29 (s, 9H), 0.88 (t, J = 6.7 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 171.0, 55.2, 47.9, 31.2, 29.8, 29.3, 26.3, 23.7, 22.4, 13.8.

IR (neat) v 3290 (br), 2958 (w), 2931 (w), 2859 (w), 1669 (m), 1427 (m), 1393 (m), 1348 (s), 1258 (m), 1232 (m), 1205 (m), 1151 (s), 1092 (m), 1039 (m), 1000 (m), 946 (m), 848 (m), 759 (w), 727 (w), 696 (m), 667 (m), 598 (s), 582 (s), 546 (s) cm⁻¹.

TLC $R_f = 0.22$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₂H₂₆N₂O₃S 277.1591; Found 277.1584.

N-tert-Butyl-*N*'-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (S8m)



Me Prepared from *N*-(*leri*-buly1)-12-(2,2,2 unitscore) - (761 mg, 3.3 mmol) and 1-hexanol (0.3 mL, 2.5 mmol) following general procedure F. The product was obtained as a colorless oil (575 Prepared from *N*-(*tert*-butyl)-*N*-(2,2,2-trifluoroethyl)sulfamide¹¹ mg, 72% yield) after silica gel column chromatography (Gradient:

100% hexanes \rightarrow 50:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.98 (br s, 1H), 3.80 (q, J = 9.0 Hz, 2H), 3.27 (dd, J = 8.0, 8.0 Hz, 2H), 1.68-1.60 (m, 2H), 1.34 (s, 9H), 1.31-1.23 (m, 6H), 0.89 (t, J = 6.7 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 124.5 (q, J = 280.4 Hz), 54.7, 49.3, 48.0 (q, J = 34.2 Hz), 31.3,

29.5, 26.9, 26.3, 22.4, 13.8.

¹⁹F NMR (376 MHz, CDCl₃) δ –69.49 (t, *J* = 9.0 Hz).

IR (neat) v 3286 (br), 2959 (w), 2932 (w), 2861 (w), 1780 (w), 1468 (w), 1428 (w), 1393 (w), 1369 (w), 1321 (m), 1273 (m), 1233 (m), 1141 (s), 1040 (m), 986 (m), 867 (m), 832 (w), 771 (m), 725 (w), 665 (m), 607 (m), 562 (m) cm^{-1} .

TLC $R_f = 0.24$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₂H₂₅F₃N₂O₂S 317.1516; Found 317.1510.

N'-tert-Butyl-*N*-trifluoroacetyl-*N*-pentylsulfamide (S8n)



A flame-dried round bottom flask equipped with stir bar was charged and DMAP (90.7 mg, 0.74 mmol, 1.1 equiv). The flask was fitted with a rubber septum and evacuated and backfilled with N₂. CH₂Cl₂ (3.3 mL,

0.2 M) was added followed by triluoroacetic anhydride (TFAA, 0.12 mL, 0.87 mmol, 1.3 equiv). The resulting solution was stirred at 22 °C overnight. After stirring overnight, the solution was concentrated under reduced pressure. The product was isolated as a colorless oil (0.67 mmol scale, 129.3 mg, 60% yield) after purification on a Teledyne Isco CombiFlashRf system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.54 (br s, 1H), 3.79–3.74 (m, 2H), 1.85–1.77 (m, 2H), 1.39–1.34 (m, 4H), 1.31 (s, 9H), 0.91 (t, J = 6.9 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 156.5 (q, J = 38.3 Hz), 115.5 (q, J = 288.9 Hz), 56.2, 47.9, 30.1, 29.3, 28.6, 22.0, 13.8. ¹⁹F NMR (376 MHz, CDCl₃) δ –70.70.

IR (neat) v 3310 (br), 2960 (w), 2875 (w), 1703 (m), 1431 (m), 1396 (m), 1364 (m), 1286 (w), 1232 (m), 1208 (m), 1168 (s), 1148 (s), 1064 (s), 862 (w), 792 (w), 758 (m), 697 (m), 684 (m), $640 \text{ (w)}, 613 \text{ (s)}, 580 \text{ (m)}, 528 \text{ (m)} \text{ cm}^{-1}.$

TLC $R_f = 0.57$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₁H₂₀F₃N₂O₃S 317.1146; Found 317.1151.

N-tert-Butoxycarbonyl-*N*'-(2,2,2-trifluoroethyl)-*N*-hexylsulfamide (S80)



Prepared from sulfamide S5b (1.8 g, 6.5 mmol) and 1-hexanol (0.63 mL, 5.0 mmol) following general procedure F. The product was obtained as a colorless oil (1.59 g, 88% yield) after silica gel column chromatography (hexanes/EtOAc (20:1).

¹H NMR (400 MHz, CDCl₃) δ 5.79 (t, J = 6.5 Hz, 1H), 3.70–3.61 (m, 4H), 1.65–1.59 (m, 2H), 1.52 (s, 9H), 1.32-1.29 (m, 6H), 0.88 (t, J = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 151.8, 123.4 (q, J = 279.0 Hz), 84.4, 48.2, 45.1, (q, J = 35.3 Hz), 31.2, 29.6, 27.8, 26.1, 22.4, 13.9.

¹⁹F NMR (376 MHz, CDCl₃) δ –72.10 (t, J = 8.9 Hz).

IR (neat) v 3302 (br w), 2933 (w), 2861 (w), 1705 (m), 1458 (w), 1369 (m), 1277 (m), 1256 (m), 1139 (s), 1047 (w), 963 (m), 832 (m), 773 (w), 718 (s), 664 (m), 630 (m), 581 (m), 549 (m) cm⁻¹. TLC $R_f = 0.26$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₃H₂₅F₃N₂O₄S 361.1414; Found 361.1405.

N-tert-Butyl-*N*'-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (S8p)



Prepared from *N*-(*tert*-butyl)-*N*-(2,2,2-trifluoroethyl)sulfamide¹¹ (761 mg, 3.3 mmol) and 4-methylpentanol (255 mg, 2.5 mmol) following general procedure F. The product was obtained mg, 91% yield) after silica gel column chromatography (Gradient:

100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.96 (br s, 1H), 3.81 (q, J = 9.0 Hz, 2H), 3.26 (dd, J = 8.0, 8.0 Hz, 2H), 1.69–1.58 (m, 3H), 1.34 (s, 9H), 1.18–1.13 (m, 2H), 0.89 (d, *J* = 6.7 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 124.5 (q, J = 280.6 Hz), 54.7, 49.5, 48.0 (q, J = 34.6 Hz), 35.7, 29.5, 27.6, 24.8, 22.4.

¹⁹F NMR (376 MHz, CDCl₃) δ –69.50 (t, J = 8.8 Hz).

IR (neat) v 3285 (br), 2958 (w), 2873 (w), 1469 (w), 1429 (w), 1393 (w), 1368 (w), 1321 (m), 1274 (m), 1234 (w), 1141 (s), 1041 (m), 985 (s), 929 (w), 904 (w), 871 (m), 831 (w), 770 (m), 731 (m), 664 (m), 607 (m), 562 (m) cm⁻¹.

TLC $R_f = 0.30$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₂H₂₅F₃N₂O₂S 317.1516; Found 317.1508.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-4-methylpentylsulfamide (S8g)



Prepared from sulfamide S5a (820 mg, 3.3 mmol) and 4-methylpentanol (255 mg, 2.5 mmol) following general procedure F The product was obtained as a white solid (794 mg, 94% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.29 (br s, 1H), 3.60 (dd, J = 7.7, 7.7 Hz, 2H), 1.71–1.63 (m, 3H), 1.51 (s, 9H), 1.28 (s, 9H), 1.20–1.14 (m, 2H), 0.87 (d, J = 6.6 Hz, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 152.2, 83.3, 55.0, 47.7, 35.7, 29.4, 28.1, 27.5, 27.4, 22.5. IR (neat) v 3296 (m), 2971 (m), 2871 (w), 1702 (s), 1457 (m), 1442 (m), 1396 (m), 1380 (m), 1369 (m), 1347 (s), 1322 (s), 1283 (m), 1250 (m), 1166 (s), 1137 (s), 1044 (m), 996 (m), 936 (w), 866 (w), 843 (m), 791 (m), 770 (m), 711 (s), 641 (s), 591 (s), 565 (s) cm⁻¹. TLC R_f = 0.32 in 9:1 hexanes:EtOAc. HRMS (ESI) m/z: [M – H]⁻ Calcd for C₁₅H₃₂N₂O₄S 335.2010; Found 335.2005.

N-tert-Butoxycarbonyl-*N*-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (S8r)



Prepared from sulfamide **S5b** (820 mg, 3.3 mmol) and 4methylpentanol (255 mg, 2.5 mmol) following general procedure F The product was obtained as a pale yellow oil (693 mg, 76% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow

20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.82 (t, *J* = 7.2 Hz, 1H), 3.71–3.59 (m, 4H), 1.68–1.58 (m, 3H), 1.52 (s, 9H), 1.21–1.15 (m, 2H), 0.89 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 151.8, 123.4 (q, *J* = 278.6 Hz), 84.3, 48.3, 45.0 (q, *J* = 35.4 Hz), 35.5, 27.8, 27.4, 27.4, 22.3.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.56 (t, *J* = 8.8 Hz).

IR (neat) v 3302 (br), 2956 (w), 2872 (w), 1704 (m), 1458 (w), 1368 (m), 1278 (w), 1139 (s), 1049 (w), 963 (m), 832 (m), 791 (m), 773 (m), 719 (w), 664 (m), 630 (m), 582 (m), 549 (m) cm⁻¹.

TLC $R_f = 0.46$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₃H₂₅F₃N₂O₄S 361.1414; Found 361.1407.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N-(tert*-butyl butano-4-yl)sulfamide (S8t)

^bBu N S N CO₂^bBu Prepared from sulfamide S6s (642 mg, 2.18 mmol), Boc₂O (619 mg, 2.83 mmol), and DMAP (293 mg, 2.40 mmol) in CH₂Cl₂ (11 mL, 0.2 M) following general procedure E. The product was isolated as a colorless oil (651 mg, 76% yield) after purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (500 MHz, CDCl₃) δ 5.29 (br s, 1H), 3.71–3.68 (m, 2H), 2.28 (t, *J* = 7.5 Hz, 2H), 1.98–1.92 (m, 2H), 1.53 (s, 9H), 1.44 (s, 9H), 1.30 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 171.8, 151.9, 83.4, 80.0, 54.8, 46.5, 32.3, 29.2, 27.9, 27.8, 24.8. IR (neat) v 3321 (br), 2970 (w), 1706 (m), 1476 (w), 1453 (w), 1432 (w), 1394 (m), 1367 (m), 1346 (s), 1286 (m), 1258 (m), 1139 (s), 1098 (m), 1041 (w), 994 (m), 946 (w), 864 (w), 847 (m), 794 (w), 774 (m), 753 (w), 735 (w), 710 (m), 631 (m), 591 (m), 575 (m) cm⁻¹. TLC R_f = 0.47 in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for $C_{17}H_{33}N_2O_6S$ 393.2059; Found 393.2056.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (S8u)



Prepared from sulfamide **S6u** (664 mg, 1.9 mmol), Boc_2O (539 mg, 2.5 mmol), and DMAP (262 mg, 2.1 mmol) in CH₂Cl₂ (10 mL, 0.2 M) following general procedure E. The product was obtained as a white solid (742 mg, 86% yield) after silica gel

column chromatography (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 7.54 (d, J = 7.9 Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 5.30 (br s, 1H), 3.69 (t, J = 7.5 Hz, 2H), 2.72 (t, J = 7.7 Hz, 2H), 2.07–1.99 (m, 2H), 1.48 (s, 9H), 1.30 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 152.0, 145.4, 128.6, 128.2 (q, J = 32.3 Hz), 125.2 (q, J = 3.7 Hz), 124.3 (q, J = 271.7 Hz), 83.6, 55.1, 46.8, 32.7, 30.7, 29.4, 28.0. ¹⁹F NMR (376 MHz, CDCl₃) δ –62.38.

IR (neat) v 3296 (br w), 2977 (w), 1718 (m), 1618 (w), 1477 (w), 1462 (w), 1433 (w), 1395 (w), 1381 (w), 1369 (m), 1348 (m), 1328 (s), 1302 (m), 1270 (m), 1253 (m), 1160 (s), 1138 (s), 1112 (s), 1067 (s) 1020 (m), 991 (m), 848 (m), 838 (m), 824 (m), 792 (m), 775 (m), 717 (s), 680 (w), 624 (s), 608 (m), 595 (m), 577 (s) cm⁻¹.

TLC $R_f = 0.24$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{19}H_{29}F_3N_2O_4S\bullet Na$ 461.1692; Found 461.1691.

N-tert-Butoxycarbonyl-*N'*-(2,2,2-trfiluoroethyl)-*N*-pentylsulfamide (S8v)

 $F_3C \longrightarrow_{H} N_{Boc} N_{Boc} M_{Boc} M$

¹H NMR (400 MHz, CDCl₃) δ 5.78 (t, J = 6.9 Hz, 1H), 3.71–3.61 (m, 4H), 1.68–1.60 (m, 2H), 1.53 (s, 9H), 1.39–1.24 (m, 4H), 0.91 (t, J = 6.9 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 152.0, 123.7 (q, *J* = 278.1 Hz), 84.5, 48.4, 45.2 (q, *J* = 36.2 Hz), 29.5, 28.8, 28.0, 22.3, 14.0.

¹⁹F NMR (376 MHz, CDCl₃) δ –72.13 (t, *J* = 8.7 Hz).

IR (neat) v 3300 (br), 2961 (w), 2934 (w), 2873 (w), 1704 (m), 1457 (w), 1368 (m), 1276 (m), 1139 (s), 1044 (w), 1017 (w), 961 (m), 912 (w), 832 (m), 799 (m), 773 (w), 718 (s), 664 (m), 629 (m), 580 (m), 548 (m) cm⁻¹.

TLC $R_f = 0.21$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{12}H_{23}F_3N_2O_4S\bullet Na$ 371.1228; Found 371.1212.

N-tert-Butoxycarbonyl-*N'*-ethyl-*N*-pentylsulfamide (S8w)



Prepared from sulfamide **S5c** (729 mg, 3.25 mmol) and 1-pentanol (0.27 mL, 2.50 mmol) following general procedure F. The product was obtained as a colorless oil (520 mg, 71% yield) after purification

on a Teledyne Isco CombiFlash R_f system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes:EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.19 (t, J = 6.0 Hz, 1H), 3.65–3.61 (m, 2H), 3.06–2.99 (m, 2H), 1.68–1.61 (m, 2H), 1.52 (s, 9H), 1.36–1.26 (m, 4H), 1.19 (t, J = 7.3 Hz, 3H), 0.90 (t, J = 6.8 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 151.8, 83.4, 47.4, 38.6, 29.1, 28.4, 27.7, 21.9, 14.1, 13.6.

IR (neat) v 3311 (br), 2959 (w), 2933 (w), 2872 (w), 1703 (m), 1455 (w), 1424 (w), 1359 (m), 1279 (m), 1257 (m), 1136 (s), 1063 (m), 1044 (w), 1016 (w), 949 (w), 845 (m), 798 (w), 773 (m), 714 (s), 630 (m), 571 (s) cm⁻¹.

TLC $R_f = 0.43$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{12}H_{26}N_2O_4S \cdot Na$ 317.1511; Found 317.1498.

VI. Preparation and characterization of *N*-chlorosulfamides.

General Procedure G: Preparation of N-Chlorosulfamides with Trichloroisocyanuric acid



A flame-dried round bottom flask equipped with stir bar was charged with sulfamide (1.0 equiv) and trichloroisocyanuric acid (TCICA, 1.2 equiv). The flask was evacuated and backfilled with N₂. Anhydrous CH_2Cl_2 (0.2 M) was then added via syringe. The suspension was stirred at 21 °C until complete consumption of the starting material as evidenced by TLC.

The suspension was quenched by addition of H_2O (~0.2 M) and the biphasic mixture was transferred to a separatory funnel rinsing the flask with CH_2Cl_2 (ca. 5 mL) to ensure quantitative transfer. The organic phase was separated and the aqueous phase was extracted with CH_2Cl_2 (2 x ca. 5 mL/mmol sulfamide). The combined organic extracts were dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude reaction mixtures were then purified by flash column chromatography on silica gel or florisil eluting with a hexanes/EtOAc solvent system as noted below.

General Procedure H: Preparation of N-Chlorosulfamides with tert-butyl hypochlorite



A flame-dried round bottom flask equipped with stir bar was charged with sulfamide (1.0 equiv). The flask was evacuated and backfilled with N₂. Anhydrous CH_2Cl_2 (0.2 M) was then added via syringe. To the stirring solution was added neat *tert*-butyl hypochlorite ('BuOCl, equiv indicated below) in portions via syringe until complete consumption of the starting material as evidenced by TLC.

Upon complete consumption of the starting material as indicated by TLC, all volatiles were removed under reduced pressure to afford the pure compound or crude mixtures to be purified as indicated below.

N-tert-Butoxycarbonyl-*N'*-chloro-*N*-ethyl-*N'*-hexylsulfamide (5a)



after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.84 (q, J = 7.0 Hz, 2H), 3.61 (dd, J = 7.1 Hz, 2H), 1.74–1.67 (m, 2), 1.53 (s, 9H), 1.38–1.32 (m, 6H), 1.30 (t, *J* = 7.0 Hz, 3H), 0.89 (t, *J* = 6.8 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 150.5, 84.4, 58.3, 45.9, 31.3, 28.0, 27.5, 25.7, 22.5, 15.0, 14.0. IR (neat) v 2934 (w), 2860 (w), 1731 (m), 1458 (w), 1383 (m), 1368 (m), 1331 (w), 1282 (m), 1254 (m), 1185 (m), 1137 (s), 1087 (w), 1041 (w), 997 (m), 954 (m), 844 (m), 770 (m), 720 (m), 646 (m), 590 (m), 559 (m), 465 (w) cm⁻¹. TLC $R_f = 0.50$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₃H₂₇ClN₂O₄S•Na 365.1272; Found 365.1274.

N-tert-Butoxycarbonyl-*N*'-chloro-*N*'-hexyl-*N*-(2,2,2-trifluoro)ethylsulfamide (5b)

Prepared from suffamilies 570 (101 mg, one line) Me (139 mg, 0.6 mmol) in CH_2Cl_2 (5 mL) following general procedure is shown as a colorless oil (191 mg, 96% yield) Prepared from sulfamide S7b (181 mg, 0.5 mmol) and TCICA

after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.42 (q, J = 8.1 Hz, 2H), 3.67 (dd, J = 7.0 Hz, 2H), 1.75–1.68 (m, 2H), 1.54 (s, 9H), 1.38–1.30 (m, 6H), 0.90 (t, *J* = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 149.5, 123.2 (q, J = 280 Hz), 86.2, 58.7, 49.3 (q, J = 36.3 Hz), 31.2, 27.7, 27.5, 25.6, 22.4, 13.9.

¹⁹F NMR (376 MHz, CDCl₃) δ –70.54 (t, *J* = 8.2 Hz).

IR (neat) v 2935 (w), 1746 (m), 1459 (w), 1389 (m), 1371 (m), 1338 (m), 1296 (w), 1250 (m), 1139 (s), 1046 (m), 1027 (m), 909 (w), 847 (w), 831 (w), 797 (w), 772 (w), 728 (w), 711 (m), 680 (w), 646 (w), 611 (m), 580 (m), 567 (m), 529 (w), 463 (w) cm⁻¹.

TLC $R_f = 0.50$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{13}H_{24}ClF_3N_2O_4S \cdot NH_4$ 414.1436; Found 414.1444.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-neopentylsulfamide (1a)



Prepared from sulfamide S8a (322 mg, 1.0 mmol) and TCICA (279 mg, 1.2 ^tBu N_{Cl} N_{Me} Me_{Me} Me_{Me} chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.71 (s, 2H), 1.54 (s, 9H), 1.52 (s, 9H), 0.93 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 151.0, 84.1, 68.3, 59.4, 33.3, 28.9, 27.8, 27.6.

IR (neat) v 2968 (w), 1737 (m), 1478 (w), 1380 (m), 1365 (s), 1334 (w), 1278 (m), 1252 (m), 1186 (m), 1146 (s), 1073 (m), 1039 (w), 1004 (m), 871 (m), 849 (m), 819 (m), 800 (m), 771 (m), 731 (w), 656 (m), 587 (w) cm⁻¹.

TLC $R_f = 0.56$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₄H₂₉ClN₂O₄S•Na 379.1429; Found 379.1429.

N-tert-Butoxycarbonyl-*N*-butyl-*N*'-tert-butyl-*N*'-chlorosulfamide (1b)



Prepared from sulfamide S8b (308 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a colorless oil (258 mg, 75% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.75 (dd, J = 7.6, 7.6 Hz, 2H), 1.70–1.62 (m, 2H), 1.53 (s, 9H), 1.53 (s, 9H), 1.38–1.29 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 150.3, 84.1, 68.3, 50.1, 31.8, 29.0, 28.0, 19.8, 13.7.

IR (neat) v 2979 (w), 2938 (w), 2877 (w), 1715 (s), 1466 (w), 1440 (w), 1382 (m), 1367 (s), 1336 (m), 1294 (s), 1257 (m), 1184 (m), 1148 (s), 1046 (m), 1021 (m), 1009 (m), 925 (m), 875 (m), 848 (s), 830 (m), 770 (m), 763 (m), 731 (m), 648 (s), 581 (s), 548 (m) cm⁻¹.

TLC $R_f = 0.47$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{13}H_{27}ClN_2O_4S$ •Na 365.1272; Found 365.1281.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-isopentylsulfamide (1c)

^tBu N S N Me L Boc

Prepared from sulfamide **S8c** (208 mg, 0.65 mmol) and TCICA (180 mg, 0.77 mmol) in CH_2Cl_2 (3.2 mL) following general procedure G. The product was isolated as a white solid (161 mg, 70% yield) after silica gel column chromatography (95:5 hexanes/EtOAc).

¹H NMR (500 MHz, C₆D₆) δ 3.90–3.86 (m, 2H), 1.68–1.62 (m, 2H), 1.47–1.42 (m, 1H), 1.35 (s, 9H) 1.33 (s, 9H), 0.76 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 150.3, 84.1, 68.4, 49.0, 38.5, 29.0, 28.0, 26.0, 22.4. IR (neat) v 2957 (w), 2872 (w), 1728 (m), 1380 (m), 1366 (s), 1287 (m), 1257 (m), 1187 (m), 1146 (s), 1046 (m), 1022 (m), 873 (m), 771 (m), 745 (m), 730 (m) cm⁻¹. TLC $R_f = 0.53$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: [M + Na]⁺ Calcd for C₁₄H₂₉ClN₂O₄S•Na 379.1434; Found 379.1428.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(2-(cyclopentyl)eth-1-yl)sulfamide (1d)



Prepared from sulfamide **S8d** (439 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a colorless oil that solidified upon storage at -20 °C (331 mg, 86% yield) after silica gel column chromatography (20:1

hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.75 (dd, J = 7.7, 7.7 Hz, 2H), 1.80–1.75 (m, 3H), 1.74–1.67 (m, 3H), 1.62–1.57 (m, 2H), 1.53 (s, 9H), 1.53 (s, 9H), 1.11–1.18 (m, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 150.3, 84.1, 68.3, 49.8, 37.4, 36.0, 32.4, 29.0, 28.0, 25.1.

IR (neat) v 2943 (w), 2867 (w), 1728 (m), 1454 (w), 1380 (m), 1366 (s), 1335 (m), 1286 (m), 1257 (m), 1187 (m), 1146 (s), 1046 (m), 978 (w), 873 (m), 849 (m), 771 (m), 747 (w), 731 (w), 634 (m), 611 (m), 586 (m) cm⁻¹.

TLC $R_f = 0.57$ in 9:1 hexanes:EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₆H₃₁ClN₂O₄S•Na 405.1585; Found 405.1580.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(2-(cyclohexyl)eth-1-yl)sulfamide (1e)



Prepared from sulfamide **S8e** (363 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a colorless oil (293 mg, 74% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1

hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.79–3.75 (m, 2H), 1.74–1.65 (m, 7H), 1.53 (s, 9H), 1.52 (s, 9H), 1.23–1.13 (m, 4H), 0.98–0.90 (m, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 150.2, 84.0, 68.2, 48.5, 37.0, 35.4, 33.0, 28.9, 27.9, 26.4, 26.1.

IR (neat) v 2979 (w), 2923 (m), 2851(w), 1730 (m), 1449 (w), 1380 (m), 1367 (s), 1334 (w), 1310 (w), 1287 (m), 1257 (m), 1185 (m), 1146 (s), 1043 (w), 1025 (w), 966 (m), 870 (m), 850 (m), 829 (m), 771 (m), 730 (w), 648 (m), 601 (m), 586 (m), 554 (w) cm⁻¹.

TLC $R_f = 0.63$ in 4:1 hexanes:EtOAc

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{17}H_{33}ClN_2O_4S \cdot Na 419.1742$; Found 419.1738.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-((*2R*)-methyl 4-methylpentano-2yl)sulfamide (1f)

⁷Bu N S N I Boc Cl Me Me

Prepared from sulfamide **S8f** (280 mg, 0.74 mmol) and TCICA (205 mg, 0.88 mmol) in CH_2Cl_2 (3.7 mL) following general procedure G. The product was obtained as a colorless oil (228 mg, 75% yield) after purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal phase

silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.77 (dd, J = 7.1, 5.5 Hz, 1H), 3.74 (s, 3H), 2.22 (ddd, J = 13.9, 6.8, 6.8 Hz, 1H), 1.92–1.82 (m, 1H), 1.70 (ddd, J = 14.0, 7.2, 5.4 Hz, 1H), 1.56 (s, 9H), 1.50 (s, 9H), 0.96 (t, J = 7.0 Hz, 6H).

¹³C NMR (101 MHz, CDCl₃) δ 170.5, 149.4, 84.9, 69.2, 59.8, 52.3, 40.4, 29.0, 27.8, 25.7, 22.6, 22.3.

IR (neat) v 2956 (w), 2871 (w), 1746 (m), 1459 (w), 1382 (m), 1366 (s), 1295 (m), 1236 (m), 1209 (m), 1186 (m), 1143 (s), 1044 (m), 1029 (m), 986 (w), 948 (w), 919 (w), 868 (m), 835 (m), 770 (m), 723 (m), 664 (w), 613 (s), 589 (m) cm⁻¹.

TLC $R_f = 0.49$ in 8:2 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{16}H_{31}ClN_2O_6S \cdot Na 437.1489$; Found 437.1485.

N-tert-Butoxycarbonyl-*N*'-*tert*-butyl-*N*'-chloro-*N*-((*S*)-2-(1,3-dioxoisoindolin-2-yl)-3-methylbutyl)sulfamide (1g)



Prepared from sulfamide **S8g** (468 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a white foam (403 mg, 80% yield) after silica gel column chromatography (Gradient: 20:1 hexanes:EtOAc \rightarrow 9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 7.84 (dd, J = 3.1, 5.3 Hz, 2H), 7.68 (dd, J = 3.1, 5.3 Hz, 2H), 4.44 (dd, J = 10.8, 14.5, 1H), 4.17 (ddd, J = 2.5, 2.5, 10.8, 1H), 4.09 (dd, J = 2.5, 14.5 Hz, 1H), 2.64–2.55 (m, 1H), 1.45 (s, 9H), 1.43 (s, 9H), 1.15 (d, J = 6.6 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 168.4, 149.8, 133.6, 131.9, 131.4, 123.1, 122.8, 84.5, 68.2, 57.3, 49.3, 28.7, 27.7, 27.2, 20.3, 20.0.

IR (neat) v 2976 (w), 1776 (w), 1713 (s), 1468 (w), 1384 (m), 1368 (m), 1318 (w), 1288 (w), 1258 (w), 1189 (w), 1150 (m), 1064 (w), 1009 (w), 991 (w), 875 (w), 845 (w), 771 (w), 722 (m), 644 (w), 588 (w), 530 (w) cm⁻¹.

TLC $R_f = 0.33$ in 4:1 hexanes:EtOAc

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{22}H_{32}ClN_3O_6S \cdot NH_4$ 519.2039; Found 519.2045.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(3,7-dimethyloct-1-yl)sulfamide (1h)



Prepared from sulfamide **S8h** (709 mg, 1.8 mmol) and TCICA (504 mg, 2.2 mmol) in CH_2Cl_2 (9 mL) following general procedure G. The product was isolated as a colorless oil (662 mg, 86% yield) after purification on a Teledyne Isco

 $CombiFlashR_f$ system using a Redi Sep R_f normal phase silica gel column (95:5 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.79–3.70 (m, 2H), 1.75–1.67 (m, 2H), 1.57–1.48 (m, 19H), 1.33– 1.22 (m, 4H), 1.16–1.11 (m, 3H), 0.91 (d, *J* = 6.4 Hz, 3H), 0.86 (d, *J* = 6.7 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 150.2, 84.0, 68.3, 48.8, 39.1, 37.0, 36.7, 30.8, 29.0, 28.0, 27.9, 24.6, 22.7, 22.6, 19.4.

IR (neat) v 2954 (w), 2928 (w), 2869 (w), 1730 (m), 1458 (w), 1380 (m), 1366 (s), 1284 (m), 1257 (m), 1147 (s), 1042 (w), 1018 (w), 957 (w), 873 (m), 850 (m), 771 (w), 731 (m), 645 (m), 586 (m) cm⁻¹.

TLC $R_f = 0.66$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₉H₃₉ClN₂O₄S•Na 449.2216; Found 449.2213.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-pentylsulfamide (1i)



Prepared from sulfamide S8i (500 mg, 1.55 mmol) and TCICA (432 mg, 1.86 mmol, 1.20 equiv) in CH₂Cl₂ (8.3 mL) following general procedure G. The product was isolated as a colorless oil (503 mg, 91% yield) after purification on Florisil by solid deposition (95:5

hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.76–3.72 (m, 2H), 1.72–1.64 (m, 2H), 1.53 (s, 9H), 1.53 (s, 9H), 1.38–1.26 (m, 4H), 0.89 (t, *J* = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 150.3, 84.1, 68.3, 50.2, 29.3, 28.9, 28.7, 28.0, 22.2, 13.9.

IR (neat) v 2958 (w), 2934 (w), 2872 (w), 1729 (m), 1458 (w), 1380 (m), 1366 (s), 1333 (w), 1282 (m), 1256 (m), 1186 (m), 1147 (m), 1043 (m), 1017 (m), 962 (w), 874 (m), 848 (m), 823 (m), 770 (m), 727 (m), 644 (m), 633 (m), 585 (s) cm⁻¹.

TLC $R_f = 0.49$ in 9:1 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{14}H_{29}ClN_2O_4S$ •Na 379.1434; Found 379.1427.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-hexylsulfamide (1j)

Prepared from sulfamide S8j (336 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a colorless oil (291 mg, 79% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.74 (dd, J = 7.6, 7.6 Hz, 2H), 1.69–1.65 (m, 2H), 1.53 (s, 9H), 1.53 (s, 9H), 1.53 (s, 9H), 1.32–1.27 (m, 6H), 0.87 (t, J = 6.7 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 150.3, 84.1, 68.3, 50.3, 31.3, 29.6, 28.9, 28.0, 26.2, 22.5, 14.0. IR (neat) v 2932 (w), 2859 (w), 1729 (m), 1458 (w), 1381 (m), 1367 (s), 1333 (w), 1285 (m), 1257 (m), 1185 (m), 1148 (s), 1046 (m), 984 (w), 912 (w), 873 (m), 849 (m), 770 (m), 731 (s), 646 (m), 634 (m), 587 (s) cm⁻¹.

TLC $R_f = 0.57$ in 9:1 hexanes:EtOAc. HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{15}H_{31}ClN_2O_4S$ •Na 393.1585; Found 393.1585.

N-tert-Butyoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(methyl hexano-6-yl)sulfamide (1k)



Prepared from sulfamide **S8k** (266 mg, 0.7 mmol) and TCICA (195 mg, 0.84 mmol) in CH_2Cl_2 (3.5 mL) following general procedure G. The product was obtained as a colorless oil (217 mg, 75% yield) after silica gel column chromatography (Gradient:

100% hexanes \rightarrow 9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.74 (d, *J* = 7.4, 7.4 Hz, 2H), 3.65 (s, 3H), 2.31 (t, *J* = 7.5 Hz, 2H), 1.72–1.61 (m, 4H), 1.53 (s, 9H), 1.52 (s, 9H), 1.38–1.30 (m, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 173.9, 150.3, 84.2, 68.4, 51.4, 49.9, 33.9, 29.3, 28.9, 28.0, 26.0, 24.4.

IR (neat) v 2981 (w), 2940 (w), 1279 (s), 1437 (w), 1380 (m), 1366 (s), 1335 (w), 1285 (m), 1257 (m), 1146 (s), 1042 (w), 1009 (w), 874 (m), 848 (m), 770 (w), 730 (m), 634 (m), 586 (s) cm⁻¹.

TLC $R_f = 0.44$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{16}H_{31}ClN_2O_6S \cdot NH_4$ 432.1930; Found 432.1937.

N-Acetyl-*N*'-*tert*-butyl-*N*'-chloro-*N*-hexylsulfamide (11)

^{*t*}Bu, N, S, N, C, Me Prepared from sulfamide S8I (278 mg, 1.0 mmol) and 'BuOCl (217 mg, 2.0 mmol) in CH₂Cl₂ (5 mL) following general procedure H. The product was obtained as a colorless oil (235 mg, 75% yield) after

silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.78 (dd, J = 7.8, 7.8 Hz, 2H), 2.54 (s, 3H), 1.66–1.59 (m, 2H), 1.55 (s, 9H), 1.26–1.31 (m, 6H), 0.88 (t, J = 6.8 Hz, 3H).

¹³C NMR (126 MHz, C₆D₆) δ 169.5, 68.5, 49.1, 31.6, 29.4, 28.7, 26.7, 24.6, 22.8, 14.1.

¹³C NMR (101 MHz, CDCl₃) δ 170.2, 68.9, 49.0, 31.3, 28.9, 26.3, 24.7, 22.5, 14.0.

IR (neat) v 2931 (w), 2858 (w), 1709 (m), 1462 (w), 1400 (w), 1365 (s), 1329 (w), 1232 (m), 1177 (s), 1162 (s), 1092 (m), 1040 (w), 948 (m), 912 (w), 864 (m), 823 (m), 781 (m), 732 (m), 709 (w), 678 (w), 649 (w), 602 (s), 583 (s), 554 (m) cm⁻¹.

TLC $R_f = 0.43$ in 9:1 hexanes:EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{12}H_{25}ClN_2O_3S$ •Na 335.1167; Found 335.1175.

N-tert-Butyl-*N*-chloro-*N*'-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (1m)

0,	o /	
'Bu S	$\sim \sim$	∼Me
L CI	L	
•		

Prepared from sulfamide **S8m** (318 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a colorless oil (318 mg, 90% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1

hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.93 (q, J = 8.7 Hz, 2H), 3.38 (dd, J = 8.1, 8.1 Hz, 2H), 1.73–1.65 (m, 2H), 1.50 (s, 9H), 1.34–1.28 (m, 6H), 0.89 (t, J = 6.8 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 123.8 (q, J = 280.1 Hz), 67.7, 50.8, 50.5 (q, J = 35.2 Hz), 31.2, 28.9, 26.8, 26.2, 22.5, 13.9.

¹⁹F NMR (376 MHz, CDCl₃) δ –70.11 (t, *J* = 8.7 Hz).

IR (neat) v 2933 (w), 2860 (w), 1466 (w), 1399 (w), 1359 (m), 1314 (w), 1274 (m), 1238 (w), 1151 (s), 1119 (m), 1043 (m), 994 (m), 875 (m), 820 (m), 785 (m), 733 (m), 663 (m), 603 (m), $564 (m) cm^{-1}$.

TLC $R_f = 0.57$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{12}H_{24}ClF_3N_2O_2S \cdot NH_4$ 370.1537; Found 370.1539.

N'-tert-Butyl-*N'*-chloro-*N*-trifluoroacetyl-*N*-pentylsulfamide (1n)

Prepared from sulfamide S8n (284 mg, 0.89 mmol) and 'BuOCl (4.2 ⁶ Prepared from sulfamide **S8n** (284 mg, 0.89 mmol) and 'BuOCl (4.2 mL, 37.2 mmol, 2 x 21 equiv portions, 2nd portion added after 24 h) following general procedure H. The product was isolated as a colorless cil (272 mg, 870/ viald) without purification oil (273 mg, 87% yield) without purification.

¹H NMR (400 MHz, CDCl₃) δ 3.87-3.82 (m, 2H), 1.78-1.72 (m, 2H), 1.57 (s, 9H), 1.38-1.28 (m, 4H), 0.91 (t, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 155.8 (q, J = 40.4 Hz), 115.3 (q, J = 291.0 Hz), 70.3, 50.1, 29.5, 29.0, 28.5, 22.0, 13.8.

¹⁹F NMR (376 MHz, CDCl₃) δ –69.75.

IR (neat) v 2960 (w), 2874 (w), 1741 (m), 1464 (w), 1390 (m), 1371 (m), 1231 (m), 1209 (m), 1155 (s), 1128 (s), 1060 (m), 969 (w), 874 (m) 784 (m), 754 (m), 715 (m), 688 (m), 615 (s), 581 (m), 537 (m) cm^{-1} .

TLC $R_f = 0.29$ in 98:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for $C_{11}H_{19}ClF_3N_2O_3S$ 351.0757; Found 351.0764.

N-tert-Butoxycarbonyl-*N*'-chloro-*N*'-(2,2,2-trifluoroethyl)-*N*-hexylsulfamide (10)



Prepared from sulfamide S80 (382 mg, 1.0 mmol) and TCICA \sim_{Me} (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a colorless oil (378 mg, 95% yield) after silica gel column chromatography (Gradient:

100% hexanes \rightarrow 50:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.28 (q, J = 8.2 Hz, 2H), 3.74 (dd, J = 7.7, 7.7 Hz, 2H), 1.75–1.68 (m, 2H), 1.54 (s, 9H), 1.36-1.27 (m, 6H), 0.90 (t, J = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 150.8, 123.2 (q, J = 279.3 Hz), 85.2, 59.5 (q, J = 36.1 Hz), 50.8, 31.3, 29.5, 27.9, 26.1, 22.5, 13.9.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.64 (t, *J* = 8.3 Hz).

IR (neat) v 2934 (w), 2860 (w), 1730 (m), 1458 (w), 1382 (m), 1372 (m), 1338 (w), 1305 (m), 1274 (m), 1255 (m), 1137 (s), 1045 (w), 967 (m), 841 (m), 820 (m), 772 (w), 721 (s), 697 (m), 641 (w), 617 (w), 563 (s) cm⁻¹.

TLC $R_f = 0.50$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₃H₂₄ClF₃N₂O₄S 395.1025; Found 395.1023.

N-tert-Butyl-*N*-chloro-*N*'-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (1p)



Prepared from sulfamide **S8p** (318 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a colorless oil (306 mg, 87% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1

hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.93 (q, *J* = 8.5 Hz, 2H), 3.37 (dd, *J* = 7.7, 7.7 Hz, 2H), 1.74–1.66 (m, 2H), 1.61–1.54 (m, 1H), 1.49 (s, 9H), 1.20–1.15 (m, 2H), 0.90 (d, *J* = 6.6 Hz, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 123.8 (q, *J* = 280.1 Hz), 67.7, 51.0, 50.4 (q, *J* = 35.5 Hz), 35.6,

28.9, 27.6, 24.7, 22.4.

¹⁹F NMR (376 MHz, CDCl₃) δ –70.13 (t, *J* = 8.7 Hz).

IR (neat) v 2957 (w), 2873 (w), 1466 (w), 1360 (m), 1313 (m), 1275 (m), 1238 (w), 1180 (m), 1152 (s), 1120 (m), 1042 (m), 991 (m), 875 (m), 822 (m), 786 (m), 765 (w), 735 (w), 663 (m), 604 (m), 564 (m) cm⁻¹.

TLC $R_f = 0.57$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₂H₂₄ClF₃N₂O₂S 353.1272; Found 353.1279.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-4-methylpentylsulfamide (1q)

Prepared from sulfamide **S8q** (336 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a white solid (284 mg, 77% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1

hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.72 (dd, *J* = 7.4 Hz, 2H), 1.71–1.64 (m, 3H), 1.53 (s, 9H), 1.52 (s, 9H), 1.20–1.15 (m, 2H), 0.87 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 150.3, 84.1, 68.3, 50.5, 35.6, 29.0, 28.0, 27.6, 27.5, 22.5.

IR (neat) v 2956 (w), 2871 (w), 1729 (m), 1458 (w), 1380 (m), 1366 (s), 1331 (w), 1284 (m), 1257 (m), 1186 (m), 1147 (s), 1048 (m), 981 (m), 874 (m), 793 (m), 771 (m), 730 (m), 645 (m), 634 (m), 586 (s) cm⁻¹.

TLC $R_f = 0.55$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₅H₃₁ClN₂O₄S•Na 393.1585; Found 393.1587.

N-tert-Butoxycarbonyl-*N*'-chloro-*N*-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (1r)

F₃C	0 NS CI	O N Boc	Me Me
			INC
			INC

Prepared from sulfamide **S8r** (362 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL) following general procedure G. The product was obtained as a colorless oil (357 mg, 90% yield) after product (Candianty 100% have no 50.1 have n

silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.28 (q, *J* = 8.2 Hz, 2H), 3.72 (dd, *J* = 7.7, 7.7 Hz, 2H), 1.75–1.68 (m, 2H), 1.59–1.55 (m, 1H), 1.54 (s, 9H), 1.22–1.16 (m, 2H), 0.89 (d, *J* = 6.5 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 150.8, 123.2 (q, *J* = 279.4 Hz), 85.2, 59.5 (q, *J* = 35.4 Hz), 50.9, 35.5, 27.8, 27.5, 27.4, 22.4.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.56 (t, *J* = 8.3 Hz).

IR (neat) v 2958 (w), 2872 (w), 1730 (m), 1459 (w), 1382 (m), 1371 (m), 1335 (w), 1305 (m), 1274 (m), 1138 (s), 1047 (w), 967 (m), 841 (m), 822 (m), 794 (m), 772 (w), 721 (s), 697 (m), 641 (w), 617 (w), 563 (s) cm⁻¹.

TLC $R_f = 0.49$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₃H₂₄ClF₃N₂O₄S 397.1170; Found 397.1166.

N-tert-Butoxycarbonyl-*N'*-tert-butyl-*N*-(*tert*-butyl butano-4-yl)-*N'*-chlorosulfamide (S9t)



Following a modified literature procedure,⁶ a flame-dried round bottom flask equipped with a stir bar and shielded from light with aluminum foil was charged with sulfamide **S8t** (200 mg, 0.51 mmol, 1.0 equiv) by brief removal of the septum. The septum was tightly

replaced and the flask was sequentially charged with EtOAc (0.91 mL, 0.56 M), 'BuOH (48 μ L, 0.51 mmol, 1.0 equiv), 0.9 M aqueous bleach solution (3.8 mL, 3.39 mmol, 6.7 equiv), and AcOH (0.29 mL, 5.07 mmol, 10 equiv) via syringe. The biphasic mixture was stirred until complete consumption of the starting material as was evident by TLC.

Upon complete consumption of the starting material as indicated by TLC, the reaction was diluted with EtOAc (19.7 mL/mmol of sulfamide) and the biphasic mixture was partitioned in a separatory funnel. The aqueous phase was separated and the organic phase was rinsed with saturated aqueous NaHCO₃ solution (19.7 mL/mmol sulfamide), saturated aqueous NaCl solution (19.7 mL/mmol sulfamide), and H₂O (19.7 mL/mmol sulfamide). The organic phase was collected, dried over Na₂SO₄, filtered, & concentrated to afford the crude product. The product was isolated as a colorless oil (168 mg, 77% yield) after purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.81 (t, *J* = 7.1 Hz, 2H), 2.26 (t, *J* = 7.5 Hz, 2H), 1.99–1.93 (m, 2H), 1.54 (s, 9H), 1.53 (s, 9H), 1.44 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 172.0, 150.2, 84.4, 80.3, 49.3, 32.5, 28.9, 28.0, 28.0, 25.0. IR (neat) v 2979 (w), 2935 (w), 1726 (s), 1457 (w), 1380 (m), 1365 (s), 1334 (w), 1285 (m), 1256 (m), 1143 (s), 1099 (m), 1040 (w), 997 (w), 874 (m), 847 (m), 769 (m), 730 (w), 632 (m), 586 (m) cm⁻¹.

TLC $R_f = 0.61$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{17}H_{33}ClN_2O_6S$ •Na 451.1645; Found 451.1644.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(3-((4-trifluoromethyl)phenyl)prop-1-yl) sulfamide (S9u)



Prepared from sulfamide **S8u** (439 mg, 1.0 mmol) and TCICA (279 mg, 1.2 mmol) in CH₂Cl₂ (5 mL, 0.2 M) following general procedure G. The product was obtained as colorless oil that solidified upon storage at -20 °C (449 mg, 95% yield) after silica

gel column chromatography (20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, J = 8.1 Hz, 2H), 7.31 (d, J = 8.1 Hz, 2H), 3.81 (t, J = 7.5 Hz, 2H), 2.71 (t, J = 7.9 Hz, 2H), 2.08–2.00 (m, 2H), 1.53 (s, 9H), 1.52 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 150.2, 145.3, 128.6, 128.3 (q, J = 32.4 Hz), 125.3 (q, J = 3.7 Hz), 124.3 (q, J = 271.6 Hz), 84.4, 68.5, 49.6, 32.7, 30.8, 28.9, 27.9. ¹⁹F NMR (376 MHz, CDCl₃) δ –62.37.

IR (neat) v 2985 (w), 1731 (w), 1618 (w), 1458 (w), 1380 (m), 1368 (m), 1324 (m), 1285 (w), 1265 (m), 1148 (m), 1121 (m), 1067 (m), 1018 (w), 996 (w), 951 (w), 875 (w), 843 (w), 798 (w), 782 (w), 734 (s), 704 (m), 627 (m), 587 (m) cm⁻¹.

TLC $R_f = 0.5$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for C₁₉H₂₈ClF₃N₂O₄S•NH₄ 490.1749; Found 490.1740.

N-tert-Butoxycarbonyl-*N*'-chloro-*N*'-(2,2,2-trifluoroethyl)-*N*-pentylsulfamide (S9v)



 F_3C N_L B_{oc} Me Prepared from sultamide Sov (220 Hig, 0.00 Hintor) and 1.00 mg, 0.78 mmol) following general procedure G. The product was isolated as a colorless oil (229 mg, 92% yield) after purification on a Prepared from sulfamide S8v (228 mg, 0.65 mmol) and TCICA (182 Teledyne Isco CombiFlashRf system using a Redi Sep Rf normal

phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.28 (q, J = 8.2 Hz, 2H), 3.76–3.72 (m, 2H), 1.75–1.68 (m, 2H), 1.53 (s, 9H), 1.36–1.29 (m, 4H), 0.91 (t, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 150.8, 123.2 (q, J = 279.3 Hz), 85.2, 59.5 (q, J = 35.3 Hz), 50.7, 29.2, 28.6, 27.9, 22.2, 13.9.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.55 (t, J = 8.2 Hz).

IR (neat) v 2961 (w), 2873 (w), 1729 (m), 1458 (w), 1381 (m), 1371 (m), 1338 (w), 1305 (m), 1272 (m), 1137 (s), 1043 (w), 1017 (w), 966 (m), 840 (m), 817 (m), 771 (w), 720 (s), 697 (m), 640 (w), 616 (w), 563 (s) cm⁻¹.

TLC $R_f = 0.61$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{12}H_{22}ClF_3N_2O_4S \cdot NH_4$ 400.1284; Found 400.1269.

N-tert-Butoxycarbonyl-*N*'-chloro-*N*'-ethyl-*N*-pentylsulfamide (S9w)



Prepared from sulfamide S8w (175 mg, 0.59 mmol) and 'BuOCl (1.4 Me N. Boc Me mL, 12.4 mmol) following general procedure H. The product was isolated as a colorless oil (180 mg, 92% yield) after purification on a Teledyne Isco CombiFlashRf system using a Redi Sep Rf normal

phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.77–3.73 (m, 2H), 3.69 (q, J = 7.0 Hz, 2H), 1.75–1.68 (m, 2H), 1.52 (s, 9H), 1.37-1.25 (m, 4H), 1.32 (t, J = 7.0 Hz, 3H), 0.90 (t, J = 7.0 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 150.5, 84.4, 53.3, 50.4, 29.3, 28.6, 27.9, 22.2, 13.9, 13.1.

IR (neat) v 2934 (w), 2872 (w), 1730 (m), 1457 (w), 1368 (m), 1335 (w), 1280 (m), 1256 (m), 1179 (m), 1136 (s), 1042 (m), 1015 (m), 961 (w), 846 (m), 802 (w), 770 (m), 720 (m), 642 (m), $606 \text{ (m)}, 584 \text{ (m)}, 570 \text{ (m)}, 534 \text{ (m)} \text{ cm}^{-1}.$

TLC $R_f = 0.61$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₂H₂₅ClN₂O₄S•Na 351.1121; Found 351.1108.
VII. Preparation and characterization of y-chlorinated sulfamides.



A flame-dried vial equipped with a stir bar was charged with sulfamide (1.0 equiv, 0.2 mmol). The vial was transferred to a nitrogen-filled glovebox where it was charged with anhydrous benzene (PhH, 0.04 M). The vial was sealed with a Teflon lined screw cap and removed from the glovebox. The vial was placed on a stir plate in the center of a Southern New England Ultraviolet Co. RPR-100 Photochemical Reactor barrel and irradiated with 16 ultraviolet lamps until consumption of the starting material as indicated by TLC or ¹H NMR analysis of a smaller scale reaction set up simultaneously.

Upon consumption of starting material as evidenced by TLC or ¹H NMR, the solution was concentrated under reduced pressure and the crude material was purified as noted below.

N-tert-Butoxycarbonyl-*N'*-(4-chloro-hex-1-yl)-*N*-ethylsulfamide (6a)

 $O_{\rm N} O_{\rm Boc} N = {\rm e}^{\delta} O_{\rm R} O_{\rm Cl} {\rm e}^{\delta} O_{\rm R} O_{\rm Cl} {\rm e}^{\delta} O_{\rm R} O_{\rm Cl} {\rm e}^{\delta} O_{\rm R} O_{$

purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.27 (t, J = 6.4 Hz, 1H), 3.86–3.80 (m, 1H), 3.72 (q, J = 7.0 Hz, 2H), 2.98 (dt, J = 6.4, 6.4 Hz, 2H), 1.85–1.68 (m, 6H), 1.53 (s, 9H), 1.2 (t, J = 7.0 Hz, 3H), 1.03 (t, J = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 151.9, 83.8, 64.7, 43.2, 42.8, 34.8, 31.6, 28.0, 26.0, 15.0, 10.9. IR (neat) v 3315 (br), 2977 (w), 2937 (w), 1704 (m), 1457 (w), 1425 (w), 1368 (m), 1335 (m), 1280 (m), 1257 (m), 1185 (m), 1138 (s), 1085 (m), 1000 (w), 954 (w), 897 (w), 844 (w), 816 (w), 774 (w), 736 (m), 715 (s), 631 (m), 569 (m), 464 (w) cm⁻¹.

TLC $R_f = 0.21$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₃H₂₇ClN₂O₄S•Na 365.1272; Found 365.1271.

N-tert-Butoxycarbonyl-*N'*-(4-chloro-hex-1-yl)-*N*-(2,2,2-trifluoro)ethylsulfamide (6b)



Prepared from chlorosulfamide 5b (79 mg, 0.2 mmol) according to F_3C N_{boc} N C_I N_{c_1} N_{c_1}

hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.33 (t, J = 6.2 Hz, 1H), 4.31 (q, J = 8.3 Hz, 2H), 3.86–3.80 (m, 1H), 3.07 (dt, J = 6.3 Hz, 2H), 1.84-1.68 (m, 6H), 1.53 (s, 9H), 1.03 (t, J = 7.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 150.9, 123.4 (q, J = 280.5 Hz), 85.6, 64.7, 47.1 (q, J = 35.4 Hz), 43.3, 34.7, 31.5, 27.8, 26.0, 10.9.

¹⁹F NMR (376 MHz, CDCl₃) δ –70.85 (t, J = 8.3 Hz).

IR (neat) v 3323 (br), 2979 (w), 1723 (m), 1423 (w), 1397 (w), 1370 (m), 1344 (m), 1298 (w), 1265 (m), 1252 (m), 1142 (s), 1079 (w), 1046 (w), 1028 (w), 965 (w), 897 (w), 849 (w), 830 (w), 795 (w), 775 (w), 736 (s), 704 (s), 643 (m), 577 (m), 530 (w), 463 (w), 421 (w) cm⁻¹. TLC $R_f = 0.21$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for C₁₃H₂₄ClF₃N₂O₄S•NH₄ 414.1436; Found 414.1438.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-2,2-dimethylprop-1-yl)sulfamide (4a)



Prepared from chlorosulfamide 1a (71 mg, 0.2 mmol) according to general procedure I. After irradiating for 15 minutes, the product was isolated as a white solid (67 mg, 94% yield) following purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.43 (br s, 1H), 3.73 (s, 2H), 3.44 (s, 2H), 1.54 (s, 9H), 1.28 (s, 9H), 1.08 (s, 6H).

¹³C NMR (101 MHz, CDCl₃) δ 152.4, 84.0, 54.9, 54.3, 54.1, 38.0, 29.4, 28.0, 23.6.

IR (neat) v 3296 (br m), 2969 (m), 2938 (w), 1705 (s), 1471 (m), 1441 (m), 1394 (m), 1366 (m), 1350 (s), 1293 (m), 1278 (m), 1254 (m), 1164 (s), 1141 (s), 1041 (w), 1005 (m), 912 (m), 894 (w), 864 (w), 844 (m), 791 (m), 773 (m), 757 (m), 707 (s), 605 (s), 576 (s) cm⁻¹.

TLC $R_f = 0.24$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₄H₂₉ClN₂O₄S 355.1464; Found 355.1461.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chlorobut-1-yl)sulfamide (4b)

^o ^o ^{cl} Prepared from chlorosulfamide **1b** (69 mg, 0.2 mmol) according to general procedure I. After irradiating for 15 minutes, the product was isolated as a white solid (64 mg, 93% yield) following purification by

silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, C₆D₆) δ 5.37 (br s, 1H), 3.98–3.91 (m, 1H), 3.85–3.79 (m, 1H), 3.76–3.68 (m, 1H), 2.17-2.09 (m, 1H), 2.05-1.96 (m, 1H), 1.32 (s, 9H), 1.14 (d, J = 6.6 Hz, 3H), 1.04 (s, 9H).

¹H NMR (400 MHz, CDCl₃) δ 5.32 (br s, 1H), 4.09–4.00 (m, 1H), 3.92–3.85 (m, 1H), 3.82–3.75 (m, 1H), 2.18–2.10 (m, 1H), 2.08–1.98 (m, 1H), 1.55 (d, J = 6.3 Hz, 3H), 1.54 (s, 9H), 1.31 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 152.0, 83.9, 55.7, 55.1, 45.0, 39.8, 29.4, 28.1, 25.4.

IR (neat) v 3292 (br), 2978 (w), 2927 (w), 1714 (m), 1474 (w), 1440 (m), 1394 (m), 1365 (m), 1348 (s), 1335 (s), 1301 (m), 1256 (m), 1204 (w), 1163 (s), 1137 (s), 1073 (m), 1043 (m), 993 (m), 956 (m), 872 (m), 850 (m), 810 (m), 767 (m), 714 (s), 684 (m), 601 (s), 576 (s) cm⁻¹. TLC $R_f = 0.22$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: [M – H][–] Calcd for C₁₃H₂₇ClN₂O₄S 341.1307; Found 341.1302.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3-methylbut-1-yl)sulfamide (4c)



Prepared from chlorosulfamide 1c (71 mg, 0.2 mmol) according to general procedure I. After irradiating for 1 hour, the product was isolated as a white solid (70 mg, 98% yield) after purification by filtration over a pad of Florisil (EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.32 (br s, 1H), 3.91–3.87 (m, 2H), 2.15–2.11 (m, 2H), 1.61 (s, 6H), 1.54 (s, 9H), 1.32 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 152.0, 83.8, 68.2, 55.1, 44.4, 44.2, 32.5, 29.4, 28.1.

IR (neat) v 3321 (br), 2970 (w), 1713 (m), 1431 (w), 1394 (w), 1370 (w), 1349 (w), 1297 (m), 1250 (w), 1219 (w), 1161 (m), 1135 (m), 1000 (m), 932 (w), 844 (m), 804 (w), 775 (w), 759 (w), 712 (m), 600 (m), 579 (m) cm⁻¹.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₄H₂₈ClN₂O₄S 355.1458; Found 355.1464.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(1-chlorocyclopent-1-yl)ethyl)sulfamide (4d)

The product was obtained following purification in 94% yield (72 mg) after irradiating for 3 h in ⁱPrOAc (2.0 mL, 0.1 M) in front of two 26W CFL bulbs (1600 lumens).

¹H NMR (400 MHz, CDCl₃) δ 5.32 (br s, 1H), 3.96–3.92 (m, 2H), 2.24–2.20 (m 2H), 2.15–2.08 (m, 2H), 1.97–1.91 (m, 2H), 1.79–1.71 (m, 4H), 1.53 (s, 9H), 1.31 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 152.1, 83.7, 80.0, 55.1, 44.9, 42.4, 42.3, 29.4, 28.1, 23.0. IR (neat) v 3325 (br w), 2974 (w), 1711 (m), 1426 (w), 1393 (w), 1355 (m), 1290 (w), 1247 (w), 1164 (m), 1142 (m), 1068 (w), 982 (w), 850 (w), 775 (w), 716 (w), 622 (w), 574 (w) cm⁻¹. TLC R_f = 0.29 in 9:1 hexanes:EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{16}H_{31}ClN_2O_4S$ •Na 405.1585; Found 405.1584.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(1-chlorocyclohex-1-yl)ethyl)sulfamide (4e)

Ő,	0	\bigcap
′Bu S N H		

Prepared from chlorosulfamide 1e (79 mg, 0.2 mmol) according to general procedure I. After irradiating for 15 minutes, the product was isolated as a white solid (75 mg, 95% yield) following purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 9:1

hexanes/EtOAc).

 $\label{eq:hardenergy} \begin{array}{l} ^{1}\text{H NMR (400 MHz, CDCl_3) } \delta \ 5.32 \ (br \ s, 1H), \ 3.94-3.90 \ (m, 2H), \ 2.14-2.10 \ (m, 2H), \ 1.96-1.91 \ (m, 2H), \ 1.73-1.66 \ (m, 2H), \ 1.61-1.57 \ (m, 4H), \ 1.53 \ (s, 9H), \ 1.30 \ (s, 9H), \ 1.26-1.20 \ (m, 2H). \ 1^{3}\text{C NMR (126 MHz, CDCl_3) } \delta \ 152.1, \ 83.7, \ 73.4, \ 55.1, \ 43.7, \ 43.4, \ 39.7, \ 29.4, \ 28.1, \ 25.3, \ 22.1. \ IR \ (neat) \ \nu \ \ 3221 \ (br), \ 2976 \ (w), \ 2934 \ (m), \ 2864 \ (w), \ 1708 \ (m), \ 1446 \ (w), \ 1425 \ (w), \ 1393 \ (m), \ 1352 \ (s), \ 1300 \ (m), \ 1277 \ (m), \ 1254 \ (m), \ 1229 \ (m), \ 1160 \ (s), \ 1138 \ (s), \ 1040 \ (w), \ 977 \ (m), \ 849 \ (m), \ 798 \ (w), \ 774 \ (m), \ 713 \ (s), \ 612 \ (m), \ 589 \ (m), \ 569 \ (m) \ cm^{-1}. \ TLC \ R_f = 0.45 \ in \ 4:1 \ hexanes: EtOAc. \end{array}$

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{17}H_{33}ClN_2O_4S$ •Na 419.1742; Found 419.1742.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N-((2R)*-methyl 4-chloro-4-methylpentano-2yl)sulfamide (4f)



Prepared from chlorosulfamide 1f (83 mg, 0.2 mmol) according to general procedure I. After irradiating for 1 hour, the product was isolated as a

colorless oil that solidified upon standing (67 mg, 81% yield) after purification on a Teledyne Isco CombiFlash R_f system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.33 (br s, 1H), 5.09 (t, *J* = 4.4 Hz, 1H), 3.76 (s, 3H), 2.97 (dd, *J* = 15.3, 5.4 Hz, 1H), 2.17 (dd, 15.3, 3.7 Hz, 1H), 1.67 (s, 3H), 1.62 (s, 3H), 1.49 (s, 9H), 1.37 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 170.7, 151.4, 84.7, 69.1, 56.9, 56.1, 52.6, 47.6, 32.7, 32.6, 29.5, 28.0.

IR (neat) v 3307 (br), 2977 (w), 2360 (w), 2340 (w), 1750 (m), 1718 (m), 1652 (w), 1558 (w), 1540 (w), 1506 (w), 1473 (w), 1456 (w), 1436 (w), 1395 (w), 1370 (m), 1352 (m), 1314 (w), 1249 (w), 1147 (m), 1115 (w), 998 (w), 844 (w), 774 (w), 711 (w), 667 (w), 614 (w), 576 (w) cm⁻¹.

TLC $R_f = 0.30$ in 8:2 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{16}H_{31}ClN_2O_6S$ •Na 437.1489; Found 437.1492.

N-tert-Butoxycarbonyl-*N*'-*tert*-butyl-*N*-((*S*)-2-(1,3-dioxoisoindolin-2-yl)-3-chloro-3-methylbutyl)sulfamide (4g)



Prepared from chlorosulfamide **1g** (100 mg, 0.2 mmol) according to general procedure I. After irradiating for 15 minutes, the product was isolated a white solid (85 mg, 85% yield) following purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 9:1

hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 7.88–7.83 (m, 2H), 7.71–7.69 (m, 2H), 5.26 (br s, 1H), 4.92 (dd, J = 2.2, 10.8 Hz, 1H), 4.78 (dd, J = 10.8, 14.5 Hz, 1H), 4.19 (dd, J = 2.2, 14.5 Hz, 1H), 1.85 (s, 3H), 1.67 (s, 3H), 1.56 (s, 9H), 1.23 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 168.5, 168.2, 151.7, 134.1, 133.8, 132.0, 131.4, 123.5, 123.3, 84.7, 69.8, 59.1, 55.1, 44.3, 31.3, 30.4, 29.3, 28.1.

IR (neat) v 3308 (br), 2977 (w), 2935 (w), 1780 (w), 1717 (s), 1468 (w), 1428 (w), 1393 (m), 1356 (m), 1334 (m), 1249 (w), 1164 (m), 1140 (m), 1074 (w), 1042 (w), 991 (w), 957 (w), 876 (w), 848 (w), 794 (w), 774 (w), 721 (m), 710 (m), 604 (w), 577 (w), 531 (w) cm⁻¹.

TLC $R_f = 0.16$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{22}H_{32}ClN_3O_6S \cdot Na 524.1593$; Found 524.1591.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3,7-dimethyloct-1-yl)sulfamide (4h)

 ^{V}Bu , ^{V}H ,

purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes/EtOAc).

The product was obtained following purification in 95% yield (81 mg) after irradiating for 2 h in ¹PrOAc (2.0 mL, 0.1 M) in front of two 26W CFL bulbs (1600 lumens).

¹H NMR (400 MHz, CDCl₃) δ 5.32 (br s, 1H), 3.90–3.86 (m, 2H), 2.20–2.13 (m, 1H), 2.10–2.03 (m, 1H), 1.76–1.68 (m, 2H), 1.55 (s, 3H), 1.54 (s, 9H), 1.48–1.42 (m, 2H), 1.31 (s, 9H), 1.21–1.15 (m, 3H), 0.88 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 152.0, 83.7, 72.2, 55.1, 44.6, 44.0, 42.6, 38.9, 29.6, 29.4, 28.1, 27.7, 22.5, 22.5, 22.2.

IR (neat) v 3340 (br), 2953 (w), 1709 (m), 1425 (w), 1392 (w), 1351 (m), 1294 (m), 1245 (w), 1139 (s), 986 (w), 912 (w), 848 (w), 802 (w), 773 (w), 713 (m), 606 (m), 576 (m) cm⁻¹. TLC $R_f = 0.49$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₉H₃₈ClN₂O₄S 425.2240; Found 425.2245.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloropent-1-yl)sulfamide (4i)

Prepared from chlorosulfamide **1i** (71 mg, 0.2 mmol) according to "Bu, "S", "Me" Prepared from chlorosulfamide **1i** (71 mg, 0.2 mmol) according to general procedure I. After irradiating for 15 minutes, the product was isolated as a colorless oil (53 mg, 75% yield) after purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal phase silica gel column (Gradient: 100% hexanes \rightarrow 8:2 hexanes/Et₂O).

In order to determine the ratio of γ -chlorinated: δ -chlorinated isomers, duplicate reactions of chlorosulfamide **1i** (11 mg, 0.03 mmol) were subjected to general procedure I. After irradiating for 15 minutes, each sample was concentrated under reduced pressure and 1,2,4,5-tetrachloro-3-nitrobenzene (1.0 equiv) was added as an internal standard. ¹H NMR analysis of the crude reaction mixtures revealed a 8.8:1.0 mixture of γ -chlorinated: δ -chlorinated isomers as an average of 2 runs.

Sample 1: 88% yield γ -chlorinated 4i, 8% yield δ -chlorinated 7i, 7% yield protodehalogenated S8i.

Sample 2: 85% yield γ -chlorinated 4i, 9% yield δ -chlorinated 7i, 5% yield protodehalogenated S8i.

¹H NMR (400 MHz, CDCl₃) δ 5.32 (br s, 1H), 3.95–3.75 (m, 3H), 2.20–2.12 (m, 1H), 2.08–1.98 (m, 1H), 1.85–1.69 (m, 2H), 1.54 (s, 9H), 1.30 (s, 9H), 1.03 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 152.1, 83.9, 62.4, 55.1, 45.1, 37.7, 31.6, 29.4, 28.1, 10.8.

IR (neat) v 3318 (br), 2973 (w), 1707 (m), 1392 (m), 1351 (m), 1286 (m), 1252 (m), 1138 (s), 986 (m), 911 (w), 847 (m), 793 (w), 773 (w), 712 (s), 603 (m), 577 (m) cm⁻¹.

TLC $R_f = 0.54$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₄H₂₉ClN₂O₄S•Na 379.1434; Found 379.1428.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chlorohex-1-yl)sulfamide (4j)



► Prepared from chlorosulfamide 1j (74 mg, 0.2 mmol) according to general procedure I. After irradiating for 15 minutes, the product was isolated as a white solid (62 mg, 84% yield) following purification by

silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

In order to determine the ratio of γ -chlorinated: δ -chlorinated isomers, duplicate reactions of chlorosulfamide **1j** (11 mg, 0.03 mmol) were subjected to general procedure I. After irradiating for 15 minutes, each sample was concentrated under reduced pressure and 1,2,4,5-tetrachloro-3-nitrobenzene (1.0 equiv) was added as an internal standard. ¹H NMR analysis of the crude

reaction mixtures revealed a 14.0:1.0 mixture of γ -chlorinated: δ -chlorinated isomers as an average of 2 runs.

Sample 1: 84% yield γ -chlorinated 4**i**, 6% yield δ -chlorinated 7**i**, 9% yield protodehalogenated **S8i**.

Sample 2: 84% yield γ -chlorinated 4j, 6% yield δ -chlorinated 7j, 8% yield protodehalogenated **S8j**.

¹H NMR (400 MHz, CDCl₃) δ 5.32 (br s, 1H), 3.95–3.88 (m, 2H), 3.83–3.75 (m, 1H), 2.20–2.12 (m, 1H), 2.07–1.98 (m, 1H), 1.75–1.69 (m, 2H), 1.54 (s, 9H), 1.49–1.40 (m, 2H), 1.30 (s, 9H), 0.92 (t, J = 7.3 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 152.0, 83.8, 60.6, 55.1, 45.0, 40.5, 38.0, 29.4, 28.1, 19.5, 13.4. IR (neat) v 3316 (br w), 2969 (w), 2874 (w), 1708 (m), 1426 (w), 1393 (m), 1352 (s), 1291 (m), 1256 (m), 1139 (s), 1042 (w), 986 (m), 848 (m), 810 (w), 772 (m), 713 (s), 604 (m), 578 (s) cm⁻¹. TLC $R_f = 0.22$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: [M – H]⁻ Calcd for C₁₅H₃₁ClN₂O₄S 369.1620; Found 369.1617.

N-tert-Butyoxycarbonyl-*N'-tert*-butyl-*N*-(methyl 4-chlorohexano-6-yl)sulfamide (4k)



Prepared from chlorosulfamide 1k (83 mg, 0.2 mmol) according to ${}^{t}Bu \xrightarrow{N} S \xrightarrow{N} CO_{2}Me$ general procedure I. After irradiating for 15 minutes, the product was isolated as a colorless oil (69 mg, 83% yield) following purification by silica gel column chromatography (Gradient: 100%

hexanes \rightarrow 9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.31 (br s, 1H), 3.99–3.87 (m, 2H), 3.83–3.76 (m, 1H), 3.68 (s, 3H), 2.61–2.49 (m, 2H), 2.21–1.95 (m, 4H), 1.53 (s, 9H), 1.30 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 173.1, 152.0, 84.0, 59.7, 55.2, 51.7, 44.8, 38.1, 33.4, 30.8, 29.4, 28.1.

IR (neat) v 3315 (br), 2976 (w), 1711 (m), 1436 (w), 1393 (w), 1352 (m), 1290 (m), 1255 (m), 1139 (s), 989 (m), 916 (w), 848 (m), 792 (w), 773 (w), 712 (m), 604 (m), 576 (m) cm⁻¹. TLC $R_f = 0.29$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{16}H_{31}ClN_2O_6S \cdot NH_4 432.1930$; Found 432.1930.

N-Acetyl-*N*'-*tert*-butyl-*N*-(3-chlorohex-1-yl)sulfamide (41)



 ${}^{\prime}Bu$, N, N_{Ac} , N_{C} , N

by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

In order to determine the ratio of γ -chlorinated: δ -chlorinated isomers, duplicate reactions of chlorosulfamide 11 (9 mg, 0.03 mmol) were subjected to general procedure I. After irradiating for 15 minutes, each sample was concentrated under reduced pressure and 1,2,4,5-tetrachloro-3nitrobenzene (1.0 equiv) was added as an internal standard. ¹H NMR analysis of the crude reaction mixtures revealed a 22.5:1.0 mixture of γ -chlorinated: δ -chlorinated isomers as an average of 2 runs.

Sample 1: 89% yield γ -chlorinated 4I, 4% yield δ -chlorinated 7I. Sample 2: 93% yield γ -chlorinated 4I, 4% yield δ -chlorinated 7I. ¹H NMR (400 MHz, CDCl₃) δ 5.42 (br s, 1H), 3.99–3.92 (m, 2H), 3.90–3.82 (m, 1H), 2.33 (s, 3H), 2.30–2.23 (m, 1H), 2.06–1.97 (m, 1H), 1.77–1.71 (m, 2H), 1.55–1.42 (m, 2H), 1.31 (s, 9H), 0.98 (t, *J* = 7.4 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 171.1, 60.7, 55.5, 45.5, 40.5, 38.2, 29.5, 23.9, 19.5, 13.4.

IR (neat) v 3290 (br), 2962 (w), 2874 (w), 1673 (m), 1426 (m), 1394 (m), 1348 (s), 1265 (m), 1232 (m), 1154 (s), 1098 (w), 1039 (w), 1001 (m), 927 (m), 853 (m), 771 (m), 736 (s), 702 (m), 663 (m), 605 (s), 546 (s) cm⁻¹.

TLC $R_f = 0.22$ in 4:1 hexanes:EtOAc.

HRMS (ESI) m/z: [M – H]⁻ Calcd for C₁₂H₂₅ClN₂O₃S 311.1202; Found 311.1195.

N-tert-Butyl-*N'*-(3-chlorohex-1-yl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (4m)



Prepared from chlorosulfamide **1m** (71 mg, 0.2 mmol) according to general procedure I. After irradiating for 15 minutes, the product was isolated as a colorless oil (69 mg, 97% yield) following purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.00 (br s, 1H), 3.94–3.88 (m, 1H), 3.81 (qd, J = 8.8, 2.7 Hz, 2H), 3.59–3.42 (m, 2H), 2.21–2.14 (m, 1H), 2.04–1.95 (m, 1H), 1.74–1.69 (m, 2H), 1.59–1.42 (m, 2H), 1.35 (s, 9H), 0.93 (t, J = 7.4 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 124.4 (q, J = 281.1 Hz), 60.7, 55.1, 49.0 (q, J = 34.2 Hz), 47.4, 36.1, 29.6, 19.5, 13.4.

¹⁹F NMR (376 MHz, CDCl₃) δ –69.71 (t, *J* = 8.9 Hz).

IR (neat) v 3288 (br), 2963 (w), 2876 (w), 1465 (w), 1429 (w), 1393 (w), 1369 (w), 1317 (m), 1272 (m), 1231 (w), 1140 (s), 1081 (m), 1042 (m), 981 (m), 929 (w), 908 (w), 870 (m), 832 (w), 740 (m), 665 (m), 604 (m), 566 (m) cm⁻¹.

TLC $R_f = 0.20$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₂H₂₄ClF₃N₂O₂S 351.1126; Found 351.1118.

N'-tert-Butyl-*N*-(3-chloropent-1-yl)-*N*-trifluoroacetylsulfamide (4n)



Prepared from chlorosulfamide **1n** (71 mg, 0.2 mmol) according to general procedure I at 0.013 M. After irradiating for 15 minutes, the product was isolated as a colorless oil (45 mg, 63% yield) after purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal phase silica gel column (95:5 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.57 (br s, 1H), 4.15 (ddd, *J* = 15.9, 11.1, 5.3 Hz, 1H), 3.91–3.82 (m, 2H), 2.29–2.11 (m, 2H), 1.86–1.73 (m, 2H), 1.32 (s, 9H), 1.05 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 156.2 (q, *J* = 38.6 Hz), 115.0 (q, *J* = 274.6 Hz), 61.6, 56.1, 45.4, 37.7, 31.3, 29.1, 10.5.

¹⁹F NMR (376 MHz, CDCl₃) δ –70.75.

IR (neat) v 3311 (br), 2975 (w), 1705 (m), 1431 (w), 1396 (m), 1364 (m), 1320 (w), 1227 (m), 1210 (m), 1167 (s), 1081 (m), 1059 (m), 997 (m), 862 (w), 791 (w), 758 (m), 691 (m), 612 (s), 580 (m), 529 (m) cm⁻¹.

TLC $R_f = 0.49$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for $C_{11}H_{19}ClF_3N_2O_3S$ 351.0757; Found 351.0765.

N-tert-Butoxycarbonyl-*N*-(3-chlorohex-1-yl)-*N*'-(2,2,2-trfiluoroethyl)sulfamide (40)

Prepared from chlorosulfamide **10** (74 mg, 0.19 mmol) according to general procedure I. After irradiating for 15 minutes, the product was isolated as a colorless oil (58 mg, 79% yield) following

purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

In order to determine the ratio of γ -chlorinated: δ -chlorinated isomers, duplicate reactions of chlorosulfamide **1o** (12 mg, 0.03 mmol) were subjected to general procedure I. After irradiating for 15 minutes, each sample was concentrated under reduced pressure and 1,2,4,5-tetrachloro-3-nitrobenzene (1.0 equiv) was added as an internal standard. ¹H NMR analysis of the crude reaction mixtures revealed a 10.5:1.0 mixture of γ -chlorinated: δ -chlorinated isomers as an average of 2 runs.

Sample 1: 77% yield γ -chlorinated **40**, 7% yield δ -chlorinated **70**, 14% protodehalogenated **S80**. Sample 2: 79% yield γ -chlorinated **40**, 8% yield δ -chlorinated **70**, 20% protodehalogenated **S80**.

¹H NMR (400 MHz, CDCl₃) δ 5.82 (t, J = 6.9 Hz, 1H), 3.93–3.86 (m, 2H), 3.80–3.74 (m, 1H), 3.70–3.64 (m, 2H), 2.14–2.05 (m, 1H), 2.05–1.94 (m, 1H), 1.74–1.67 (m, 2H), 1.52 (s, 9H), 1.47–1.39 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 151.6, 123.4 (q, *J* = 278.3 Hz), 84.9, 60.2, 45.7, 45.2 (q, *J* = 36.0 Hz), 40.5, 38.1, 27.9, 19.5, 13.4.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.93 (t, *J* = 9.0 Hz).

IR (neat) v 3309 (br), 2964 (w), 1712 (m), 1456 (w), 1371 (m), 1265 (m), 1144 (s), 963 (w), 832 (w), 734 (s), 704 (s), 664 (m), 583 (m), 550 (m) cm⁻¹.

TLC $R_f = 0.21$ in 9:1 hexanes/EtOAc.

HRMS (ESI) m/z: [M – H][–] Calcd for C₁₃H₂₄ClF₃N₂O₄S 395.1025; Found 395.1015.

N-tert-Butyl-*N*'-(3-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (4p)



Prepared from chlorosulfamide **1p** (71 mg, 0.2 mmol) according to general procedure I. After irradiating for 15 minutes, the product was isolated as a colorless oil (50 mg, 70% yield) following purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1

hexanes/EtOAc).

In order to determine the ratio of γ -chlorinated: δ -chlorinated isomers, duplicate reactions of chlorosulfamide **1p** (11 mg, 0.03 mmol) were subjected to general procedure I. After irradiating for 15 minutes, each sample was concentrated under reduced pressure and 2-bromo-5-(trifluoromethyl)pyridine (1.0 equiv) was added as an internal standard. ¹⁹F NMR analysis of the crude reaction mixtures revealed a 13:1.0 mixture of γ -chlorinated: δ -chlorinated isomers as an average of 2 runs.

Sample 1: 64% yield γ -chlorinated **4p**, 6% yield δ -chlorinated **7p**, 7% yield of β -chlorinated **S11p**, and 14% yield of protodehalogenated **S8p**.

Sample 2: 66% yield γ -chlorinated **4p**, 5% yield δ -chlorinated **7p**, 7% yield of β -chlorinated **S11p**, and 10% yield of protodehalogenated **S8p**.

¹H NMR (400 MHz, CDCl₃) δ 4.11 (br s, 1H), 3.84–3.78 (m, 3H), 3.56 (ddd, J = 14.8, 9.9, 4.9Hz, 1H), 3.44 (ddd, J = 15.4, 9.9, 6.1 Hz, 1H), 2.17–2.09 (m, 1H), 2.04–1.91 (m, 2H), 1.34 (s, 9H), 1.02 (d, J = 6.7 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 124.4 (q, J = 280.7 Hz), 67.2, 55.1, 49.0 (q, J = 33.8 Hz), 34.6, 33.6, 29.7, 19.7, 17.4.

¹⁹F NMR (376 MHz, CDCl₃) δ –69.70 (t, J = 9.0 Hz).

IR (neat) v 3289 (br), 2969 (w), 1464 (w), 1426 (w), 1392 (m), 1369 (w), 1323 (m), 1272 (m), 1229 (w), 1141 (s), 1084 (m), 1043 (m), 981 (m), 928 (w), 906 (w), 870 (w), 823 (w), 738 (s), 704 (w), 664 (m), 604 (m), 561 (m) cm^{-1} .

TLC $R_f = 0.32$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₂H₂₄ClF₃N₂O₂S 351.1126; Found 351.1118.



Chlorosulfamide 1q (74 mg, 0.2 mmol) was subjected to general procedure I. After irradiating for 15 minutes, products 4q and 5q (73 mg, 98% yield) were isolated as a mixture following purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 9:1 hexanes/EtOAc).

In order to determine the ratio of 4q:7q, duplicate reactions of chlorosulfamide 1q (11 mg, 0.03) mmol) were subjected to general procedure I. After irradiating for 1 hour, each sample was concentrated under reduced pressure and 1,2,4,5-tetrachloro-3-nitrobenzene (1.0 equiv) was added as an internal standard. ¹H NMR analysis of the crude reaction mixtures revealed a 2.0:1.0 mixture of 4q:7q as an average of 2 runs.

Sample 1: 68% yield 4q, 35% yield 7q. Sample 2: 69% yield 4q, 35% yield 7q.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-4-methylpentyl)sulfamide (4q)



Isolated for characterization by silica gel column chromatography ${}^{t}Bu$, S, Me (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc) from a mixture of chlorinated isomers (4q and 7q).

¹H NMR (400 MHz, CDCl₃) δ 5.33 (br s, 1H), 3.93 (ddd, J = 14.6, 9.2, 5.0 Hz, 1H), 3.86–3.73 (m, 2H), 2.15–2.00 (m, 2H), 1.99–1.91 (m, 1H), 1.54 (s, 9H), 1.30 (s, 9H), 1.02 (d, J = 6.7 Hz, 3H), 0.98 (d, J = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 152.1, 83.9, 67.2, 55.1, 45.5, 35.6, 34.5, 29.4, 28.1, 19.7, 17.4. IR (neat) v 3313 (br), 2971 (w), 1708 (m), 1426 (w), 1393 (m), 1352 (s), 1292 (m), 1250 (m), 1138 (s), 1042 (w), 986 (m), 848 (m), 772 (m), 713 (s), 631 (m), 604 (m), 578 (m) cm⁻¹. TLC $R_f = 0.47$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₅H₃₁ClN₂O₄S 369.1620; Found 369.1614.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(4-chloro-4-methylpentyl)sulfamide (7g)

Isolated for characterization by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes/EtOAc) from a mixture of chlorinated isomers (4q and 7q).

¹H NMR (400 MHz, CDCl₃) δ 5.32 (br s, 1H), 3.68 (t, J = 7.3 Hz, 2H), 1.94–1.86 (m, 2H), 1.78– 1.74 (m, 2H), 1.57 (s, 6H), 1.54 (s, 9H), 1.30 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 152.2, 83.6, 70.3, 55.1, 47.3, 42.7, 32.4, 29.4, 28.1, 25.4.

IR (neat) v 3318 (br), 2974 (w), 2932 (w), 1707 (m), 1457 (w), 1425 (w), 1393 (m), 1368 (m), 1353 (s), 1292 (m), 1257 (m), 1138 (s), 1040 (w), 984 (m), 847 (m), 790 (w), 774 (m), 713 (s), $580 (s) cm^{-1}$.

TLC $R_f = 0.43$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₅H₃₁ClN₂O₄S 369.1520; Found 369.1615.



Chlorosulfamide 1r (79 mg, 0.2 mmol) was subjected to general procedure I. After irradiating for 1 hour, products 4r and 7r (66 mg, 84% yield) were isolated as a mixture following purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes/acetone).

In order to determine the ratio of 4r:7r, duplicate reactions of chlorosulfamide 1r (12 mg, 0.03 mmol) were subjected to general procedure I. After irradiating for 1 hour, each sample was concentrated under reduced pressure and 1.2.4.5-tetrachloro-3-nitrobenzene (1.0 equiv) was added as an internal standard. ¹H NMR analysis of the crude reaction mixtures revealed a 1.0:1.9 mixture of **4r**:**7r** and 13% protodehalogenated material as an average of two runs.

Sample 1: 30% yield 4r, 57% yield 7r, 13% yield protodehalogenated S8r.

Sample 2: 30% yield 4r, 56% yield 7r, 13% yield protodehalogenated S8r.

N-tert-Butoxycarbonyl-*N*-(3-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (4r)

 $V_{\text{N}} \stackrel{\text{Cl}}{\xrightarrow{}} V_{\text{Boc}} \stackrel{\text{Cl}}{\xrightarrow$ chlorinated isomers (4r and 7r) that had already been purified by the

column conditions used to isolate the mixture (Gradient: 100% hexanes \rightarrow 50:1 hexanes/acetone).

¹H NMR (400 MHz, CDCl₃) δ 5.86 (t, J = 6.9 Hz, 1H), 3.93 (ddd, J = 14.5, 9.4, 5.1 Hz, 1H), 3.81-3.66 (m, 4H), 2.11-1.99 (m, 2H), 1.98-1.91 (m, 1H), 1.54 (s, 9H), 1.02 (d, J = 6.7 Hz, 3H),0.99 (d, J = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 151.7, 123.4 (q, J = 278.1 Hz), 85.0, 66.8, 46.2, 45.3 (q, J = 35.6) Hz), 35.6, 34.5, 27.9, 19.7, 17.4.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.93 (t, J = 8.8 Hz).

IR (neat) v 3302 (br), 2971 (w), 1706 (m), 1456 (w), 1369 (m), 1342 (m), 1292 (m), 1276 (m), 1140 (s), 962 (m), 831 (m), 772 (m), 718 (s), 664 (m), 625 (m), 582 (m), 549 (m) cm⁻¹.

TLC $R_f = 0.41$ in 4:1 hexanes:EtOAc. HRMS (ESI) m/z: $[M - H]^-$ Calcd for $C_{13}H_{24}ClF_3N_2O_4S$ 395.1025; Found 395.1015.

N-tert-Butoxycarbonyl-*N*-(4-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (7r)

 $F_{3}C \xrightarrow{N}_{H} \overset{\delta}{\underset{Boc}{\overset{N}{\overset{N}}}} \overset{Me}{\underset{Me}{\overset{\delta}{\overset{N}}}} \overset{Me}{\underset{Me}{\overset{\delta}{\overset{N}}}}$

Isolated for characterization by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes/EtOAc) from a mixture of chlorinated isomers (4r and 7r) that had already been purified by the

column conditions used to isolate the mixture (Gradient: 100% hexanes \rightarrow 50:1 hexanes/acetone).

¹H NMR (400 MHz, CDCl₃) δ 5.84 (t, *J* = 7.0 Hz, 1H), 3.73–3.65 (m, 4H), 1.91–1.83 (m, 2H), 1.76–1.72 (m, 2H), 1.58 (s, 6H), 1.53 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 151.7, 123.4 (q, *J* = 278.8 Hz), 84.7, 70.1, 47.9, 45.2 (q, *J* = 35.4 Hz), 42.5, 32.4, 27.9, 25.5.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.93 (t, *J* = 8.9 Hz).

IR (neat) v 3300 (br), 2978 (w), 1707 (m), 1457 (w), 1369 (m), 1340 (m), 1291 (m), 1276 (m), 1141 (s), 1008 (w), 963 (w), 832 (m), 793 (w), 774 (w), 719 (s), 664 (m), 630 (m), 584 (m), 549 (m) cm⁻¹.

TLC $R_f = 0.38$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for $C_{13}H_{24}ClF_3N_2O_4S$ 395.1025; Found 395.1014.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N-(tert*-butyl 2-chlorobutano-4-yl)sulfamide (S10t)

^vBu N B_{oc} C_{0_2} ^tBu C_{0_2} ^tBu

¹H NMR (400 MHz, CDCl₃) δ 5.30 (br s, 1H), 4.24 (dd, *J* = 8.5, 4.8 Hz, 1H), 3.84 (t, *J* = 7.4 Hz, 2H), 2.42–2.33 (m, 1H), 2.29–2.22 (m, 1H), 1.54 (s, 9H), 1.49 (s, 9H), 1.30 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 167.8, 151.9, 84.1, 83.0, 55.9, 55.2, 44.1, 34.4, 29.4, 28.1, 27.7. IR (neat) v 3318 (br), 2977 (w), 2935 (w), 1710 (m), 1476 (w), 1425 (w), 1393 (w), 1368 (m), 1353 (m), 1293 (m), 1254 (m), 1139 (s), 1040 (w), 988 (w), 912 (w), 845 (m), 773 (w), 711 (m), 604 (m), 576 (m) cm⁻¹.

TLC $R_f = 0.17$ in 6:4 CH₂Cl₂/hexanes. HRMS (ESI) m/z: [M – H]⁻ Calcd for C₁₇H₃₂ClN₂O₆S 427.1669; Found 427.1664.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3-((4-trifluoromethyl)phenyl)prop-1-yl) sulfamide (S10u)



Prepared from chlorosulfamide **S9u** (94 mg, 0.2 mmol) according to general procedure I. After irradiating for 2 hours, the product was isolated as a white solid (46 mg, 49% yield) after two purifications by silica gel column chromatography (100% PhH).

¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, *J* = 8.3 Hz, 2H), 7.53 (d, *J* = 8.3 Hz, 2H), 5.31 (br s, 1H), 4.94 (dd, *J* = 7.5 Hz, 6.6 Hz, 1H), 3.76–3.92 (m, 2H), 2.41–2.46 (m, 2H), 1.53 (s, 9H), 1.30 (s, 9H).

¹³C NMR (126 MHz, CDCl₃, ¹H and ¹⁹F decoupled) δ 151.9, 144.8, 130.6, 127.3, 125.8, 123.8, 84.2, 59.5, 55.3, 44.9, 39.3, 29.4, 28.1.

¹⁹F NMR (376 MHz, CDCl₃) δ –62.73.

IR (neat) v 3325 (br w), 2977 (w), 1709 (m), 1620 (w), 1422 (w), 1394 (m), 1369 (m), 1353 (m), 1323 (s), 1294 (m), 1257 (m), 1160 (s), 1125 (s), 1092 (w), 1068 (s), 1042 (w), 1017 (w), 990 (w), 845 (m), 774 (w), 714 (m), 626 (w), 603 (m), 579 (w) cm⁻¹.

TLC $R_f = 0.24$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{19}H_{28}ClF_3N_2O_4S\bullet Na$ 495.1303; Found 495.1298.

N-tert-Butoxycarbonyl-*N*-(3-chloropent-1-yl)-*N*'-(2,2,2-trfiluoroethyl)sulfamide (S10v)

^o ^o ^c ^c ⁿ ^s ^s ⁿ ^b ^s ⁿ ^b ^s ⁿ ^s ⁿ ^s ⁿ ^s ⁿ ^s ⁿ ^s ⁿ ^s ⁿ ⁿ ^s ^s ⁿ ^s ^s ⁿ ^s ^s ⁿ ^s ^s

Teledyne Isco CombiFlash R_f system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.92 (t, J = 7.1 Hz, 1H), 3.94–3.65 (m, 5H), 2.15–1.95 (m, 2H), 1.84–1.69 (m, 2H), 1.53 (s, 9H), 1.03 (t, J = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 151.6, 123.4 (q, *J* = 278.7 Hz), 84.9, 62.1, 45.2 (q, *J* = 35.1 Hz), 37.7, 31.6, 27.9, 10.8.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.95 (t, *J* = 8.9 Hz).

IR (neat) v 3302 (br), 2976 (w), 1707 (m), 1368 (m), 1277 (m), 1140 (s), 1045 (w), 831 (m), 795 (m), 773 (m), 718 (s), 663 (m) cm⁻¹.

TLC $R_f = 0.36$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{12}H_{22}ClF_3N_2O_4S\bullet NH_4$ 400.1284; Found 400.1269.

N-tert-Butoxycarbonyl-*N*-(3-chloropent-1-yl)-*N*'-ethylsulfamide (S10w)



Prepared from chlorosulfamide **S9w** (66 mg, 0.2 mmol) according to general procedure I. After irradiating for 45 minutes, the product was isolated as a colorless oil (29 mg, 44% yield) after purification on a

Teledyne Isco CombiFlash R_f system using a Redi Sep R_f normal phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.24 (t, *J* = 6.2 Hz, 1H), 3.95–3.74 (m, 3H), 3.03 (qd, *J* = 7.2, 5.9 Hz, 2H), 2.16–1.96 (m, 2H), 1.85–1.68 (m, 2H), 1.53 (s, 9H), 1.19 (t, *J* = 7.3 Hz, 3H), 1.03 (t, *J* = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 151.6, 83.9, 62.0, 45.1, 38.7, 37.6, 31.3, 27.8, 14.1, 10.6.

IR (neat) v 3310 (br), 2975 (w), 2937 (w), 1705 (m), 1345 (m), 1286 (m), 1251 (m), 1137 (s), 1063 (m), 846 (m), 794 (m), 773 (m), 714 (s) cm⁻¹.

TLC $R_f = 0.33$ in 8:2 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{12}H_{25}ClN_2O_4S$ •Na 351.1121; Found 351.1110.

VIII. Preparation and characterization of non-y-chlorinated sulfamides.

N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(4-chloropent-1-yl)sulfamide (7i)



Prepared from sulfamide S5a (268 mg, 1.1 mmol) and 4- Bu , ${}^{N}_{H}$, ${}^{\delta}_{Boc}$, ${}^{\delta}_{CI}$, ${}^{\delta}_{$

Redi Sep R_f normal phase silica gel column (Gradient: 100% hexanes \rightarrow 9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.30 (br s, 1H), 4.09–4.01 (m, 1H), 3.68 (t, J = 3.7 Hz, 2H), 1.94– 1.89 (m, 1H), 1.85–1.71 (m, 3H), 1.53 (s, 9H), 1.52 (d, J = 10.5 Hz, 3H), 1.30 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 152.0, 83.5, 57.9, 54.9, 46.6, 37.0, 29.3, 28.0, 26.6, 25.2.

IR (neat) v 3293 (br), 2975 (m), 2933 (w), 2872 (w), 1699 (s), 1396 (m), 1369 (m), 1346 (s), 1307 (m), 1287 (m), 1254 (m), 1203 (m), 1164 (s), 1135 (s), 1072 (m), 1043 (m), 1001 (m), 869 (w), 843 (m), 794 (m), 769 (m), 711 (s), 677 (m), 642 (s) cm^{-1} .

TLC $R_f = 0.51$ in 8:2 hexanes: EtOAc.

HRMS (ESI) m/z: [M – H]⁻ Calcd for C₁₄H₂₈ClN₂O₄S 355.1458; Found 355.1457.

N-tert-Butyl-*N'*-(4-chlorohex-1-yl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (7m)



57% yield) after purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.02 (br s, 1H), 3.88–3.78 (m, 3H), 3.32 (t, J = 7.5 Hz, 2H), 1.99– 1.89 (m, 1H), 1.83–1.66 (m, 5H), 1.34 (s, 9H), 1.03 (t, J = 7.3 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 124.4 (q, J = 280.6 Hz), 64.9, 54.9, 48.7, 48.1 (q, J = 34.5 Hz), 34.9, 31.5, 29.7, 24.1, 10.9.

¹⁹F NMR (376 MHz, CDCl₃) δ –69.41 (t, J = 8.9 Hz).

IR (neat) v 3288 (br), 2972 (w), 1464 (w), 1429 (w), 1393 (w), 1369 (w), 1315 (m), 1273 (m), 1234 (w), 1141 (s), 1082 (w), 1042 (m), 992 (s), 909 (w), 871 (m), 831 (w), 771 (m), 733 (m), $662 \text{ (m)}, 603 \text{ (m)}, 565 \text{ (m)} \text{ cm}^{-1}.$

TLC $R_f = 0.43$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₂H₂₄ClF₃N₂O₂S 351.1126; Found 351.1118.

N-tert-Butoxycarbonyl-*N*-(4-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (70)



Prepared from sulfamide S5b (181 mg, 0.65 mmol) and S1 (68 mg, 0.5 mmol) following general procedure F. The product was obtained as a colorless oil (133 mg, 67% yield) after purification by silica gel column chromatography (20:1 hexanes:EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.84 (t, J = 6.6 Hz, 1H), 3.88–3.82 (m, 1H), 3.72–3.64 (m, 4H), 1.95-1.87 (m, 1H), 1.81-1.69 (m, 5H), 1.53 (s. 9H), 1.03 (t, J = 7.3 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 151.7, 123.4 (q, J = 279.1 Hz), 84.7, 64.8, 47.5, 45.2 (q, J = 35.5 Hz), 34.8, 31.5, 27.9, 26.7, 10.8.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.95 (t, *J* = 9.0 Hz).

IR (neat) v 3300 (br), 2975 (w), 1706 (m), 1456 (w), 1369 (m), 1276 (m), 1140 (s), 993 (w), 963 (m), 912 (w), 832 (m), 774 (m), 718 (s), 664 (m), 630 (m), 582 (m), 549 (m) cm⁻¹. TLC $R_f = 0.18$ in 9:1 hexanes:EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₃H₂₄ClF₃N₂O₄S 395.1025; Found 395.1017.

N-tert-Butyl-*N*'-(4-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (7p).



Isolated for characterization by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes:EtOAc) from a mixture of chlorinated isomers (**4p**, **7p** and **S11p**).

¹H NMR (400 MHz, CDCl₃) δ 3.97 (br s, 1H), 3.83 (q, J = 3.9 Hz, 2H), 3.33 (dd, J = 7.7, 7.7 Hz, 2H), 1.92–1.84 (m, 2H), 1.74–1.70 (m, 2H), 1.59 (s, 6H), 1.35 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 124.5 (q, *J* = 278.3 Hz), 70.2, 55.0, 49.1, 48.1, (q, *J* = 33.7 Hz), 42.6, 32.4, 29.8, 22.9.

¹⁹F NMR(376 MHz, CDCl₃) δ –69.41 (t, *J* = 9.0 Hz).

IR (neat) v 3290 (br), 2974 (w), 2922 (w), 1428 (w), 1393 (w), 1370 (w), 1320 (m), 1273 (m), 1227 (w), 1141 (s), 1068 (m), 990 (m), 907 (w), 870 (w), 831 (w), 770 (w), 734 (w), 664 (m), 604 (m), 570 (m), 518 (w) cm⁻¹.

TLC $R_f = 0.42$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₂H₂₄ClF₃N₂O₂S 353.1272; Found 353.1274.

N-tert-Butyl-*N*'-(2-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (S11p).



Prepared from *N*-(*tert*-butyl)-*N*-(2,2,2-trifluoroethyl)sulfamide (111 mg, 0.48 mmol) and 2-chloro-4-methylpentanol (50 mg, 0.37 mmol, following general procedure F. The product was obtained as a colorless oil (70 mg, 53% yield) after purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 50:1 hexanes:EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.40–4.35 (m, 1H), 4.10–3.97 (m, 3H), 3.70 (dd, J = 15.6, 4.2 Hz, 1H), 3.40 (dd, J = 15.6, 9.0 Hz, 1H), 1.95–1.87 (m, 1H), 1.65–1.59 (m, 1H), 1.52–1.47 (m, 1H), 1.36 (s, 9H), 0.96 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 124.4 (q, J = 282.3 Hz), 59.5, 55.4, 55.2, 49.9 (q, J = 33.6 Hz), 44.7, 29.8, 25.0, 23.0, 21.1.

¹⁹F NMR(376 MHz, CDCl₃) δ –69.27 (t, *J* = 7.9 Hz).

IR (neat) v 3287 (br), 2962 (w), 1717 (w), 1471 (w), 1429 (w), 1394 (w), 1369 (w), 1328 (m), 1273 (m), 1204 (w), 1143 (s), 1078 (w), 1036 (m), 989 (m), 940 (m), 907 (w), 870 (w), 823 (w), 767 (w), 739 (w), 663 (m), 613 (m), 560 (m), 520 (w), 486 (w) cm⁻¹.

TLC $R_f = 0.57$ in 4:1 hexanes:EtOAc.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₂H₂₄ClF₃N₂O₂S 353.1272; Found 353.1273.

N-tert-Butoxycarbonyl-*N*-(4-chloropent-1-yl)-*N*'-(2,2,2-trfiluoroethyl)sulfamide (S12v)



Prepared from sulfamide **S5b** (295 mg, 1.1 mmol) and 4chloropentanol⁶ (100 mg, 0.82 mmol) following general procedure F. The product was obtained as a colorless oil (217 mg, 70% yield) following purification on a Teledyne Isco CombiFlashR_f system

using a Redi Sep R_f normal phase silica gel column (4:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.78 (br s, 1H), 4.08–4.00 (m, 1H), 3.72–3.66 (m, 4H), 1.92–1.87 (m, 1H), 1.80–1.69 (m, 3H), 1.53 (s, 9H), 1.52 (d, *J* = 6.4 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 151.6, 123.4 (q, *J* = 279.0 Hz), 84.7, 57.9, 47.5, 45.1 (q, *J* = 35.3 Hz), 36.9, 27.8, 26.7, 25.2.

¹⁹F NMR (376 MHz, CDCl₃) δ –71.93 (t, *J* = 8.9 Hz).

IR (neat) v 3299 (br), 2978 (w), 1705 (m), 1368 (m), 1278 (m), 1139 (s), 1010 (w), 910 (w), 832 (m), 796 (w), 773 (w), 718 (s), 664 (m), 611 (m) cm⁻¹.

TLC $R_f = 0.45$ in 8:2 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for $C_{12}H_{21}ClF_3N_2O_4S$ 381.0862; Found 381.0862.

N-tert-Butoxycarbonyl-*N*-(4-chloropent-1-yl)-*N*'-ethylsulfamide (S12w)



Prepared from sulfamide **S5c** (238 mg, 1.1 mmol) and 4-chloropentanol⁶ (100 mg, 0.82 mmol, following general procedure F. The product was obtained as a colorless oil (268 mg, \geq 98% yield) following purification on a Teledyne Isco CombiFlashR_f system using a Redi Sep R_f normal

phase silica gel column (9:1 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.20 (t, J = 5.0 Hz, 1H), 4.09–4.01 (m, 1H), 3.68 (t, J = 7.0 Hz, 2H), 3.04 (qd, J = 7.2, 6.3 Hz, 2H), 1.94–1.87 (m, 1H), 1.79–1.70 (m, 3H), 1.53 (m, 9H), 1.52 (d, J = 7.8 Hz, 3H), 1.20 (t, J = 7.3 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 151.7, 83.7, 57.8, 46.8, 38.7, 36.9, 27.8, 26.7, 25.1, 14.2.

IR (neat) v 3311 (br), 2976 (w), 1703 (m), 1357 (m), 1286 (m), 1256 (m), 1135 (s), 1062 (m), 1009 (w), 844 (m), 794 (m), 773 (m), 714 (s) cm⁻¹.

TLC $R_f = 0.36$ in 8:2 hexanes:EtOAc.

HRMS (ESI) m/z: [M – H]⁻ Calcd for C₁₂H₂₄ClN₂O₄S 327.1145; Found 327.1145.

IX. Preparation and characterization of sulfamate ester derivatives.



To a flame-dried round bottom flask equipped with magnetic stir bar and fitted with a rubber septum and nitrogen inlet was added hexanes (50 mL, 0.6 M). The reaction flask was then cooled at 0 °C in an ice water bath. *Tert*-butanol (4.3 mL, 30 mmol, 1.5 equiv) and chlorosulfonyl isocyanate (3.9 mL, 45 mmol, 1.5 equiv) were then sequentially added dropwise via syringe. Upon complete addition, the ice water bath was removed and replaced with an oil bath. The oil bath was heated to 45 °C and the reaction was stirred for 3 h. After 3 h, the reaction was removed from heat and allowed to cool to room temperature. The suspension was then concentrated under reduced pressure to remove all volatile materials. The crude material was then taken up in anhydrous benzene (50 mL, 0.60 M) and *tetra*-butylammonium bromide (TBAB, 0.97 g, 3.0 mmol, 0.1 equiv), 4-methylpentanol (3.06 g, 30 mmol, 1.0 equiv), and sodium carbonate (9.54 g, 90 mmol, 3.0 equiv) were added sequentially. Following addition, the reaction was left to stir at 22 °C for 18 h.

After 18 h, the reaction was quenched by dropwise addition of 1 M HCl until the aqueous phase reached a pH = 1.0. The biphasic solution was then transferred to a separatory funnel rinsing the flask with EtOAc (~50 mL) to achieve quantitative transfer. The organic phase was separated and the aqueous phase was extracted twice more with EtOAc (2 x 50 mL). The combined organic layers were washed once with brine (~50 mL), dried with MgSO₄, filtered, and concentrated under reduced pressure. The product was obtained as a colorless oil (3.06 g, 43% yield) following silica gel column chromatography (9:1 hexanes:EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.27 (br s, 1H), 4.09 (t, J = 6.7 Hz, 2H), 1.76–1.69 (m, 2H), 1.61– 1.54 (m, 1H), 1.36 (s, 9H), 1.31–1.25 (m, 2H), 0.90 (d, J = 6.6 Hz, 6H). ¹³C NMR (126 MHz, CDCl₃) δ 70.7, 54.6, 34.6, 29.7, 27.6, 26.7, 22.4. IR (neat) v 3299 (br), 2957 (w), 2872 (w), 1469 (w), 1431 (w), 1394 (w), 1345 (m), 1231 (w), 1161 (s), 1041 (w), 981 (m), 917 (w), 875 (w), 802 (w), 731 (w), 618 (w), 587 (w), 514 (w), 463 (w) cm⁻¹. TLC R_f = 0.50 in hexanes:EtOAc 4:1.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for C₁₀H₂₃NO₃S•NH₄ 255.1737; Found 255.1742.



Following a literature procedure,¹¹ a flame-dried round bottom flask equipped with magnetic stir bar was charged with triphenylphosphine oxide (2.3 g, 8.25 mmol, 1.65 equiv) and fitted with a rubber septum. The flask was evacuated and backfilled with N₂. Anhydrous CH_2Cl_2 (25 mL) was added and the flask was cooled at 0 °C in an ice water bath. Trifluoromethanesulfonic anhydride

(1.25 mL) that had been freshly removed from the glovebox was then added to the cooled solution dropwise via syringe. The reaction was allowed to stir at 0 °C in an ice water bath for 15 minutes. A solution of sulfamic acid salt (2.1 g, 7.5 mmol, 1.5 equiv) in CH₂Cl₂ (4.0 mL) was added to the activated Ph₃PO via cannula transfer. The flask was rinsed with additional CH₂Cl₂ (1 mL) to achieve quantitative transfer. The resulting pale yellow solution was stirred for 15 minutes at 0 °C. During this time, a clean, flame-dried round bottom flask equipped with stir bar was fitted with a rubber septum and subsequently evacuated and backfilled with N₂. This process was repeated two more times. The flask was then charged with Et₃N (2.1 mL, 15.0 mmol, 3.0 equiv) and CH₂Cl₂ (20 mL) and the mixture was cooled at -78 °C in an ^{*i*}PrOH/dry ice bath. The activated sulfamic acid salt solution was transferred dropwise to the Et₃N solution via cannula (during which time an intense red color developed), rinsing the flask with additional CH₂Cl₂ (5 mL) to achieve quantitative transfer. The resultant solution was stirred at -78 °C for 15 minutes. 4-Methylpentanol (511 mg, 5.0 mmol, 1.0 equiv) was then added as a solution in CH₂Cl₂ (5 mL) to the Et₃N solution via canula. The alcohol-containing flask was rinsed with additional CH₂Cl₂ (1 mL) to achieve quantitative transfer. Without removing the cooling bath, the reaction was then stirred for 18 h, during which time no additional dry ice was added and the mixture warmed to room temperature.

After 18 h, the reaction was diluted with 1 M HCl (~20 mL) and H₂O (~30 mL). The biphasic mixture was transferred to a separatory funnel, rinsing the flask with CH2Cl2 to achieve quantitative transfer. The organic phase was separated and the aqueous phase was extracted twice more with CH₂Cl₂ (2 x ~40 mL). The combined organic phases were dried with MgSO₄, filtered, and concentrated under reduced pressure. The product was obtained as a white powder (958 mg, 73% yield) following silica gel column chromatography (8:1 hexanes:EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 5.04 (br s, 1H), 4.16 (t, J = 6.6 Hz, 2H), 3.78–3.70 (m, 2H), 1.77– 1.70 (m, 2H), 1.60-1.54 (m, 1H), 1.29-1.24 (m, 2H), 0.89 (d, J = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 123.4 (q, J = 278.3), 72.3, 45.0 (q, J = 36.0), 34.3, 27.6, 26.5, 22.3.

¹⁹F NMR (376 MHz, CDCl₃) δ –72.73 (t, J = 8.6 Hz).

IR (neat) v 3296 (br), 2962 (w), 1465 (w), 1409 (w), 1348 (m), 1276 (m), 1154 (s), 1112 (m), 1061 (w), 961 (s), 924 (m), 871 (m), 835 (m), 804 (w), 737 (w), 664 (m), 561 (s), 524 (m), 469 (m) cm^{-1} .

TLC $R_f = 0.39$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for C₈H₁₆F₃NO₃S 281.1141; Found 281.1147.



Following a literature procedure,^{6b} a round bottom flask equipped with magnetic stir bar was charged with trichloroisocyanuric acid (TCICA, 1.2 equiv) and the flask was evacuated and backfilled with N₂. Anhydrous CH₂Cl₂ (0.2 M) was then added to create a suspension. Sulfamate ester S13 (1.0 equiv) was then added to the suspension via syringe (if oil) or in a single portion by brief opening of the flask (if solid). The suspension was stirred at 22 °C and monitored by TLC until complete consumption of starting material was observed.

Upon complete consumption of starting material as judged by TLC, the reaction was diluted with H_2O (~0.2 M) and the biphasic suspension was transferred to a separatory funnel. The reaction flask was rinsed with CH_2Cl_2 (5 mL) to ensure quantitative transfer. The organic phase was separated and the aqueous phase was extracted twice more with CH_2Cl_2 . The combined organic phases were dried with MgSO₄, filtered, and concentrated under reduced pressure. The crude reaction mixtures were then purified by flash column chromatography on silica gel by loading samples as a solid and eluting with a hexanes:EtOAc solvent system as noted below.

4-Methylpentyl *tert*-butylchlorosulfamate ester (9a).



Prepared from sulfamate ester **S13a** (356 mg, 1.5 mmol) and TCICA (418 mg, 1.8 mmol) following general procedure J. The product was obtained as a colorless oil (354 mg, 87% yield) after silica gel flash column chromatography using hexanes:EtOAc (20:1).

¹H NMR (400 MHz, CDCl₃) δ 4.27 (t, J = 6.7 Hz, 2H), 1.78–1.73 (m, 2H), 1.58–1.55 (m, 1H), 1.49 (s, 9H), 1.31–1.23 (m, 2H), 0.88 (d, J = 6.8 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 74.5, 67.3, 34.3, 28.4, 27.4, 26.6, 22.3.

IR (neat) v 2957 (w), 2872 (w), 1468 (w), 1366 (m), 1241 (w), 1191 (m), 1167 (m), 1040 (w), 953 (m), 886 (m), 807 (w), 734 (w), 614 (s), 591 (w), 517 (w), 469 (w), 433 (w) cm⁻¹. TLC $R_f = 0.57$ in 10:1 hexanes:EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{10}H_{22}CINO_3S \cdot NH_4$ 289.1347; Found 289.1345.

4-Methylpentyl (2,2,2-trifluoroethyl)chlorosulfamate ester (9b).



Prepared from sulfamate ester **S13b** (479 mg, 1.8 mmol) and TCICA (508 mg, 2.2 mmol) following general procedure J. The product was obtained as a colorless oil (489 mg, 90% yield) after silica gel flash column chromatography using hexanes:EtOAc (20:1).

¹H NMR (400 MHz, CDCl₃) δ 4.39 (t, *J* = 6.5 Hz, 2H), 4.08 (q, *J* = 8.1 Hz, 2H), 1.84–1.77 (m, 2H), 1.63–158 (m, 1H), 1.34–1.28 (m, 2H), 0.91 (d, *J* = 6.6 Hz, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 122.9 (q, J = 279.8 Hz), 76.7, 57.2 (q, J = 35.6 Hz), 34.2, 27.5, 26.7, 22.3.

¹⁹F NMR (376 MHz, CDCl₃) δ –70.51 (t, *J* = 7.8 Hz).

IR (neat) v 2960 (w), 2874 (w), 1470 (w), 1382 (m), 1310 (m), 1272 (m), 1159 (s), 1072 (w), 963 (s), 930 (s), 844 (m), 736 (w), 689 (m), 648 (m), 574 (s), 520 (w), 471 (m) cm⁻¹.

TLC $R_f = 0.65$ in 8:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for C₈H₁₅ClF₃NO₃S•NH₄ 315.0752; Found 315.0746.





The reactions were performed as described for previously reported sulfamate ester guided chlorination processes.^{6b} In a flame-dried microwave vial equipped with magnetic stir bar and sealed with a crimp cap, N-chlorosulfamate ester 7 (0.2 mmol, 1.0 equiv) was dissolved in anhydrous PhH (3.0 mL, 0.07 M) under an inert atmosphere. The vial was then placed in between two Kessil lamps (ca. 5 cm away from each light source) and irradiated for 15 minutes. After 15 minutes, the vial was removed from the light, and the reaction was analyzed by TLC. If starting material remained, the reaction was irradiated between two Kessil lamps in 15 minute increments until all starting material had been consumed as judged by TLC.

Upon consumption of starting material as judged by TLC, the reaction solution was transferred to a flask rinsing the microwave vial with CH₂Cl₂ (ca. 3 mL) to make transfer quantitative. Volatiles were removed under reduced pressure and the crude material was purified by flash column chromatography on silica gel or Florisil by loading the samples as liquids in column eluent and eluting with a hexanes:EtOAc solvent system as noted below.



Chlorosulfamate 9a (54 mg, 0.2 mmol) was subjected to the general procedure. After irradiating for 1 hour, products 10a and S14a (31 mg, 57% yield) were isolated as a mixture following purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 10:1 hexanes/acetone).

In order to determine the ratio of 10a:S14a, duplicate reactions of chlorosulfamide 9a (8 mg, 0.03 mmol) were subjected to general procedure K. After irradiating for 1 hour, each sample was concentrated under reduced pressure and 1,2,4,5-tetrachloro-3-nitrobenzene (1.0 equiv) was added as an internal standard. ¹H NMR analysis of the crude reaction mixtures revealed a 3.2:1.0 mixture of 10a:S14a and 10% protodehalogenated material as an average of two runs. Sample 1: 57% yield 10a, 18% yield S14a, 7% yield protodehalogenated S13a.

Sample 2: 56% yield 10a, 18% yield S14a, 12% yield protodehalogenated S13a.

3-Chloro-4-methylpentyl tert-butylsulfamate (10a).



Isolated for characterization by silica gel column chromatography ${}^{t}Bu \xrightarrow{N} S_{0} \xrightarrow{CI} Me$ Isolated for characterization by silica gel column chromatography (Gradient: 100% hexanes $\rightarrow 25:1$ hexanes:EtOAc) from a mixture of chlorinated isomers (10a and S14a).

¹H NMR (400 MHz, CDCl₃) δ 4.41 (br s, 1H), 4.32–4.29 (m, 2H), 3.99 (ddd, J = 6.7, 2.6, 2.6 Hz, 1H), 2.21–2.13 (m, 1H), 2.03–1.94 (m, 2H), 1.37 (s, 9H), 1.04 (d, J = 6.7 Hz, 3H), 0.99 (d, J = 6.7 Hz).

¹³C NMR (126 MHz, CDCl₃) δ 67.5, 65.4, 54.7, 35.0, 34.4, 29.5, 19.7, 17.1.

IR (neat) v 3298 (w), 2969 (w), 1467 (w), 1430 (w), 1394 (m), 1369 (m), 1345 (m), 1232 (w), 1206 (w), 1159 (s), 1084 (w), 1043 (w), 986 (s), 914 (m), 884 (m), 832 (w), 781 (m), 616 (m), 591 (w), 513 (m), 471 (w) cm⁻¹.

TLC $R_f = 0.47$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₀H₂₂ClNO₃S 270.0936; Found 270.0932.

4-Chloro-4-methylpentyl tert-butylsulfamate (S14a).

 $\bigvee_{Me}^{\delta} \bigvee_{Re}^{Me}$ Isolated for characterization by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 25:1 hexanes:EtOAc) from a mixture of chlorinated isomers (10a and S14a).

¹H NMR (400 MHz, CDCl₃) δ 4.32 (br s, 1H), 4.15 (t, J = 6.1 Hz, 2H), 1.99–1.94 (m, 2H), 1.87–1.85 (m, 2H), 1.59 (s, 6H), 1.36 (s, 9h).

¹³C NMR (126 MHz, CDCl₃) δ 70.2, 70.0, 54.7, 42.0, 32.4, 29.7, 24.9.

IR (neat) v 3297 (br), 2974 (w), 1471 (w), 1430 (w), 1394 (m), 1370 (m), 1343 (m), 1233 (w), 1210 (w), 1159 (s), 981 (m), 924 (m), 874 (m), 804 (m), 733 (m), 615 (m), 587 (m), 512 (m), 425 (w) cm⁻¹.

TLC $R_f = 0.35$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M - H]^-$ Calcd for C₁₀H₂₂ClNO₃S 270.0936; Found 270.0931.



Chlorosulfamate **9b** (60 mg, 0.2 mmol) was subjected to the general procedure. After irradiating for 1 hour, products **10b** and **S14b** (40 mg, 67% yield) were isolated as a mixture following purification by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 10:1 hexanes/acetone).

In order to determine the ratio of **10b**:**S14b**, duplicate reactions of chlorosulfamide **9b** (8 mg, 0.03 mmol) were subjected to general procedure K. After irradiating for 1 hour, each sample was concentrated under reduced pressure and 1,2,4,5-tetrachloro-3-nitrobenzene (1.0 equiv) was added as an internal standard. ¹H NMR analysis of the crude reaction mixtures revealed a 4:1 mixture of **10b**:**S14b** and 5% protodehalogenated material as an average of two runs. Sample 1: 56% yield **10b**, 14% yield **S14b**, 5% yield protodehalogenated **S13b**.

Sample 2: 53% yield 10b,13% yield S14b, 4% yield protodehalogenated S13b.

3-Chloro-4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (10b).



Isolated for characterization by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 25:1 hexanes:EtOAc) from a mixture of chlorinated isomers (10b and S14b).

¹H NMR (400 MHz, CDCl₃) δ 5.13 (t, J = 6.5 Hz, 1H), 4.40–4.37 (m, 2H), 3.97 (ddd, J = 6.7, 4.0, 4.0 Hz, 1H), 3.80–3.72 (m, 2H), 2.22–2.14 (m, 1H), 2.04–1.94 (m, 2H), 1.04 (d, J = 6.7 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 123.3 (q, *J* = 278.3 Hz), 69.1, 65.0, 45.2 (q, *J* = 35.8 Hz), 34.7, 34.4, 19.6, 17.2.

¹⁹F NMR (376 MHz, CDCl₃) δ -72.67 (t, J = 8.6 Hz).

IR (neat) v 3307 (br), 2970 (w), 1465 (w), 1359 (m), 1275 (m), 1152 (s), 1044 (w), 963 (m), 918 (m), 868 (m), 816 (w), 777 (m), 664 (m), 561 (s), 512 (m), 471 (w), 439 (w) cm⁻¹.

TLC $R_f = 0.41$ in 4:1 hexanes: EtOAc.

HRMS (ESI) m/z: [M – H]⁻ Calcd for C₈H₁₅ClF₃NO₃S 296.0341; Found 296.0334.

4-Chloro-4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (S14b).



Isolated for characterization by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 25:1 hexanes:EtOAc) from a mixture of chlorinated isomers (**10b** and **S14b**).

¹H NMR (400 MHz, CDCl₃) δ 4.90 (t, *J* = 6.3 Hz, 1H), 4.24 (t, *J* = 6.0 Hz, 2H), 3.20–3.72 (m, 2H), 2.02–1.95 (m, 2H), 1.86–1.82 (m, 2H), 1.59 (s, 6H).

¹³C NMR (126 MHz, CDCl₃) δ 123.3 (q, *J* = 277.1 Hz), 71.7, 69.8, 45.2 (q, *J* = 35.7 Hz), 41.7, 32.4, 24.7.

¹⁹F NMR (376 MHz, CDCl₃) δ –72.67 (t, *J* = 8.8 Hz).

IR (neat) v 3304 (br), 2923 (w), 2850 (w), 1457 (w), 1361 (m), 1276 (m), 1156 (s), 966 (m), 929 (m), 861 (w) 739 (w), 665 (w), 563 (m), 512 (w) cm⁻¹.

TLC $R_f = 0.26$ in 4:1 hexanes:EtOAc.

HRMS (ESI) m/z: [M – H][–] Calcd for C₈H₁₅ClF₃NO₃S 296.0341; Found 296.0333.

X. Sulfamide cleavage to access 3-chloroalkylamines.



A clean microwave vial equipped with a stir bar was charged with sulfamide (1 equiv) and DMAP (1.5 equiv) and sealed with an aluminum seal cap. The vial was evacuated and backfilled with N₂ and the process was repeated two more times. 1,4-dioxane (0.13 M) and H₂O (2 equiv) were then added via syringe and the resulting solution was heated in an oil bath at 80 °C overnight.

After stirring overnight, the suspension was allowed to cool to 21 °C and then concentrated under reduced pressure. The crude mixture was then purified by silica gel flash chromatography as indicated below.

Methyl 6-((tert-butoxycarbonyl)amino)-4-chlorohexanoate (S15k)

Prepared from sulfamide 4k (150 mg, 0.36 mmol) according to the $\begin{array}{c} \text{Boc} \\ \text{M} \\ \text{H} \\ \end{array} \\ \begin{array}{c} \text{CO}_2 \text{Me} \\ \text{S}\% \\ \text{yield} \end{array} \\ \begin{array}{c} \text{Frequency from summary for the frequency of the second seco$ system using a Redi Sep R_f normal phase silica gel column (8:2 hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.67 (br s, 1H), 4.02–3.95 (m, 1H), 3.69 (s, 3H), 3.40–3.33 (m, 1H), 3.30–3.23 (m, 1H), 2.61–2.47 (m, 2H), 2.19–2.10 (m, 1H), 2.07–1.91 (m, 2H), 1.87–1.78 (m, 1H), 1.44 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ173.2, 155.9, 79.3, 60.1, 51.7, 38.4, 37.9, 33.4, 30.8, 28.3. IR (neat) v 3364 (br), 2975 (w), 1689 (m), 1514 (m), 1437 (m), 1391 (w), 1365 (w), 1247 (m), 1162 (s), 994 (w), 838 (w), 780 (w), 606 (w) cm⁻¹.

TLC $R_f = 0.54$ in 6:4 hexanes/EtOAc.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₂H₂₂ClNO₄•Na 302.1135; Found 302.1134.

XI. Preparation and characterization of compounds related to the radical clock experiment

N-tert-butyl-*N'*trifluoro)ethylsulfamide (S8s) (3-(2,2-dimethylcyclopropyl)propan-1-yl)-N'-(2,2,2-

Me Prepared from *N*-(*tert*-butyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (513 mg, 2.2 mmol) and 3-(2,2-dimethylcylcopropyl)propanon-1-ol¹² (216 g, 1.7 mmol) following general procedure F. The product was obtained as a colorless oil (319 mg, 55% yield) after purification by

silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1 hexanes:EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 4.19 (br s, 1H), 3.80 (q, J = 8.9 Hz, 2H), 3.36–3.24 (m, 2H), 1.77–1.69 (m, 2H), 1.33 (s, 9H), 1.28–1.21 (m, 2H), 1.01 (s, 6H), 0.48–0.37 (m, 2H), -0.11 – 0.13 (m, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 124.5 (q, *J* = 280.4 Hz), 54.8, 49.1, 48.0 (q, *J* = 33.9 Hz), 29.7, 27.5, 27.4, 26.8, 24.0, 19.9, 19.7, 15.4.

¹⁹F NMR(376 MHz, CDCl₃) δ –69.49 (t, J = 8.9 Hz)

IR (neat) v 3286 (br), 2941(w), 1429 (w), 1393 (w), 1369 (w), 1323 (m), 1274 (m), 1229 (w), 1141 (s), 1085 (w), 995 (m), 908 (w), 871 (w), 831 (w), 770 (w), 734 (m), 665 (m), 609 (m), 564 (m), 519 (w) cm⁻¹.

TLC $R_f = 0.26$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₄H₂₇F₃N₂O₂S 345.1818; Found 345.1815.

N-tert-butyl-*N*-chloro-*N*'trifluoro)ethylsulfamide (1s)

(3-(2,2-dimethylcyclopropyl)propan-1-yl)-N'-(2,2,2-

^tBu N S N CF₃

Prepared from sulfamide **S8s** (245 mg, 0.71 mmol) and TCICA (198 mg, 0.85 mmol) in CH₂Cl₂ (4 mL) following general procedure G. The product was obtained as a colorless oil (220 mg, 82% yield) after silica gel column chromatography (Gradient: 100% hexanes \rightarrow 20:1

hexanes/EtOAc).

¹H NMR (400 MHz, CDCl₃) δ 3.94 (q, J = 8.8 Hz, 2H), 3.45–3.40 (m, 2H), 1.82–1.75 (m, 2H), 1.50 (s, 9H), 1.38–1.25 (m, 2H), 1.03 (s, 6H), 0.50–0.38 (m, 2H), -0.09 – -0.11 (m, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 123.8 (q, J = 280.8 Hz), 67.7, 50.5 50.4 (q, J = 35.2 Hz), 28.9, 27.5, 27.4, 26.7, 23.9, 19.9, 19.7, 15.4.

¹⁹F NMR(376 MHz, CDCl₃) δ –70.13 (t, *J* = 8.8 Hz).

IR (neat) v 2941 (w), 1463 (w), 1400 (w), 1360 (m), 1313 (w), 1276 (m), 1233 (w), 1153 (s), 1109 (w), 1085 (w), 1026 (m), 1006 (m), 873 (m), 820 (m), 787 (w), 736 (w), 663 (m), 606 (m), 566 (m), 519 (w), 487 (m) cm⁻¹.

TLC $R_f = 0.53$ in 9:1 hexanes: EtOAc.

HRMS (ESI) m/z: $[M + NH_4]^+$ Calcd for $C_{14}H_{26}ClF_3N_2O_2S \cdot NH_4$ 396.1699; Found 397.1701.



In order to determine the yield of the ring-opened isomers, duplicate reactions of chlorosulfamide **1s** (10 mg, 0.027 mmol) were subjected to general procedure I. After irradiating for 15 minutes, each sample was concentrated under reduced pressure and 2-bromo-5- (trifluoromethyl)pyridine (0.03 mmol, 1.11 equiv) was added as an internal standard. ¹⁹F NMR analysis of the crude reaction mixtures revealed an 80% yield of ζ -chlorinated ring-opened isomer **12s** as an average of 2 runs.

Sample 1: 78% yield **12s** Sample 2: 82% **12s**

N-tert-butyl-*N*'-(6-chloro-6-methylhept-3-en-1-yl)-*N*'-(2,2,2-trifluoro)ethylsulfamide (12s)



Chlorosulfamide 1s (76 mg, 0.2 mmol) was subjected to general procedure I. After irradiating for 15 minutes, product 12s was isolated for characterization by silica gel column chromatography (Gradient: 100% hexanes \rightarrow 4:1 hexanes:Et₂O).

¹H NMR (400 MHz, CDCl₃) δ 5.66 (ddd, J = 14.4, 7.5, 7.5 Hz, 1H), 5.47 (dt, J = 14.4, 7.2, 7.2 Hz, 1H), 4.02 (br s, 1H), 3.83 (q, J = 8.8 Hz, 2H), 3.25 (dd, J = 7.4 Hz, 2H), 2.45–2.40 (m, 4H), 1.54 (s, 6H), 1.34 (s, 9H).

¹³C NMR (126 MHz, CDCl₃) δ 130.0, 128.5, 124.4 (q, *J* = 281.5 Hz), 69.8, 54.9, 48.9, 48.9, 48.3 (q, *J* = 34.3 Hz), 32.1, 30.7, 29.7.

¹⁹F NMR(376 MHz, CDCl₃) δ –69.48 (t, J = 9.0 Hz).

IR (neat) v 3290 (br), 2974 (w), 1426 (w), 1393 (w), 1370 (w), 1324 (m), 1273 (m), 1232 (w), 1141 (s), 1085 (m), 1040 (m), 975 (m), 907 (w), 871 (w), 833 (w), 767 (w), 738 (w), 665 (m), 609 (w), 568 (m), 520 (w), 406 (w) cm⁻¹.

TLC $R_f = 0.41$ in 4:1 hexanes:EtOAc.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for $C_{14}H_{26}ClF_3N_2O_2S$ 379.1430; Found 379.14284.

XII. Description of quantum yield experiments.

Determination of Light Intensity.

The light intensity was measured to determine the photon flux of the fluorimeter.²⁰ All solutions were stored in the dark and used the same day as prepared. Manipulations were performed in the dark and care was taken such that samples were protected from ambient light.

Preparation of stock solutions.

A 0.15 M solution of ferrioxalate was prepared by dissolving potassium ferrioxalate trihydrate $(K_3[Fe(C_2O_4)_3] \cdot 3H_2O, 1.84 \text{ g}, 3.75 \text{ mmol})$ in 0.05 M H_2SO_4 and diluting to 25 mL total volume with 0.05 M H_2SO_4 in a 25 mL volumetric flask.

A buffered 1,10-phenanthroline solution was prepared by dissolving phenanthroline (50 mg, 0.277 mmol) and sodium acetate (11.25 g) in 0.5 M H_2SO_4 and diluting to 50 mL total volume with 0.5 M H_2SO_4 in a 50 mL volumetric flask.

Determination of background Fe^{2+} concentration.

2.00 mL of the ferrioxalate solution was added to a quartz cuvette. Next 0.35 mL of the phenanthroline solution was added and the mixture was stored in the dark for 1 h. The UV-vis spectrum was subsequently obtained and the absorbance value recorded at 510 nm. The process was repeated 2 additional times for 3 total trials.

Trial 1: 0.2440203428 Trial 2: 0.2468722761 Trial 3: 0.1206529737 Average: 0.2038485309

Determination of photon flux.

2.00 mL of the ferrioxalate solution was added to a quartz cuvette. The cuvette was immediately irradiated with ultraviolet light (313 nm \pm 5 nm) in a fluorimeter for 90 seconds. The cuvette was then removed from the fluorimeter and 0.35 mL of the phenanthroline solution was added to the ferrioxalate solution. The resulting solution was stored in the dark for 1 h and the UV-vis spectrum was obtained. The absorbance value at 510 nm was recorded and the process was repeated 2 additional times for 3 total trials.

Trial 1: 1.293553352 Trial 2: 1.417163253 Trial 3: 1.422570229 Average: 1.377762278

Calculations.

The amount of Fe^{2+} formed after irradiation was calculated according to the Beer-Lambert law:

$$mol \ Fe(II) = \frac{V \cdot \Delta A}{l \cdot \varepsilon}$$

where V is the volume of the sample analyzed (2.35 mL), ΔA is the difference in average absorbances (between the irradiated and unirradiated ferrioxalate solutions) at 510 nm, l is the path length of the cuvette, and ε is the molar absorptivity at 510 nm.

$$mol \ Fe(II) = \frac{(0.00235 \ L) \cdot (1.173913747)}{(1.00 \ cm) \cdot (11, 100 \ \frac{L}{mol \cdot cm})} = 2.48531 \cdot 10^{-7} \ mol$$

The fraction of light absorbed by the ferrioxalate actinometer was calculated by the following equation:

$$f = 1 - 10^{-A}$$

where A is the absorbance at 313 nm of the ferrioxalate actinometer solution prior to irradiation and addition of phenanthroline.

$$f = 1 - 10^{-10} = 0.999 \approx 1.000$$

The photon flux was calculated using the following equation:

$$photon \ flux = \frac{mol \ Fe(II)}{\phi \cdot t \cdot f}$$

where ϕ is the quantum yield of the ferrioxalate actinometer at 313 nm,²¹ t is the time and f is the fraction of light absorbed by the ferrioxalate actinometer solution.

$$photon flux = \frac{2.48531 \cdot 10^{-7} \ mol}{(1.24 \ einstein^{-1}) \cdot (90 \ s) \cdot (1.000)} = 2.22698 \cdot 10^{-9} \ einstein \cdot s^{-1}$$

Determination of quantum yield.

In a nitrogen-filled glovebox, a quartz cuvette was charged with sulfamide **1h** (42.7 mg, 0.10 mmol, 1 equiv) and PhH (2.5 mL, 0.04 M). The cuvette was fitted with a Teflon cap and sealed with parafilm. The vial was then placed in a fluorimeter and irradiated with ultraviolet light (313 nm \pm 5 nm) for 60 minutes. After 60 minutes, the vial was removed from the fluorimeter and the reaction mixture was transferred to a scintillation vial and concentrated under reduced pressure. The residue was purified as detailed above to provide the desired product (25.7 mg, 60% yield, 0.064 mmol). A duplicate experiment afforded 24.0 mg of the desired product (56% yield). The quantum yield was calculated as an average of the two runs.

The minimum quantum yield (ϕ) was calculated using the following equation:

$$\phi = \frac{mol \ product}{flux \cdot t \cdot f}$$

Where t is the reaction time and f is the fraction of light absorbed by sulfamide **1h**.

 $\phi = \frac{0.000058 \,mol}{(2.22698 \cdot 10^{-9} einstein \cdot s^{-1}) \cdot (3600 \,s) \cdot (1.000)} = 7.25$

XIII. UV-Vis Spectra.





Absorbance at 313 nm: 2.142662287 Fraction of light absorbed at 313 nm: 0.99279991



N-tert-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3,7-dimethyloct-1-yl)sulfamide **4h** in PhH (0.04 M).

Absorbance at 313 nm: 0.05732247606 Fraction of light absorbed at 313 nm: 0.12365014

XIV. S-N bond lengths in related sulfamide	es
--	----

Structure	S–N(1) [Å]	S–N(2) [Å]	N(2)–S– N(1) °	Reference
((Cl(CH ₂) ₂)N)SO ₂ (N((CH ₂) 2Cl)Boc) ₂	1.6875 (10)	1.6147 (11)	108.16 (5)	A.Seridi, H.Akkari, J Y.Winum, P.Benard- Rocherulle, M.Abdaoui, <i>Acta</i> <i>Crystallographica</i> <i>Section E: Structure</i> <i>Reports</i> <i>Online</i> , 2009, 65, o2543, DOI: 10.1107/S1600536 809038185
$ \begin{array}{c} 0,0\\ N^{1},S,N^{2}\\ Ph \\ \end{array} $ $ \begin{array}{c} 0,0\\ Ph \\ Ph $	1.602(2)	1.689(2)	105.51(9)	Jorge Vargas-Caporali, Arie van der Lee, Georges Dewynter, Eusebio Juaristi, <i>Letters</i> <i>in Organic</i> <i>Chemistry</i> , 2018, 15, 352, DOI: 10.2174/157017861 5666180110162202
N ⁰ , O N ^{1,S} N ² H	1.589 (3)	1.661 (3)	108.9 (1)	Chafika Bougheloum, Carole Barbey, Malika Berredjem, Abdelrani Messalhi, Nathalie Dupont, Journal of Molecular Structure, 2013, 1041, 6, DOI: 10.1016/j.molstruc. 2013.02.018
(^{<i>t</i>} BuNH) ₂ SO ₂	1.615	1.616	110.8 (1)	J.L.Atwood, A.H.Cowley, W.E.Hunter, S.K.Mehrotra, <i>Inorganic</i> <i>Chemistry</i> , 1982, 21, 435, DOI: 10.1021/ic00131a0 81
((Me ₂ CHCH ₂)NH) ₂ SO ₂	1.615 (5)	1.615 (5)	111.5 (3)	Bing Gong, Zhong Zheng, E.Skrzypczak- Jankun, Yinfa Yan, Jianhua Zhang, Journal of the American Chemical Society, 1998, 120, 1119, DOI: 10.1021/ja981707c

((PhCH ₂)NH) ₂ SO ₂	1.602 (2)	1.616 (2)	112.06 (13)	DOI: 10.1021/ja981707c
((H ₂ NCOCH ₂ CH ₂)NH) ₂ SO ₂	1.612 (2)	1.612 (2)	111.79 (12)	DOI: 10.1021/ja981707c
((CH ₃ OC ₆ H ₄ CH ₂)NH) ₂ SO ₂	1.615 (5)	1.618 (8)	112.9 (3)	DOI: 10.1021/ja981707c
((PhCH(CH ₃))NH) ₂ SO ₂	1.608 (2)	1.609 (2)	112.16 (12)	DOI: 10.1021/ja981707c
(CyNH)2SO2	1.6062(13)	1.6062(13)	102.33(11)	M.B.Hursthouse, T.Gelbrich, N.Bricklebank CCDC 223234: Experimental Crystal Structure Determination, 2014, DOI: <u>10.5517/cc7h933</u>
((H2NCO(CH2)3)NH)2SO2	1.618 (2)	1.618 (2)	111.8 (2)	Bing Gong, Chong Zheng, Jianhua Zhang, Journal of Chemical Crystallography, 1999, 2 9, 645, DOI: 10.1023/A:100956 9417467
((ⁱ PrCH ₂ CH ₂)NH) ₂ SO ₂	1.617 (5)	1.586 (6)	110.7 (3)	Bing Gong, Chong Zheng, E.Skrzypczak- Jankun, Jin Zhu, <i>Organic</i> <i>Letters</i> , 2000, 2, 3273, DOI: 10.1021/ol006343j
((CyCH ₂)NH) ₂ SO ₂	1.591 (12)	1.624 (12)	110.5 (10)	DOI: 10.1021/ol006343j
$((CH_3(CH_2)_4)NH)_2SO_2$	1.614 (2)	1.614 (2)	111.47 (18)	DOI: 10.1021/o1006343j
$((CH_3(CH_2)_5)NH)_2SO_2$	1.623 (3)	1.623 (3)	110.5 (2)	DOI: 10.1021/o1006343j
$((CH_3(CH_2)_7)NH)_2\overline{SO_2}$	1.6235 (12)	1.6235 (12)	111.97 (9)	DOI: 10.1021/ol006343j

XV. Computational Calculations

Computational Methods

Density functional theory (DFT) calculations were performed using Gaussian 09^{22} (revision D.01)²³ or Gaussian 16 (revision B.01).²⁴ GaussView²⁵ was used to generate input geometries and visualize output. Geometry minimizations and frequency calculations for 1,6- and 1,7-HAT pathways were initially performed using the uB3LYP²⁶ functional and the 6-31+G(d,p) basis set²⁷ with inspiration from related calculations by Leonori and co-workers.²⁸ The calculations were performed using the polarizable continuum model (PCM) to account for solvation effects in benzene and an ultrafine (99,590) integration grid to limit errors associated with low-frequency vibrational modes.²⁹. These calculations were performed without any corrections for quantum tunneling.

Table S2. In	vestigations com	paring experimen	tal product rati	os to computational	lly-calculated
differences in	n transition state	energies for 1,6-	vs 1,7-HAT pa	thways.	

optru		experimental	calculated ∆∆ <i>G</i> [‡] (kcal•mol ⁻¹) ^[b] uB3LYP / 6-32+G(d,p)			
entry	parent compound	(kcal•mol ⁻¹) ^[a]	RRHO Approximation	Quasi-RRHO Approximation ^[c]	Quasi-Harmonic Approximation ^[d]	
1	F_3C N S O γ δ Me Me	-0.82	-3.33	-2.94	-2.76	
2	⁷ Bu N S O γ δ Me H Me	-0.69	-1.09	-0.63	-0.55	
3	⁷ Bu N S N γ δ Me H CH ₂ CF ₃	≤-1.77	-3.74	-3.21	-2.90	
4	^t Bu、NSN HBoc	-1.56	-2.98	-2.66	-2.48	
5	F ₃ C N S N γ δ Me H Boc	-1.39	-2.06	-1.77	-1.65	
6	^{t}Bu N S N $^{\gamma}$ Me H CH_2CF_3 Me	-1.52	+0.35	+0.84	+0.87	
7	⁰ Bu NSN → γ δ Me H Boc Me	-0.41	+2.24	+2.59	+2.58	
8	$F_3C \sim N \xrightarrow{S} N \xrightarrow{\gamma} \delta Me$ H Boc Me	+0.38	+1.04	+1.42	+1.49	

^{*a*} $\Delta\Delta G^{\ddagger} = -RT \ln(\gamma\text{-chlorinated product / }\delta\text{-chlorinated product)}$ as determined by ¹H NMR of crude reaction mixture. ^{*b*} $\Delta\Delta G^{\ddagger} = (\Delta G(1,6\text{-HAT TS}) - \Delta G(1,7\text{-HAT TS}))$ as determined from the

calculated Gibbs free energies using the functional/basis set combination reported at the top of each column. [c] Corrected using the quasi-RRHO approximation of Grimme.³⁰ [d] Corrected using the quasi-harmonic approximation of Cramer and Truhlar.³¹

The computed energies of the transition states were found to be highly dependent upon the molecule's orientation,²⁹ which we expect leads, at least in part, to the discrepancies in both qualitative and quantitative trends between the experimental and calculated values. These discrepancies appear to be most drastic for sulfamide substrates where there is a significant difference in BDE of the hydrogen atoms being engaged by the associated 1,6- and 1,7-HAT processes (entries 6–8). The observed trends hold even when quasi-harmonic corrections have been applied.^{30,31} These corrections should limit error associated with contributions with the sensitive entropic component of small vibrational frequencies.

The calculations were evaluated for spin contamination by comparing the value of total spin (S^{**2}) at the optimized energy to s(s+1) for the system (s = $\frac{1}{2}$ times the number of unpaired electrons). The aforementioned calculations did not appear to suffer from any significant spin contamination using this approach.

Table S3. Computed Energies

DFT Method: uB3LYP / 6-31+G(d,p) / PCM – benzene [values in Hartrees]

entry	species	total electronic energy	sum of electronic and zero- point energies	sum of electronic and thermal enthalpies	Gibbs free energy
1	^O ,O F ₃ C ∧ N.S.O ∧ γ ^δ Me Me	-1291.971313	-1291.731514	-1291.712045	-1291.782881
2	F ₃ C N S O H Me Me Me	-1291.949419	-1291.713544	-1291.695571	-1291.760012
3	$ \begin{bmatrix} 0 & 0 \\ \mathbf{F}_{3}\mathbf{C} & \mathbf{N} & \mathbf{S} \\ \mathbf{N} & \mathbf{N} & \mathbf{S} \\ \mathbf{H} \\ \mathbf{H} \\ \mathbf{M} \\ \mathbf{M} \\ \mathbf{M} \\ \mathbf{M} \\ \mathbf{H} \\ \mathbf{M} \\ \mathbf{H} \\ \mathbf{M} \\ \mathbf{H} \\ H$	-1291.944541	-1291.708985	-1291.690935	-1291.754709
4	^O ^S ,O F ₃ C M ^S O [→] Me H Me	-1291.976256	-1291.737506	-1291.717239	-1291.791126
5	$F_3C \sim N \rightarrow V$	-1291.976256	-1291.737506	-1291.717239	-1291.791126
6	⁰ ,0 ⁷ Bu`,N,S,0 ,0 Me	-1072.872454	-1072.553343	-1072.533194	-1072.603021
7	^{*Bu} , N, S, O H, Me Me Me	-1072.843678	-1072.528804	-1072.510182	-1072.573582
8	^t Bu, ∨, S N, S H Me Me γ Me γ	-1072.842968	-1072.528043	-1072.509493	-1072.571838
9	°,°,°,°,°,°,°,°,°,°,°,°,°,°,°,°,°,°,°,	-1072.870243	-1072.552259	-1072.531837	-1072.603126
10	⁰ ^ν Bu , Ν΄ ^S ο ^γ δ Me Η Me	-1072.875201	-1072.557278	-1072.536536	-1072.608835
11	⁰ , 0 ⁴ Bu, Ν ² S, Ν ^{γδ} Me CF ₃	-1429.370182	-1429.005472	-1428.980228	-1429.063409

12	$\begin{bmatrix} & & & & \\ & & & & \\ & & & & \\ & & & & $	-1429.340594	-1428.98022	-1428.956321	-1429.03403
13	$\begin{bmatrix} 0,0\\ 'BU,NS,N\\ .\\.\\.\\.\\.\\.\\.\\.\\.\\.\\.\\.\\.\\.\\.\\.\\.\\.\\.$	-1429.33668	-1428.975845	-1428.952239	-1429.028074
14		-1429.367828	-1429.004451	-1428.978892	-1429.063585
15	⁶ Bu _N S _N CF ₃ H Me	-1429.368048	-1429.004394	-1428.978925	-1429.06269
16		-1398.851453	-1398.393464	-1398.3647	-1398.4541
17	^{'Bu} , N-S, NBoc H, δ, γ Me	-1398.819166	-1398.365841	-1398.338331	-1398.423107
18		-1398.815491	-1398.361922	-1398.334535	-1398.418357
19	ο, ο ^{'Bu} , N ^{-S} NBoc H Me	-1398.843427	-1398.386613	-1398.357576	-1398.44844
20	⁷ Bu N ^S NBoc H N ^S NBoc	-1398.84364	-1398.386767	-1398.357735	-1398.447839
21	F ₃ C N S N A Me	-1617.952624	-1617.637302	-1617.545982	-1617.637302

22	$\begin{bmatrix} 0, 0 \\ F_3C & N^{-S} \\ N^{-S} \\ H \\ Me \end{bmatrix}^{\frac{1}{2}}$	-1617.924212	-1617.549869	-1617.522918	-1617.60877
23	$\begin{bmatrix} \mathbf{v}_{\mathbf{y}} $	-1617.922067	-1617.54754	-1617.520787	-1617.605488
24	G, O F ₃ C N ^S NBoc H δ γ	-1617.951581	-1617.573757	-1617.545288	-1617.637108
25	F ₃ C N ^{-S} NBoc H Me	-1617.951698	-1617.573934	-1617.545422	-1617.637009
	0.0	Γ	Γ	Γ	Γ
26	⁷ Bu N ^S N ⊂F ₃ Me N ⁷ Me	-1429.369513	-1429.005144	-1428.979957	-1429.062929
27	$\begin{bmatrix} 0, 0 \\ ^{t}Bu, N \\ N \\ H \\ H \\ Me \\ Me \end{bmatrix}^{\gamma}$	-1429.334723	-1428.974624	-1428.950768	-1429.027491
28	$\begin{bmatrix} 0 & 0 \\ & & & & \\ & & & \\ & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & $	-1429.337386	-1428.976563	-1428.953032	-1429.028051
29	° ⁰ ,0 ^{′′Bu} N S N → ^γ Ne CF ₃ Me	-1429.367669	-1429.004146	-1428.978771	-1429.06217
30	⁶ Bu NS N → ↑ Å Me CF ₃ Me	-1429.37336	-1429.010181	-1428.984453	-1429.06929
31	O,O ^t Bu,N ^S NBoc Me Me	-1398.846083	-1398.38882	-1398.360001	-1398.44937
-					
----	--	--------------	--------------	--------------	--------------
32	(^{'Bu} ,N ^{-S} ,NBoc H, Me Me Me	-1398.811272	-1398.358247	-1398.330722	-1398.414987
33	^{'Bu} , ^O , ^O , ^O ^{'Bu} , ^{S'} , ^{NBoc} ^H , ^A Me ['] Me ^γ ^A	-1398.8158	-1398.362738	-1398.335325	-1398.418555
34	⁴ Bu、NSSNOC · ⁶ Me Me	-1398.847203	-1398.390511	-1398.361581	-1398.451464
35	°Bu, NSS North Me H Boc Me	-1398.851937	-1398.395599	-1398.366286	-1398.457894
36	ο, ο F ₃ C N ^S NBoc Me ^γ δ Me	-1617.951968	-1617.573883	-1617.545747	-1617.636694
37	$\begin{bmatrix} 0 & 0 \\ F_3 C & N^{-S} \\ H \\ Me \\ Me \end{bmatrix}^{\gamma}$	-1617.918224	-1617.544275	-1617.517293	-1617.602441
38	$ \begin{bmatrix} \mathbf{F}_{3}\mathbf{C} & \mathbf{O} & \mathbf{O} \\ \mathbf{N} & \mathbf{S} & \mathbf{NBOC} \\ \mathbf{H} & \mathbf{H} \\ \mathbf{Me} & \mathbf{Me} & \mathbf{\gamma} \end{bmatrix}^{\ddagger} $	-1617.920971	-1617.547026	-1617.520237	-1617.604101
39	F ₃ C N ^S N ^V h H Boc Me	-1617.951346	-1617.573249	-1617.545000	-1617.635358
40	F ₃ C N ^S N _{Boc} γ ^δ Me H Boc Me	-1617.956073	-1617.578672	-1617.549928	-1617.642636

Table S4. Optimized Structures and Cartesian Coordinates

DFT Method: uB3LYP / 6-31+G(d,p) / PCM – benzene

entry	species		minimized structure		
1	0,0 F₃C N ^S 0	∧ Me Me			
	Atom	C	oordinates	(Angstroms)	
		Х	Y	Z	
	C	-1.855462	0.388382	1.932594	
	N	0.143206	0.554160	0.570399	
	S	1.489731 -	0.192827	-0.146221	
	0	1.068573 -	-1.299588	-0.994717	
	0	2.462688	-0.388756	0.930078	
	C	2.551585	2.194/99	-0.560902	
	H	1./89436	2.666323	0.065988	
	H	3.40/110	1.9021/2	0.052157	
		2.953620	3.0/3339	-1./30314	
	П	3.077280	2.334432	-2.332049	
	П	2.009349	<i>J</i> .204309 <i>A</i> 306183	-2.34/765	
	Ч	2 819289	4.590185	-0.654812	
	H H	4 390742	4 169874	-0.545865	
	C II	4 109202	5 308812	-2 356760	
	H	4.836120	4.722619	-2.939105	
	C	4.852620	6.508894	-1.749531	
	H	5.669064	6.184568	-1.094295	
	H	5.282021	7.143877	-2.532280	
	Н	4.171626	7.130116	-1.153915	
	С	3.006803	5.784994	-3.316180	
	Н	2.514454	4.952946	-3.829549	
	Н	2.236811	6.349529	-2.774525	
	Н	3.421847	6.445012	-4.085905	
	С	-0.701970 -	0.369002	1.288346	
	Н	-0.146307 -	-0.892963	2.079948	
	Н	-1.116685 -	-1.135518	0.618265	
	F	-2.652298 -	0.477821	2.603207	
	F	-1.424322	1.314893	2.815886	
	F	-2.619137	1.022806	1.017350	
	Ο	1.964641	0.966874	-1.136087	

2	F ₃ C N-S H Me Me]‡		
	Atom	Coord	dinates (An	igstroms)
		X	Y	Ζ
	C	2.109103	1.111449	-0.000659
	N	-0.123832	0.8/3014	-0.941745
	S	-1.101009	0.1496/2	-2.100089
	0	-0.47/5408	-1.0896/0	-2.543919
	0	-2.461406	0.183310	-1.576164
	C	-1.804816	2.373065	-3.400222
	Н	-2.806510	2.150945	-3.025363
	H	-1.8/0/93	2.62/6/5	-4.459116
	0 C	-1.021658	1.13/295	-3.408037
	U	-1.110489	3.493/10	-2.622321
	Н	-1.642/04	4.424505	-2.808004
	H	-0.096438	3.013934	-3.019904
		-1.003332	5.552/18 2.154914	-1.108204
	П	-0.0083/1	2.134814	-0.892320
	П	-0.239070	2 / 1 8 / 08	-0.030785
	С Ц	-2.336322	2 752728	-0.303071
		-3.102188	2.752728	-0.738487
	Ч	-2.141010	2.900028	1.149785
	H	-3.075552	3 039325	1.0+8855
	H	-1 797567	1 929123	1 198001
	C III	-2 918285	4 859806	-0 341815
	Н	-3 146274	5 190847	-1 359667
	Н	-3.844820	4.910808	0.239943
	H	-2.206104	5.568584	0.096977
	C	1.299516	0.913876	-1.272969
	H	1.565870	1.719026	-1.968904
	Н	1.608656	-0.036154	-1.719933
	F	1.788758	2.269191	0.631756
	F	3.430752	1.173715	-0.301661
	F	1.940378	0.110446	0.885905



4	F₃C∕		γ δ Me Me			y de grades
		Atom	Coor	rdinates (An	gstroms)	
			Х	Y	Z	
		 N	-0 909392	-0 611561	-0 600107	
		S	-2 309246	-0.051020	0.071614	
		Õ	-3.396478	-0.781778	-0.570444	
		Ō	-2.150968	-0.051763	1.524398	
		С	-3.157132	2.465617	0.286885	
		Н	-3.005750	2.313940	1.358215	
		Н	-2.712656	3.419783	-0.003807	
		С	-4.633934	2.397523	-0.104523	
		Н	-4.687512	2.395920	-1.206704	
		Н	-5.065481	1.445854	0.226651	
		С	-5.399852	3.546712	0.474422	
		Н	-5.005564	4.551872	0.319640	
		Н	-0.993245	-0.847253	-1.582992	
		С	-6.803499	3.405101	0.984423	
		Н	-6.858477	2.472654	1.568425	
		С	-7.818013	3.262511	-0.180205	
		Н	-7.828094	4.168639	-0.797393	
		Н	-7.568853	2.414541	-0.826557	
		Н	-8.830647	3.104500	0.209550	
		С	-7.194645	4.573343	1.904206	
		Н	-8.213217	4.447051	2.287159	
		Н	-6.516325	4.649043	2.760667	
		Н	-7.158412	5.525320	1.360023	
		О	-2.334254	1.493215	-0.445568	
		С	0.408013	-0.359303	-0.051025	
		Н	1.029430	-1.244785	-0.212107	
		Н	0.325524	-0.195070	1.025022	
		C	1.148126	0.824435	-0.670838	
		F	0.612765	2.020384	-0.349437	
		F	2.436334	0.830024	-0.246234	
		F	1.168587	0.743892	-2.026051	

5	$F_{3}C \bigwedge_{M}^{O,O} \xrightarrow{\delta}_{Me} Me$
	Atom Coordinates (Angstroms)
	A I L
	C -0.741258 -1.232617 0.703845
	N -2.650424 0.220541 1.348003
	S -2.513145 1.879298 1.498449
	O -2.773900 2.162275 2.907129
	O -1.332652 2.363791 0.799796
	C -5.104411 2.203731 1.070259
	Н -5.256918 1.123753 1.173569
	Н -5.212372 2.681169 2.047934
	C -6.041995 2.807152 0.036945
	Н -5.809330 3.871599 -0.074828
	Н -5.867518 2.333143 -0.935310
	C -7.522841 2.624689 0.447114
	Н -7.735218 1.551667 0.538828
	Н -7.656437 3.054391 1.455661
	C -8.496270 3.256809 -0.511761
	Н -2.738562 -0.241078 2.247433
	C -8.668495 4.745495 -0.493170
	Н -7.742914 5.269455 -0.229928
	Н -9.428332 5.054916 0.248762
	Н -9.008942 5.127924 -1.463118
	C -9.563638 2.419619 -1.146384
	H -9.205430 1.411832 -1.387383
	H -9.942710 2.877099 -2.068260
	H = -10.437895 = 2.292428 = -0.480055
	C = -2.009898 = -0.50/978 = 0.266054
	H = -1./48/33 = 0.181300 = -0.338341 $H = -2.602542 = 1.264002 = 0.122625$
	$\Pi -2.032342 -1.204033 -0.133033$ $E -1.001403 -2.086260 -1.723471$
	F = -0.240282 - 2.000303 - 1.732471
	F = 0.232971 - 0.401393 = 1.119607
	O -3.738815 2.432050 0.594010

6	ťΒι	ο, ο , γ , ^S ο γ	δ Me Me			
		Atom	Coor	rdinates (An	gstroms)	
			Х	Y	Z	
		C	0 270275	1 0/8/18	0 522406	
		C C	1 110647	-2 091926	1 285388	
		Н	1.581342	-2.810937	0.610885	
		Н	1.888595	-1.608080	1.881815	
		H	0.452204	-2.644608	1.962242	
		С	-0.785467	-1.756558	-0.376223	
		Н	-1.453866	-2.331387	0.272973	
		Н	-1.379950	-1.023871	-0.928577	
		Н	-0.304672	-2.433821	-1.084756	
		С	-0.440887	-0.105030	1.512644	
		Н	0.287727	0.414457	2.142100	
		Н	-1.033400	0.642312	0.977647	
		Н	-1.107214	-0.683368	2.160302	
		N	1.028708	-0.159470	-0.372499	
		S	2.397879	-0.734690	-1.165311	
		0	3.521303	-0.581652	-0.233936	
		O C	2.175572	-2.001225	-1.857733	
		C	2.8/9159	1./36162	-1.984890	
		H	2.100543	2.125585	-1.315296	
		П	2.020022 2.057585	1./11399	-1.401995	
		С ц	2.937383	2.324490	3.281040	
		н Н	1 983601	2.039783	-3.941324	
		C	3 349343	3 987153	-3 018008	
		H	4.347464	4.022908	-2.556976	
		Н	2.654434	4.414190	-2.281533	
		С	3.345979	4.890115	-4.268746	
		Н	2.347673	4.818263	-4.726612	
		С	4.380508	4.450544	-5.317104	
		Н	5.394375	4.475392	-4.896995	
		Н	4.194255	3.436291	-5.684115	
		Н	4.363940	5.121168	-6.183466	
		С	3.573538	6.355931	-3.867008	
		H	3.530566	7.016193	-4.740335	
		H	2.817537	6.696783	-3.150369	
		H	4.558754	6.484981	-3.400926	
		0	2.51/665	0.358690	-2.343/6/	













	С	-0.005750	-1.417620	-0.580616
	Н	-0.346489	-0.967636	-1.516271
	Н	0.316248	-2.444690	-0.780995
	Н	-0.850642	-1.457122	0.111049
	С	4.072646	2.910359	-0.582143
	Н	4.906137	2.341978	-0.147458
	Н	3.543059	2.222773	-1.252237
	С	2.623117	2.227065	1.428974
	Н	1.812929	1.490076	0.689412
	Н	3.410289	1.513325	1.694092
	С	3.125504	3.351627	0.542094
	H	3.650848	4.076755	1.188454
	Н	2.280432	3.901772	0.108282
	С	4.624763	4.088800	-1.391924
	H	5.189786	4.779090	-0.754397
	H	5.295263	3.744008	-2.185942
	Н	3.815968	4.658640	-1.864354
	N	-0.268203	2.931969	1.131957
	C	-0.780440	3.878005	0.159461
	Н	-0.005828	4.599506	-0.123647
	Н	-1.104763	3.348483	-0.737098
	C	-1.980369	4.685539	0.656721
	L L	-3.018//1	3.915812	1.033709
	r L	-1.664406	5.4/452/	1./20041
	L L L L L L L L L L L L L L L L L L L	-2.415/21	5.512149	-0.329689
13	[#] Bu N ^S N H Me δ	∼cғ₃]‡		
	A	tom Coor	dinates (An	gstroms)
		Х	Y	Ζ
	С	0.481685	4.661034	0.456634
	С	1.896941	4.374843	-0.033620
	Н	0.479558	4.599069	1.552314
	Н	2.624463	4.990870	0.508494
	Н	0.248358	5.711488	0.221076
	С	-0.592677	2.290551	0.253423
	Н	-0.375740	2.155534	1.314763
	Н	-1.561398	1.819248	0.064512
	С	-0.661290	3.786870	-0.091930

	Н	-0.752818	3.912911	-1.178240		
	Н	-1.602112	4.166590	0.325917		
	С	3.600460	2.027611	1.875363		
	С	3.590462	3.146642	2.933056		
	Н	4.551131	3.167903	3.457621		
	Н	3.436161	4.129453	2.478410		
	Н	2.796649	2.976309	3.666008		
	С	4.740504	2.257649	0.861464		
	Н	5.704818	2.229942	1.379762		
	Н	4.739651	1.488335	0.086235		
	Н	4.646397	3.236434	0.380412		
	C	3.801880	0.671999	2.586765		
	H	4.733134	0.722923	3.160181		
	Н	2.978345	0.457619	3.271361		
	Н	3.886090 -	0.155381	1.878603		
	N	2.247820	2.091135	1.226058		
	Н	2.150193	3.209276	0.491954		
	C	2.193951	4.357982	-1.522926		
	H	3.194692	3.939912	-1.684105		
	H	1.49/260	3.698108	-2.04/902		
	C	2.13/09/	5.764075	-2.155247		
	H	2.39//55	5./14511 (202751	-3.21/12/		
	Н	1.136900	0.202/51	-2.0/6146		
	H	2.842830	0.445/30	-1.66/333		
	5	1./13090	0.802447	0.288//5		
	0	1.212559 -	0.209337	1.231800		
		2.041443	0.3330/3	-0./03834		
	N C	0.449447	1.3/1930	-0.310330		
	C C	-0.703002	1 217295	-2.133030		
	U U	1 140046	1.21/303	-1.900952		
	니 니 니	0.260047	2.062805	-2.399830		
	II F	-0.209047 0.231017	1 124600	1 576730		
	F	-0.231017 -	0 102306	-1.570739		
	F	-0.828816 -	0.172300	-3 469156		
	1	0.020010	0.215474	<u> </u>		
					🌳 🍒	
					8-3	
14	" /			2.		
14	, μγ					
	0					
	Me					
					-2	
	Λ.	om Coo	ndinatas (A	nastroma		
	At	VIII COO	ruinates (A	ngstroms)		
		Λ	1	L		

С	-0.176569	-0.929341	-0.000033
С	-0.191111	-2.206242	0.859046
Н	0.221031	-2.022805	1.854793
Н	-1.208213	-2.594781	0.972426
Н	0.419073	-2.979444	0.380699
С	1.247351	-0.368894	-0.133655
Н	1.889093	-1.114613	-0.614220
Н	1.246453	0.533716	-0.753130
Н	1.672074	-0.123253	0.840841
С	-0.743482	-1.232627	-1.398524
Н	-1.756323	-1.648754	-1.338522
Н	-0.770804	-0.328844	-2.015588
Н	-0.110608	-1.970669	-1.899684
S	-1.134836	0.553516	2.188213
0	-2.105001	-0.269132	2.920966
0	0.257365	0.633079	2.629349
Ν	-1.775278	2.104914	2.180526
С	-3.233992	2.299799	2.339044
Н	-3.567946	1.647905	3.146420
Н	-3.362215	3.329558	2.682488
С	-4.075693	2.058566	1.072898
Н	-3.605704	2.582481	0.218928
Н	-4.059827	0.990415	0.814458
Ν	-1.089337	0.148551	0.541361
Н	-2.052588	-0.029907	0.258895
С	-5.492373	2.507707	1.240690
Н	-5.676528	3.420014	1.807925
С	-6.603035	1.943925	0.415259
Н	-6.514254	0.846290	0.377326
Н	-6.494651	2.271701	-0.637521
С	-8.008023	2.329803	0.904441
Н	-8.087354	3.424821	0.935452
Н	-8.134156	1.982066	1.937845
C	-9.127569	1.759375	0.027607
H	-9.092236	0.663688	0.002735
Н	-10.114113	2.051427	0.402815
Н	-9.044372	2.117/24	-1.005481
C 	-0.999344	3.133699	1.505097
H	-0.119083	2.700248	1.02/31/
H	-1.589712	3.62/821	0.725879
C	-0.501064	4.221261	2.454685
F	0.285600	3./49451	3.438650
F	0.221071	5.136319	1./54146
F	-1.521453	4.897/060	3.047865



	~	(0	1 0 - 0 - 0 0	
	C ···	-6.837/27	0.549216	-1.859588	
	H	-6.823947	-0.434400	-2.343073	
	H	-7.875127	0.899034	-1.844190	
	H	-6.257913	1.237216	-2.484682	
	F	1.489751	2.956424	2.206357	
	F	-0.274530	2.320913	3.324900	
	F	1.599662	1.237890	3.547417	
	C	-4.040587	0.047734	0.868753	
	H	-4.197823	1.023954	1.352788	
	Н	-4.409452	-0.696709	1.600743	
16	0,0 ^t Bu _N ,S N∕ ₽ Boc	Me			
	Ato	om Co	ordinates (A	ngstroms)	
		X	Y	Z	
	Ν	-0.006407	1.320439	-0.972133	
	S	1.481679	0.888931	-0.299540	
	0	1.494816	-0.507797	0.137390	
	0	1.858338	1.944276	0.649378	
	Ν	2.533728	1.092298	-1.626757	
	С	3.423073	2.284577	-1.658636	
	Н	3.699130	2.514300	-0.629929	
	Н	4.320103	1.964387	-2.190986	
	С	2.790737	3.499181	-2.342495	
	Н	2.477619	3.217248	-3.355153	
	Н	1.887135	3.795059	-1.795660	
	С	3.764118	4.683424	-2.413095	
	Н	4.085513	4.953450	-1.396866	
	Н	4.671573	4.376788	-2.952728	
	С	4.128629	7.107965	-3.175542	
	Н	5.036178	6.801382	-3.713861	
	Н	4.451781	7.377847	-2.160551	
	С	1.427299	-1.718163	-3.735947	
	С	0.268301	-2.560167	-3.201197	
	Н	-0.645691	-1.964055	-3.131648	
	Н	0.082875	-3.399043	-3.878646	
	Н	0.503161	-2.957102	-2.209747	
	С	2.716455	-2.541846	-3.791066	
	Н	3.553123	-1.954776	-4.171806	
	Н	2.968856	-2.923340	-2.796810	

		Н	2.562712	-3.398671	-4.455033		
		С	1.069355	-1.083439	-5.081959		
		Н	0.183231	-0.448804	-4.981298		
		Н	1.892554	-0.485172	-5.474365		
		Н	0.839341	-1.876564	-5.801003		
		С	2.513215	0.269692	-2.765838		
		0	3.303105	0.436786	-3.679302		
		0	1.555653	-0.654670	-2.698512		
		C	3.162840	5.918233	-3.097622		
		Н	2.254390	6.224882	-2.559013		
		Н	2.839959	5.647585	-4.113368		
		C	3.520166	8.337124	-3.860676		
		Н	2.629945	8.688423	-3.325209		
		Н	4.233873	9.167291	-3.900394		
		H	3.218406	8.107660	-4.889693		
		C	-1.23/30/	1.139240	-0.179181		
		C	-2.183092	2.257762	-0.664355		
		H	-2.293935	2.227405	-1.751718		
		H	-3.1688/8	2.129995	-0.205927		
		H	-1.795297	3.240944	-0.381912		
		C	-1.086091	1.1960/6	1.353435		
		H	-0.461005	0.384/18	1./33043		
		H	-0.655416	2.148024	1.0/3018		
		H	-2.0/81/1	1.09/46/	1.804538		
			-1.803291	-0.24442/	-0.008393		
		П	-1.93318/	-0.291309	-1.092409		
		п u	-1.138000	-1.030004	-0.292934		
		11	-2.760110	-0.370330	-0.131739	-	
	Ì	-	٦±			<u> </u>	
		^t Bu S					
			Boc				
17		н,				0.000	
		8_ ۲					
		Me					
	L	-	_			3	
		Ato	m Coo	ordinates (A	ngstroms)		
			Х	Y	Z		
		C	1.440738	0.501914	-0.000226		
		C	0.116094	1.259357	-0.245403		
		H	1.223895	-0.4889/2	0.405236		
		H	1.982898	1.050063	0.785866		
		H	-0.602372	1.004933	0.536912		
		H	0.268140	2.337202	-0.225825		
		S	-0.759206	-0.645303	-1.999835		
		0	-1.889197	-0.773804	-2.91/031		

0	-0.853123	-1.340130	-0.706047	
Ν	0.678483	-0.925696	-2.833472	
С	3.768283	1.390361	-3.089948	
Н	4.593496	0.729753	-2.790134	
Н	3.215621	0.861098	-3.875270	
С	2.344238	0.355127	-1.213435	
Н	1.595640	-0.296769	-2.092986	
Н	3.147074	-0.368983	-1.035578	
С	2.843004	1.620204	-1.887139	
Н	3.391549	2.196995	-1.121316	
Н	2.003575	2.259426	-2.184642	
С	4.339218	2.695246	-3.656653	
Н	4.930390	3.229895	-2.903783	
Н	4.989566	2.503045	-4.516537	
Н	3.538381	3.366811	-3.987173	
Ν	-0.496495	0.998447	-1.574943	
С	-0.730561	2.095266	-2.426402	
0	-0.653713	3.243902	-2.017547	
О	-1.007647	1.716090	-3.668769	
С	-1.469181	2.682718	-4.701913	
С	-0.352050	3.682469	-5.012517	
Н	-0.650807	4.298899	-5.866857	
Н	-0.152764	4.336645	-4.162814	
Н	0.568207	3.154259	-5.281686	
С	-2.757821	3.362476	-4.232733	
Н	-2.579956	4.012597	-3.374671	
Н	-3.159097	3.969914	-5.050439	
Н	-3.509018	2.612932	-3.965404	
С	-1.736226	1.770891	-5.900712	
Н	-2.088092	2.369728	-6.746307	
Н	-0.822604	1.249104	-6.199923	
Н	-2.497335	1.024859	-5.657502	
С	1.111921	-2.334195	-3.123919	
С	-0.000327	-3.057383	-3.914560	
Н	-0.309380	-2.469729	-4.782464	
Н	0.389862	-4.019683	-4.261846	
Н	-0.881697	-3.250983	-3.298645	
С	1.473354	-3.145359	-1.862730	
С	2.351763	-2.181901	-4.022809	
Н	2.107838	-1.615889	-4.926322	
Н	3.162276	-1.666146	-3.499230	
Н	2.717429	-3.170739	-4.317224	
Н	0.612801	-3.269379	-1.203019	
Н	2.273801	-2.658120	-1.297239	
Н	1.830376	-4.136779	-2.160718	

18	$\begin{bmatrix} 0 & 0 \\ ^{\prime}Bu & ^{\prime}S' & NBoc \\ H & & \\ Me & \delta \end{bmatrix}^{\ddagger}$	
	Atom Coord	inates (Angstroms)
	ХУ	Z Z
	C -2.221695 0.	984409 0.000364
	C -0.795483 0.	945940 -0.530879
	Н -2.200187 0	.734382 1.068963
	Н -0.112133 1	.505725 0.119015
	Н -2.578245 2.	025506 -0.051664
	C -2.9/510/ -1.	422997 -0.673804
	H -2.619939 -1	.736860 0.307315
	H -3.898973 -1	961508 -0.892932
	C = -3.253037 = 0.0000000000000000000000000000000000	08/905 -0./06310
	H -3.3983/4 = 0.0000000000000000000000000000000000	393410 -1.746431
	H -4.219//1 0. $N -0.227125 -1$	240080 -0.209900 542116 0.166942
	H = 0.237133 - 1	274205 0.240027
	C = 0.531695 = 1	23/1303 - 0.249937 23/142 - 1.098382
	Н 0.495348 0	940479 _2 243334
	Н -1 184942 0	626154 -2 630852
	C = 0.720773 - 2	725444 -2 345936
	Н -0.482158 2	901213 -3 400138
	Н -1.752388 3	052009 -2.178207
	Н -0.063147 3	360747 -1.741717
	S -0.419923 -2.	486989 -1.207909
	O -0.560044 -3	.891397 -0.797806
	O 0.541871 -2.	162929 -2.267107
	N -1.976933 -1	.874109 -1.687865
	C -2.512563 -2.	213865 -2.941582
	O -3.620221 -1	.823028 -3.277916
	O -1.693097 -2	.986346 -3.649916
	C -2.001625 -3	408422 -5.041847
	C -0.762811 -4	226094 -5.412137
	Н -0.865730 -4	.607145 -6.432799
	Н 0.138379 -3.	609615 -5.355918
	H -0.643801 -5	0/4/2/ -4./32609
	C -2.134535 -2.	1/4/63 -5.938094
	H -2.231200 -2	49838/ -6.9/9651
	H -3.012088 -1 H 1.241006 -1	.302111 -3.0/08/3 547506 5.858727
	C -2.134535 -2 H -2.231200 -2 H -3.012688 -1 H -1.241096 -1	174763 -5.938094 498387 -6.979651 582111 -5.676873 547596 -5.858727

	С -3.258234 -4.1	282876 -5.048469
	Н -4.146849 -3.	709185 -4.781606
	Н -3.398416 -4.	699424 -6.051391
	Н -3.146494 -5.	115632 -4.347045
	C 1.059216 -1	590347 0.931229
	C = 0.779193 - 0.1	783678 2 213422
	H = 1.671800 0	770618 2.215422
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	779010 2.0+0003
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	233330 1.300737
	$\Pi -0.043039 -1.$	220976 2.777004
	C = 2.239821 - 0.1	900927 0.139109
	H 3.1324/2 -0.	9/6133 0./93340
	H 2.45//20 -1.	520338 -0.756275
	H 2.029529 0.0	0/258/ -0.110/61
	С 1.399914 -3.	043527 1.326339
	Н 2.245463 -3.	019059 2.021500
	Н 0.553569 -3.	525724 1.821425
	Н 1.682981 -3.	650308 0.464300
19	⁹ Bu N ^S NBoc H δ Me	
	Atom Co	ordinates (Angstroms)
	X	V Z
		1 2
	S -2 109665	1 505576 0 00000
	0 -2.888668	1 119569 1 179354
	O = 0.707164	1 873020 0 112068
	N 2 070101	2 878723 0 636134
	$C = \frac{1}{10000000000000000000000000000000000$	3 001225 0 201608
	Ц 4.602443	2.286066 = 0.586860
	II -4.002443 II 4.507056	2.380000 0.380809
	$\Pi -4.36/630$	4.043930 -0.010401
	U -5.550585	2.003073 -1.442007
	H -5.05638/	5.103407 -2.340425 1.540944 1.690440
	H -5.220328	1.540844 -1.689449
	N -2.258/95	0.1992/0 - 1.012/35
	Н -3.183878	-0.202584 -0.88/891
	С -6.791996	2.8/0283 -1.1205/6
	Н -7.026880	3.747279 -0.517455
	C -7.901526	2.211089 -1.874428
	Н -7.683426	1.137321 -1.991531
	Н_7939237	2.605374 -2.909242

	Ato	m Co X	ordinates (A Y	angstroms) Z
				~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
	Me			and a second
-	δρ			
20				3 3 4
	^{'Bu} ∖N ^S NBoc H I			
				20 2 C
	H	-1.974514	1.886880	-3.285566
	H	-3.336450	0.761450	-3.479832
	н Н	-1.857320	0.543410	-4.429822
	II C	-2.244783	0.842233	-3.449956
	п	0.290312	1 096940	-2 083485
	П Ц	0.20/493	-0.3/4/19	-1.313314 -3 256261
	C LT	-0.125/05	0.0/1364	-2.292870
	H	-1.014889	-1.855996	-3.013102
	H	-3.113207	-1.669490	-2.688954
	H	-1.622088	-2.197169	-1.8/434/
	H	0.207483	5.525820	-0.452448
	H	-1.120362	6.440012	-1.208745
	H	0.542254	6.635142	-1.793318
	C	-0.182344	5.916168	-1.397557
	Н	-0.294822	5.950849	-4.217737
	Н	-1.933539	5.768359	-3.557348
	Н	-1.149994	4.410852	-4.399927
	С	-0.984980	5.257459	-3.725683
	Н	0.834885	3.234307	-3.359701
	Н	1.381072	3.678549	-1.728363
	Н	1.683473	4.769391	-3.098167
	Č	0.966628	4.066903	-2.662519
	C	-0.361806	4.782241	-2.410213
	0	-1.198119	3.701968	-1.812957
		-3.066499	4 973629	-1 541743
		-2.023007	3 950593	-2.044024
	C	-1.033298	-0.000808	-2.330109 -2 644824
	H	-10.4/3/00	2.14852/	-3.033323
	H	-11.384631	1.8/1243	-1.301449
	H	-10.246088	0.64/992	-2.142/33
	C	-10.411328	1.727509	-2.042654
	H	-9.269558	1.971978	-0.219738
	H	-9.496561	3.460240	-1.125851
	С	-9.288383	2.387469	-1.235611
		0.00000		

S	0.771961	-0.603724	-0.013539
0	0.058792	-0.991491	1.206590
0	2.184338	-0.257518	0.020898
Ν	-0.112671	0.790063	-0.579785
С	-1.524813	0.936148	-0.136147
Н	-1.645656	0.337100	0.765020
Н	-1.657110	1.985084	0.135776
С	-2.543267	0.530844	-1.205773
Н	-2.368044	1.116362	-2.115806
Н	-2.406276	-0.525034	-1.470551
Ν	0.542657	-1.897436	-1.026971
Н	-0.377132	-2.290154	-0.846284
С	-5.021161	0.380461	-1.743433
Н	-4.765967	0.486963	-2.798168
С	-6.463446	0.237677	-1.376029
Н	-6.885846	1.230397	-1.127516
Н	-6.550387	-0.343674	-0.445277
С	-7.325508	-0.403787	-2.472280
Н	-6.980134	-1.418106	-2.700951
Н	-8.374911	-0.464957	-2.165537
Н	-7.281433	0.180937	-3.398380
С	1.058778	-2.161135	-2.409642
С	0.661272	-3.625463	-2.676659
С	0.408130	1.852705	-1.334525
0	-0.228147	2.885272	-1.481625
0	1.600262	1.586658	-1.870972
С	2.411544	2.656770	-2.519324
С	3.709235	1.923395	-2.863362
Н	4.406033	2.618604	-3.341209
H	4.179261	1.522285	-1.961424
Н	3.519104	1.098209	-3.555798
C	1.709964	3.148491	-3.788481
H	1.485259	2.307794	-4.452792
H	0.784062	3.675109	-3.555383
H	2.377957	3.831696	-4.323466
C	2.675750	3.782390	-1.516027
H	3.381989	4.493387	-1.956829
H	1.760286	4.318213	-1.261443
H	3.123190	3.381242	-0.601457
C	-3.987650	0.749238	-0.727156
H	-4.104800	1.8118/8	-0.438505
H	-4.163029	0.182255	0.200489
H	1.110973	-4.293353	-1.9302/3
H	-0.42/226	-3.755619	-2.650832
H	1.00/339	-3.923498	-3.6/0654

	(	2 587947 -2 030663 -2 443566
	E E E E E E E E E E E E E E E E E E E	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
	L.	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
	I. I	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
	f.	1  2.911397  -1.007104  -2.235712
	(	0.401504 -1.245487 -3.457525
	E. E	1 0.724487 -1.541549 -4.461353
	E. E	-0.690074 -1.322694 -3.417883
		1 0.685378 -0.202371 -3.306911
21	Q, Q F₃C N S N Boc	γδ∧Me
	Ator	n Coordinates (Angstroms)
		X Y Z
	С	0.419216 0.204566 -0.000359
	Ν	2.841017 0.297796 -0.087539
	S	4.340188 -0.061405 0.645318
	0	4.352985 -1.436449 1.138992
	0	4.596634 1.047114 1.569474
	Ν	5.412955 0.131313 -0.642561
	С	6.349220 1.290266 -0.644141
	Н	6.607436 1.504802 0.392922
	Н	7.246098 0.932662 -1.152674
	С	5.780278 2.528367 -1.339427
	Н	5.490206 2.263062 -2.363317
	Н	4.871067 2.851942 -0.818519
	С	6.796221 3.678342 -1.370302
	Н	7.095265 3.929046 -0.342437
	Н	7.708457 3.344909 -1.885287
	С	7.265079 6.094976 -2.097282
	Н	8.177720 5.763022 -2.611409
	Н	7.565987 6.343939 -1.070183
	С	1.719624 -0.113135 0.724972
	Н	1.712172 0.416324 1.689615
	Н	1.749902 -1.189095 0.943699
	С	4.144253 -2.599638 -2.773615
	С	2.908077 -3.329985 -2.248479
	Н	2.056843 -2.647404 -2.172534
	Н	2.641840 -4.137931 -2.936286
	Н	3.103201 -3.762916 -1.263243
	С	5.356676 -3.531338 -2.822813
	Н	6.244975 -3.016401 -3.191725
	Н	5.565538 -3.941115 -1.829839





Н	-0.772857	-0.560897	0.993933	
Н	1.254313	0.431382	0.145619	
Н	-1.235852	0.915351	0.174778	
С	-1.616048	-2.360776	-1.083191	
Н	-1.193601	-2.842453	-0.201920	
Н	-2.550549	-2.865357	-1.333192	
С	-1.898850	-0.870689	-0.828137	
Н	-2.085206	-0.379193	-1.788093	
Н	-2.847949	-0.824910	-0.279641	
Ν	1.153049	-2.546926	-0.471967	
Н	0.926316	-1.196001	-0.596128	
С	0.737853	0.623883	-1.965202	
Н	1.757625	0.418371	-2.310342	
Н	0.065715	0.151429	-2.688006	
С	0.508479	2.150180	-1.969426	
Н	0.696780	2.556382	-2.968586	
Н	-0.519845	2.404500	-1.692734	
Н	1.182196	2.654513	-1.267814	
S	0.909455	-3.191398	-2.009420	
О	0.938810	-4.652882	-1.871899	
О	1.784697	-2.563585	-3.003035	
Ν	-0.697913	-2.615838	-2.235071	
С	-1.315841	-2.747477	-3.494186	
Ο	-2.455552	-2.354412	-3.677317	
Ο	-0.517481	-3.339861	-4.376046	
С	-0.896411	-3.511692	-5.807725	
С	0.349353	-4.178814	-6.392099	
Н	0.196821	-4.367895	-7.458976	
Н	1.225549	-3.536027	-6.271452	
Н	0.547314	-5.131926	-5.893717	
С	-1.137422	-2.140517	-6.442654	
Н	-1.287606	-2.268599	-7.519505	
Н	-2.021035	-1.654253	-6.026147	
Н	-0.267342	-1.493004	-6.296074	
С	-2.113932	-4.433624	-5.905250	
Н	-3.005477	-3.966002	-5.484937	
Н	-2.303844	-4.663631	-6.958766	
Н	-1.922619	-5.375126	-5.381111	
С	2.517274	-2.774953	0.004366	
Н	3.241283	-2.052218	-0.390974	
Н	2.859783	-3.779486	-0.267638	
С	2.544523	-2.690255	1.522819	
F	3.811543	-2.867839	1.972687	
F	1.770002	-3.626046	2.110501	
F	2.125295	-1.481298	1.976832	

24	6,0 F ₃ C N ^S H	IBoc			
	Ator	n Co	ordinates (A	Angstroms)	
		Х	Y	Z	
	S	-0 102612	0 557737	-0.000026	
	0 0	-1.163759	-0.232201	0.621884	
	Ő	1.207168	0.701572	0.623722	
	Ν	-0.809773	2.102195	-0.225439	
	С	-2.191614	2.340414	0.267059	
	Н	-2.358457	1.691073	1.124643	
	Н	-2.211530	3.376852	0.606859	
	С	-3.264295	2.108841	-0.806737	
	Н	-2.983772	2.690450	-1.703502	
	Н	-3.261025	1.053280	-1.110169	
	Ν	0.134204	-0.013928	-1.555412	
	Н	-0.673584	-0.528506	-1.893776	
	С	-4.628324	2.500353	-0.335689	
	Н	-4.719924	3.400052	0.273112	
	С	-5.867116	1.927030	-0.944139	
	Н	-5.751892	0.837565	-1.059474	
	Н	-5.990823	2.308897	-1.976952	
	С	-7.152312	2.228615	-0.156858	
	Н	-7.257108	3.316473	-0.047278	
	Н	-7.051959	1.824702	0.858874	
	C	-8.410853	1.656607	-0.817754	
	Н	-8.347483	0.566044	-0.913371	
	Н	-9.30/495	1.88/256	-0.232578	
	Н	-8.553621	2.069979	-1.823445	
	C	1.43/040	-0.446918	-2.023051	
	H	2.210961	0.090519	-1.4/5520	
	П	1.550107	-0.210900	-5.08/9/5	
	С F	1.0/9032	-1.743/0/	-1.030321	
	E L	0.12900/ 2 870NKK	-2.071309	-2.3000+0	
	F I	1 671268	-2.203090	-0 570645	
	Ċ	-0.145300	3,175180	-0.839821	
	Ő	-0.662259	4.276393	-0.919624	
	Ő	1.055768	2.823754	-1.304568	
	Č	1.995840	3.840145	-1.864558	
	С	3.234001	3.002489	-2.187393	

	Н	4.018258	3.650108	-2.589980
	Н	3.618093	2.513157	-1.287852
	Н	3.005589	2.239243	-2.937220
	С	1.401405	4.450180	-3.136159
	Н	1.126467	3.663701	-3.846304
	Н	0.521110	5.055153	-2.916798
	Н	2.154477	5.087190	-3.611498
	С	2.314064	4.887480	-0.794776
	Н	3.102078	5.549265	-1.168247
	Н	1.440151	5.493616	-0.552808
	Н	2.679322	4.404204	0.116613
	0,0			
	۶₃C∽ŃŚ۱	NBoc		and the second
25	н	J		9 - <b>6</b> - 6 - 7 - 7
25	[ _v			•
	δ			3 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
	Me			5
	Center Atom	ic Atomic	c Co	ordinates (Angstroms)
	Number N	Jumber T	ype	X Y Z
	S	0.548313	0.204289	-0.000145
	0	-0.465194	-0.583495	0.699656
	0	1.899173	0.348926	0.529220
	Ν	-0.175010	1.746813	-0.180720
	С	-1.510504	1.991644	0.426278
	Н	-1.600564	1.345326	1.298788
	Н	-1.495652	3.028677	0.765702
	С	-2.667562	1.759072	-0.547539
	Н	-2.522756	2.386981	-1.434838
	Н	-2.664356	0.714002	-0.879206
	Ν	0.677242	-0.369938	-1.567330
	Н	-0.157204	-0.873576	-1.853625
	C	-5.185866	1.907098	-0.833561
	H	-5.024371	2.081486	-1.897/608
	C	-6.592251	1.858274	-0.328739
	H	-6.886548	2.853565	0.056678
	H	-6.645752	1.192897	0.546689
	C	-7.617050	1.4147/81	-1.381954
	H	-/.398210	0.403300	-1./41533
	H	-8.632197	1.415561	-0.9/1413
	H	-/.603968	2.08/0/6	-2.24/001
		1.942203	-0.8230/9	-2.112314
	H TT	2./3038/	-0.293030	-1.01/802
	П С	1.9//000	-0.002398	-3.102003
		2.1/4112	-2.324228	-1.732/32
	F	1.1/8398	-3.042/11	-2.339299

		F	3.335616	-2.683584	-2.551237	
		F	2.236494	-2.716135	-0.664027	
		С	0.441736	2.818124	-0.845811	
		Ο	-0.079900	3.919130	-0.889910	
		О	1.604803	2.465383	-1.397760	
		С	2.494312	3.478074	-2.040566	
		С	3.703370	2.638529	-2.455519	
		Н	4.451807	3.282833	-2.925887	
		Н	4.159472	2.157139	-1.585785	
		Н	3.415378	1.868665	-3.177533	
		С	1.797791	4.076420	-3.265097	
		Н	1.465204	3.283416	-3.942576	
		Н	0.938731	4.684690	-2.980399	
		Н	2.509545	4.707827	-3.806881	
		С	2.896211	4.534977	-1.009028	
		Н	3.649930	5.194761	-1.450683	
		Н	2.043402	5.141724	-0.701959	
		Н	3.335315	4.060071	-0.126260	
		С	-4.026272	2.082928	0.094509	
		Н	-3.999352	3.124186	0.471050	
		Н	-4.172035	1.459164	0.989991	
		<u>ر</u> و			2	
			`CE		- 35° - 👂	a the t
•		· j				and the second
26					30, 30	
		Me				<b>~</b> ~
		° Me				
		Ator	n Co	ordinates (A	Angstroms)	
			Х	Y	Ž	
	-					
		С	1.105909	-0.538957	-0.000122	
		С	0.751193	0.964031	-0.172787	
		Н	1.552946	1.603948	0.200041	
		Н	0.563424	1.198870	-1.224257	
		Н	-0.161349	1.168459	0.396415	
		С	-0.053994	-1.410914	-0.516053	
		Н	-0.254254	-1.203335	-1.570992	
		Н	0.185254	-2.473420	-0.411960	
		Н	-0.961062	-1.202374	0.059982	
		С	1.394655	-0.857642	1.483696	
		Н	1.698714	-1.900866	1.605318	
		Н	2.173447	-0.212584	1.896076	
		Н	0.477965	-0.697057	2.059475	
		Ν	2.235736	-0.837317	-0.897396	
		S	3.807451	-0.444209	-0.452200	
		О	4.342496	-1.694554	0.117253	
1		0	3.973617	0.804870	0.300985	

		N	4.439110	-0.151314	-1.981347
		С	5.451876	0.933519	-2.108001
		Н	5.989804	1.043631	-1.161714
		Н	6.175275	0.589112	-2.853167
		С	4.849495	2.275964	-2.530909
		Н	4.309121	2.145752	-3.476201
		Н	4.117696	2.578715	-1.776311
		С	5.933592	3.350795	-2.694868
		Н	6.437585	3.514025	-1.730362
		Н	6.703720	2.975170	-3.384094
		С	5.427827	4.706974	-3.228155
		Н	4.902178	4.514736	-4.175978
		С	4.529842	-1.307283	-2.866088
		Н	3.964413	-2.142535	-2.451485
		Н	5.567839	-1.635867	-2.996270
		С	3.958830	-1.038404	-4.255206
		F	4.027842	-2.173322	-4.997582
		F	4.656127	-0.085195	-4.928257
		F	2.670270	-0.644002	-4.234399
		С	6.611913	5.638971	-3.530038
		Н	7.305560	5.185309	-4.247276
		Н	6.269155	6.591148	-3.950380
		Н	7.175684	5.863120	-2.615377
		С	4.438135	5.386094	-2.267811
		Н	3.543931	4.778342	-2.097204
		Н	4.907905	5.572269	-1.293317
		Н	4.108656	6.351631	-2.667946
27		⁷ Bu 0 0 ¹ Bu N S N H H Me δ Me	F₃ +		
	L				
					37.9
		Atom		ordinates (A	Angstroms)
			Х	Y	L
		С	-0.297607	0.452434	4 0.000672
		С	-0.266281	-0.58332	0 1.148745
		Н	0.633675	0.366632	2 -0.569364
		Н	-0.281375	5 1.44705	3 0.466853
		Н	0.584358	-0.38313	5 1.805419
		Н	-1.167580	-0.51590	7 1.761055
		S	-1.515029	-2.95035	7 0.550328

	0	-1.955160 -3.346759 1.895083
	0	-1.163397 -4.031098 -0.390017
	Ν	-2.641551 -1.835267 0.001847
	С	-3.860958 -2.300172 -0.735449
	С	-4.782234 -1.069286 -0.814526
	Н	-4.329183 -0.265060 -1.402079
	Н	-5.723070 -1.345681 -1.300760
	Н	-5.005296 -0.687131 0.185741
	С	-3.546492 -2.817540 -2.153766
	Н	-2.883423 -3.684103 -2.122080
	Н	-4.477306 -3.108265 -2.652359
	Н	-3.072472 -2.037845 -2.757948
	С	-4.566158 -3.402895 0.084978
	Н	-4.762597 -3.067256 1.105943
	Н	-5.519713 -3.638012 -0.398907
	Н	-3.974915 -4.320698 0.128731
	Н	-2.034556 -0.835092 -0.634379
	Ν	-0.153456 -1.961861 0.648705
	С	1.106540 -2.442773 0.119183
	Н	0.929634 -3.230629 -0.615077
	С	2.038358 -3.018154 1.184799
	F	1.506282 -4.074444 1.830656
	F	3.197183 -3.431095 0.607017
	F	2.374423 -2.099953 2.130440
	Н	1.646277 -1.628295 -0.373432
	С	-1.315790 0.490027 -2.428832
	Н	-2.293152 0.299365 -2.893105
	С	-0.934107 1.948606 -2.773833
	Н	-0.876338 2.078031 -3.860320
	Н	-1.673465 2.658054 -2.387211
	Н	0.042676 2.212811 -2.352979
	С	-0.310754 -0.499332 -3.040507
	Н	0.710492 -0.311590 -2.690719
	Н	-0.566644 -1.536412 -2.801861
	Н	-0.299560 -0.399939 -4.130961
	С	-1.504745 0.338901 -0.921239
	Н	-2.346237 0.939988 -0.559087
28	^t Bu N ^S N H H Me Me γ	F3
		· · · · · · · · · · · · · · · · · · ·

Atom	Coo	rdinates (An	gstroms)	
	Х	Ŷ	Z	
С	-1.475525	-0.392402	0.137640	
Н	-0.504352	-0.695839	0.541132	
Н	-2.221531	-0.736406	0.852138	
S	-3.120629	-2.054357	-1.272732	
О	-3.527771	-2.466263	0.080494	
О	-2.824924	-3.078194	-2.283074	
Ν	-4.216657	-0.969730	-1.981674	
С	-5.638641	-1.440345	-2.206131	
С	-6.189291	-0.538518	-3.326244	
Н	-5.605908	-0.669830	-4.242379	
Н	-7.230402	-0.805259	-3.536802	
Н	-6.161430	0.516510	-3.050268	
С	-5.699740	-2.903805	-2.697522	
Н	-5.405122	-3.615939	-1.923697	
Н	-6.737549	-3.116940	-2.973544	
Н	-5.065161	-3.062567	-3.571032	
С	-6.494254	-1.311715	-0.929441	
Н	-6.581052	-0.270516	-0.609545	
Н	-7.505128	-1.682859	-1.128106	
Н	-6.065659	-1.894479	-0.110530	
Ν	-1.723002	-1.146390	-1.103938	
С	-0.870510	-0.967154	-2.264683	
Н	-1.366558	-1.356536	-3.154249	
С	0.471978	-1.690050	-2.155900	
F	0.353778	-3.010486	-1.928953	
F	1.167253	-1.530954	-3.313315	
F	1.251090	-1.182609	-1.160299	
Н	-0.645209	0.091099	-2.433806	
С	-1.512323	1.136928	-0.013913	
Н	-1.569924	1.553424	0.999201	
Н	-0.556789	1.490975	-0.419956	
С	-2.631146	1.720047	-0.891827	
Н	-2.562136	2.816910	-0.815735	
Н	-2.433661	1.496041	-1.947937	
С	-4.085201	1.340908	-0.596717	
Н	-4.207067	0.159631	-1.207657	
С	-5.042932	2.248579	-1.359308	
Н	-6.084993	1.933384	-1.257244	
H	-4.971517	3.267613	-0.951138	
Н	-4.794131	2.304424	-2.423589	
C	-4.461832	1.198831	0.870039	
Н	-3.904949	0.415406	1.387591	
H	-4.259240	2.147229	1.390542	

Н -5.527251 0.984900 0.990089					
29	0,0 ^{*Bu} ,N, ^S ,N, H, CF ₃	γ δ Me Me			
Atom Coordinates (Angstroms)					
		Х	Y	Z	
	C	2.191326	-2.091351	-2.370091	
	S	0.356033	-1.207191	1.063491	
	0	-0.730625	-2.033854	1.589589	
	0	1.628062	-1.088104	1.766838	
	Ν	-0.340671	0.338771	0.866615	
	С	0.363866	1.452609	0.375611	
	0	-0.166391	2.547109	0.300336	
	0	1.611994	1.144534	0.023058	
	С	2.589996	2.209819	-0.361225	
	C	2.755638	3.192752	0.800216	
	H	3.566787	3.888372	0.562463	
	H	1.846407	3.769716	0.973407	
	H	3.023352	2.659/31	1.717826	
	C	2.132541	2.886198	-1.655234	
	H	1.220/86	3.464899	-1.503675	
	H	2.922119	3.361138	-2.001630	
	H	1.95/63/	2.139598	-2.435/59	
		3.8/0904	1.414600	-0.584062	
	П	5./005/0	0.703314	-1.408043	
	П Ц	4.088309	2.101330	-0.841509	
		1 788/06	0.870480	1 156083	
	Н	-2 057153	-0 174465	1 953196	
	Н	-1 888200	1 535737	1 533645	
	C II	-2.686861	0.310928	-0.073757	
	H	-2.288625	0.936013	-0.891652	
	Н	-2.615328	-0.730496	-0.412925	
	С	-5.435627	0.346879	-1.911236	
	Н	-5.678926	1.412577	-1.995269	
	Н	-4.520501	0.163165	-2.483927	
	Н	-6.247033	-0.225516	-2.376685	
	С	-6.574279	0.165511	0.350953	
	Н	-7.403694	-0.381098	-0.111297	
	Н	-6.482919	-0.168923	1.389754	
	Н	-6.840638	1.229737	0.361838	
	Ν	0.665091	-1.755999	-0.500830	






	Х	Y	Ζ	
 C	-1 667078	0 751226	-0 282387	
C	-1 669479	-0 425352	0 715184	
Н	-0.984704	0.508482	-1.102368	
H	-1.243425	1.623185	0.237101	
H	-0.746622	-0.427408	1.290852	
H	-2.505436	-0.349817	1.412076	
S	-3.174633	-2.355313	-0.714339	
О	-3.571422	-3.621203	-0.090913	
Ο	-2.943490	-2.329852	-2.163804	
Ν	-4.206176	-1.152512	-0.182590	
С	-5.681623	-1.278495	-0.445363	
С	-6.266295	0.117625	-0.158109	
Н	-5.936368	0.853779	-0.896887	
Н	-7.358079	0.065917	-0.203197	
Н	-5.979782	0.464449	0.839313	
С	-6.038255	-1.707305	-1.880317	
Н	-5.695442	-2.721627	-2.099279	
Н	-7.125920	-1.684368	-2.005134	
Н	-5.593018	-1.031941	-2.616650	
С	-6.268751	-2.273921	0.581670	
Н	-6.005478	-1.972744	1.599742	
Н	-7.360119	-2.273322	0.488420	
Н	-5.900745	-3.286587	0.414381	
Н	-3.711116	-0.008411	-0.694744	
Н	-1.729626	-1.753455	0.063756	
С	-3.216408	1.753872	-2.173668	
Н	-4.296054	1.805120	-2.373143	
С	-2.699276	3.211998	-2.140143	
Н	-2.891462	3.701542	-3.101328	
Н	-3.193032	3.798003	-1.357236	
Н	-1.618788	3.243133	-1.959435	
С	-2.566582	0.966484	-3.322507	
H	-1.473086	0.978103	-3.252418	
H	-2.888934	-0.078025	-3.331741	
Н	-2.833876	1.420081	-4.282981	
С	-3.052815	1.116158	-0.797410	
Н	-3.627811	1.654317	-0.033611	
С	-0.586875	-2.515037	-0.203625	
0	-0.626504	-3.591619	-0.769792	
	0.518226	-1.901006	0.25/0/9	
C c	1.857202	-2.543/36	0.161535	
	2.237601	-2.732276	-1.309342	
H	1.592982	-3.463163	-1.798630	
Н	2.170093	-1.781055	-1.847/042	



	S	2.256064	1.370395	-0.511733	
	0	2.251778	-0.074018	-0.241693	
	0	3.130383	1.873478	-1.577183	
	Ν	0.628478	1.874150	-0.870673	
	С	2.695160	5.740171	1.094302	
	Н	2.574831	5.657678	2.177773	
	Н	3.755265	5.630117	0.846495	
	Н	2.404478	6.763376	0.813675	
	C	1.941280	4.947277	-1.173821	
	H	2.987324	4.925439	-1.491997	
	Н	1.398144	4.196012	-1.746239	
	Н	1 532093	5 934158	-1 439749	
	C	0.045786	1.533544	-2.101055	
	Ő	-1 110557	1 834029	-2 358060	
	0	0.888009	0.869038	-2 889246	
	C	0.529112	0.462878	-4 273391	
	C	1 816831	-0.206715	-4 756777	
	н	1.610031	-0 564727	-5 782066	
	Н	2 650661	0.500356	-4 738205	
	Н	2.030001	-1.058325	-4 119657	
	II C	0 207893	1 703263	-5 111024	
	н	0.075175	1 404059	-6 155920	
	Н	-0 706916	2 191047	-4 771052	
	Н	1 034768	2.191017	-5.065393	
	C II	-0.628296	-0 538345	-4 230474	
	н	-1 549047	-0 070432	-3 879008	
	н Н	-0 798622	-0.032500	-5 237799	
	H H	-0.380879	-0.932390 -1.378229	-3 573742	
	11	-0.380873	-1.378229	-3.3/3/42	
34	^O O [#] Bu N ^S N H Boc	γ δ Me Me			8
	Ato	om Co	ordinates (A	Angstroms)	
		Х	Y	Z	
				0.000101	
	C	0.789932	0.074282	0.000101	
	C	0.498100	-1.216092	0./8/602	
	H	0.694162	-1.089064	1.855/58	
	H	-0.543560	-1.528524	0.665122	
	H	1.143638	-2.021617	0.422488	
	C	2.240887	0.529543	0.211375	
	H	2.920941	-0.264194	-0.114/14	
	H	2.448275	1.427705	-0.376579	

Н	2.440906	0.750431	1.260975	
С	0.533304	-0.158937	-1.499174	
Н	-0.491268	-0.504561	-1.681182	
Н	0.702426	0.757419	-2.073204	
Н	1.214624	-0.929008	-1.872210	
S	-0.518294	1.564884	1.960261	
Ο	-1.585755	0.700532	2.481366	
О	0.726945	1.671121	2.713458	
Ν	-1.280478	3.093910	1.777404	
С	-0.620220	4.266702	1.366409	
Ο	-1.231410	5.315233	1.234988	
О	0.679811	4.074679	1.162535	
С	1.584886	5.204789	0.811093	
С	1.567207	6.247677	1.931935	
Н	2.334009	7.002071	1.727933	
Н	0.599943	6.746671	2.002432	
Н	1.799613	5.778405	2.892985	
С	1.184582	5.786968	-0.546856	
Η	0.214467	6.283267	-0.500010	
Н	1.937346	6.519028	-0.857390	
Н	1.146745	4.997680	-1.304416	
С	2.949570	4.519339	0.732027	
Н	2.957109	3.757632	-0.052133	
Н	3.718920	5.262194	0.500858	
Н	3.198245	4.041474	1.683528	
С	-2.729092	3.207108	2.092440	
Н	-2.956320	2.495379	2.883975	
Н	-2.872212	4.216589	2.478992	
С	-3.638403	2.972058	0.874741	
Н	-3.271014	3.609604	0.051741	
Н	-3.541283	1.931170	0.538034	
С	-6.415168	2.906067	-0.923805	
Н	-6.693426	3.962895	-1.011379	
Н	-5.503196	2.747754	-1.509181	
Н	-7.214684	2.304873	-1.373355	
С	-7.513373	2.705491	1.356309	
Н	-8.332012	2.129602	0.910623	
Η	-7.395760	2.381889	2.395849	
Н	-7.812944	3.760890	1.363868	
Ν	-0.146967	1.205998	0.359707	
Н	-1.037258	1.108010	-0.127858	
С	-5.071297	3.274947	1.179622	
Н	-5.293166	4.216077	1.684269	
С	-6.209496	2.516259	0.563389	
Н	-5.950132	1.445464	0.578379	

35	ر Bu ر _N H	) S Boc	γ ð Me ∙ Me			
		Ator	n Co X	ordinates (A Y	Angstroms) Z	
		C	0.956946	-0.037207	0.000126	
		C	0.755948	-1.280022	0.886193	
		H	1.033560	-1.083350	1.925338	
		H	-0.285456	-1.615508	0.866948	
		H	1.386/04	-2.096/28	0.519999	
		C	2.410241	0.453730	0.064709	
		H	3.078448	-0.346/61	-0.269269	
		H	2.550241	1.318369	-0.589678	
		H	2.690057	0.740214	1.079672	
		C	0.586101	-0.368487	-1.456181	
		H	-0.442522	-0.740561	-1.532413	
		H	0.689721	0.512462	-2.09/254	
		Н	1.251062	-1.149965	-1.835033	
		S	-0.219612	1.557736	1.962771	
		0	-1.220592	0.711093	2.625914	
		0	1.080025	1.736381	2.601830	
		N	-1.027/94	3.058722	1.747709	
		C	-0.424760	4.216983	1.224332	
		0	-1.061632	5.250189	1.093223	
		0	0.856057	4.029988	0.918823	
		C	1.713766	5.152736	0.447532	
		C	1.775332	6.240548	1.523202	
		H	2.511928	6.994174	1.226192	
		H	0.810317	6./31/4/	1.654276	
		H	2.093120	5.813407	2.4/945/	
		C	1.194965	5.6/4405	-0.89498/	
		H	0.22/382	6.166154	-0./8/49/	
		Н	1.911/49	0.39/019	-1.298819	
		H C	1.101013	4.833144	-1.012039	
		U U	2.02012094	4.4/0992	0.282440	
		П U	3.02043/ 2.815250	5.000300	-0.4/1420 0.027515	
		П U	3.013238	J.21/138 1 026500	-0.05/313	
		п С	2.402240 2.402240	+.050508 3 157117	1.22/130	
		с u	-2.400490	2.12/112 2/77202	2.134222	
		Н	-2.603928	4.179460	2.486957	

	С	-3.420710	2.849462	0.982368
	Н	-3.184984	3.502786	0.135039
	Н	-3.281826	1.813199	0.649486
	С	-5.884089	2.816366	0.291278
	С	-6.039343	3.866620	-0.767131
	Н	-6.779009	4.633524	-0.469190
	Н	-5.102219	4.398036	-0.966681
	Н	-6.397723	3.442677	-1.713456
	C	-6.983664	1.814914	0.469167
	H	-7.386285	1.478195	-0.494112
	Н	-6 648150	0.932981	1 027346
	Н	-7 837680	2 237503	1 032232
	N N	0.027659	1 099307	0 363770
	Н	-0.897423	0.954214	-0.040387
	C II	-4 895343	3 045974	1 402835
	С Н	-5.002127	4 073707	1 793487
	н Н	-5.002127	2 373076	2 2/1020
	11	-5.114555	2.373070	2.241929
36	^Q , 0 F₃C N ^S N Boc	∕γ Å Me Me		
	<u> </u>	tam Caa	ulinatar (Au	
	А		rdinates (An	igstroms)
		Λ	Y	L
		2 527820	1 162760	0 052/28
		-2.337839	1.105700	-0.953458
	IN S	-0.119220	1.303893	-1.030932
	3	1.392370	0.970840	-0.340390
	0	1.439932	-0.410998	0.131476
	U N	1.020330	2.070334	0.399338
		2.432083	1.209080	-1.031337 1.610646
		2.501005	2.389307	-1.019040
	П	3.022007	2.391643	-0.360797
	П	4.2021/4	2.001040	-2.140332
	U TT	2.13/140	3.020308	-2.200334
	H	2.4//800	3.3/3290 2.004017	-3.318882
	H	1.839983	3.90491/	-1./39890
	C	5./525//	4./96443	-2.293115
	H	4.001508	5.0/0037	-1.200/38
	H	4.690237	4.439263	-2./2001/
	C	3.267813	6.057236	-3.038192
	Н	2.992267	5.752706	-4.059380

		Н	5.281089	6.659817	-3.651813	
		Н	4.088415	7.968645	-3.710388	
		Н	4.724500	7.420999	-2.151727	
		С	2.029984	6.690562	-2.382726	
		Н	1.175088	6.007242	-2.364885	
		Н	2.246176	6.984934	-1.347499	
		Н	1.720050	7.590400	-2.925951	
		С	-1.225436	0.860875	-0.243571	
		Н	-1.234936	1.374865	0.729356	
		Н	-1.172180	-0.217601	-0.042117	
		С	1.233906	-1.515743	-3.799708	
		С	0.026687	-2.291916	-3.272989	
		Н	-0.842596	-1.635934	-3.171260	
		Н	-0.226141	-3.093137	-3.973621	
		Н	0.248312	-2.738757	-2.299662	
		С	2.471487	-2.411151	-3.884243	
		Н	3.339386	-1.863943	-4.255120	
		Н	2.706175	-2.833937	-2.902549	
		Н	2.264749	-3.238943	-4.570104	
		C	0.908911	-0.818126	-5.121700	
		H	0.061214	-0.137359	-4.997187	
		H	1.764600	-0.257966	-5.501077	
		H	0.631117	-1.573996	-5.863377	
		С	2.430452	0.396575	-2.785467	
		0	3.239187	0.551380	-3.680264	
		0	1.438537	-0.488365	-2.732233	
		F	-3.577499	0.749696	-0.188861	
		F	-2./01690	2.483381	-1.185163	
		F	-2.629331	0.527293	-2.142892	
	Г		٦±		. 🔶 🔶	
	_		1			
	F	3 ^C N ² NE	Boc			
37		н,				
		Me_ ⁸			A. 20	
		Ме				
	L				500	
		Aton	n Co	ordinates (A	Angstroms)	
			Х	Y	Ζ	
		С	-2.147133	1.042188	-0.001262	
		č	-1.582397	-0.351611	0.341257	
		H	-1.321812	1.686407	-0.331525	
		H	-2.539536	1.469244	0.929642	
		Н	-0.652127	-0.253848	0.898528	
		Н	-2.287243	-0.908959	0.956617	
		S	-2.481702	-2.154887	-1.605210	

(	)	-2.363132	-3.554570	-1.189306	
(	)	-2.522960	-1.843967	-3.036394	
1	N	-1.275498	-1.175807	-0.851578	
(	2	0.010775	-1.302242	-1.394519	
(	)	0.287755	-2.121267	-2.249613	
(	)	0.837570	-0.405198	-0.838388	
	2	2.287547	-0.364306	-1.189187	
	2	2.945754	-1.696474	-0.822847	
]	Η	2.579596	-2.510857	-1.449064	
]	Η	4.028110	-1.609363	-0.962602	
]	Н	2.758656	-1.941336	0.227570	
	2	2.447041	-0.011160	-2.669701	
]	Н	3.508887	0.143236	-2.887241	
]	Η	2.071683	-0.807039	-3.313870	
]	Н	1.915174	0.917019	-2.901876	
	С	2.803004	0.766153	-0.296972	
]	Η	3.875093	0.906014	-0.463886	
]	Η	2.292772	1.706441	-0.526469	
	Η	2.646213	0.530983	0.760037	
נ	V	-3.803547	-1.504685	-0.778295	
(	2	-6.118815	-1.938738	-0.168849	
	2	-4.350092	2.060841	-0.970262	
]	Н	-4.838452	1.935494	0.006399	
	2	-5.402191	1.881268	-2.074809	
]	Η	-4.948966	1.988280	-3.067470	
]	Η	-5.881070	0.899236	-2.025159	
]	Η	-6.190116	2.635878	-1.982789	
	2	-3.764640	3.493218	-1.018816	
]	Η	-4.572692	4.227627	-0.932266	
]	Η	-3.056384	3.675163	-0.205128	
]	Η	-3.247677	3.670245	-1.969327	
	2	-3.228704	1.038327	-1.076074	
I	H	-3.712944	-0.162479	-0.962047	
]	Η	-2.817270	0.967905	-2.090011	
(	2	-5.073573	-2.037145	-1.269876	
I	H	-4.976870	-3.097981	-1.525366	
I	ł	-5.453488	-1.512291	-2.153966	
	F	-6.291810	-0.661774	0.258925	
]	7	-7.318376	-2.372708	-0.628738	
	F	-5.805823	-2.681339	0.913239	

38		Boc		222 222 222 222 222 222 222 222 222 22
	Ato	m Coord X Y	linates (A Y	ngstroms) Z
			00(10)	0.000220
	C	-5.492609 2	.026106	0.000239
	C	-4.1850/8 2.	.1/3923	-0./85543
	Н	-5.243438 1	.808580	1.04/303
	H C	-5.969619 3	.019501	0.008387
		-6.163516 -0	.480318	-0.411855
	H	-5.5/9532 -0	076149	0.481181
	H	-/.0/0808 -1	.0/0148	-0.377782
		-0.340184 1.	.009234	-0.484998
	П	-0.8/3/93 1	.230930	-1.300943
	П N	-7.423782 1	.133944	0.155770
	IN II	-5.545476 -0 2 $-5.545476 -0$	066722	-0.200037
	H	-3.0/1/38 1 2 71/212 1	226227	-0.043377
	3	-5./14215 -1.	.520257	-1.341300
	0	-3.4/1033 -2	201671	-1.008402
	U N	-5.129890 -0	070007	-2.000044
	IN C	-3.404870 -0	128877	-1.393243
	U U	-2.032373 -0	242505	1 204574
	11 11	-2.013400 0	456800	0.747202
		-1.919383 -1	120680	0.747303
	C F	-0.778333 -0.000000000000000000000000000000000	.139089	1 381850
	L, E	0.280367 0	056057	0.364710
	F	-0.860188 1	030450	-1 133974
	r C	-6.184211 -1	472800	-2 658098
		-7 372269 -1	207551	-2.742601
	0	-5 473434 -2	239239	-3 479674
	C C	-6.036530 -2	.788645	-4.745159
	C C	-6.484290 -1	.638802	-5.650223
	H	-6.774258 -2	.044870	-6.624753
	H	-7.338821 -1	.105719	-5.230209
	H	-5.662087 -0	.933850	-5.807293
1	С	-7.170814 -3	.762648	-4.417873
1	Н	-8.029509 -3	.246501	-3.986197
	Н	-7.489183 -4	.262382	-5.338675
	Н	-6.824974 -4	.529348	-3.717539

		C	-4.834650	-3.522954	-5.340815
		Н	-4.484486	-4.305408	-4.661680
		Н	-5.122707	-3.987104	-6.288904
		Н	-4.009474	-2.830002	-5.525663
		С	-4.330436	2.406934	-2.282458
		Н	-4.827884	3.373354	-2.452538
		Н	-3.353941	2.443232	-2.773456
		Н	-4.927416	1.634123	-2.770618
		С	-3.224161	3.154702	-0.119933
		Н	-3.647532	4.168560	-0.165069
		Н	-3.063657	2.916646	0.937048
		Н	-2.255351	3.178261	-0.625297
39	F₃C	O N S H Boc	γ δ Me Me		
		Ator	n Co	ordinates (A	Angstroms)
			Х	Y	Z
		С	1.143479	-0.911028	0.000228
		S	-0.692169	-0.026600	3.433551
		О	-1.778846	-0.853247	3.959642
		О	0.579793	0.092617	4.137000
		Ν	-1.388917	1.519276	3.236376
		С	-0.684316	2.633169	2.745560
		0	-1.214540	3.727689	2.670369
		0	0.563821	2.325107	2.393052
		С	1.541805	3.390415	2.008794
		С	1.707367	4.373384	3.170221
		Н	2.518553	5.068974	2.932513
		Н	0.798133	4.950369	3.343328
		Н	1.974997	3.840380	4.087865
		С	1.084350	4.066733	0.714756
		Н	0.172517	4.645328	0.866260
		Н	1.873865	4.741791	0.368408
		Н	0.909585	3.320111	-0.065781
		С	2.828812	2.595240	1.786030
		H	2.712278	1.886082	0.962103
		H	3.640320	3.282202	1.528738
		Н	3.111817	2.051212	2.691850
		C	-2.836717	1.697693	3.526884
		H	-3.105346	1.006102	4.323117
		Н	-2.936349	2.716302	3.903532
		С	-3.735145	1.491491	2.296191

		Н	-3.336943	2.116591	1.478286	
		Η	-3.663607	0.450074	1.957009	
		С	-6.484312	1.528227	0.458917	
		Η	-6.727763	2.593935	0.375445	
		Н	-5.569290	1.344900	-0.114065	
		Н	-7.295752	0.955955	-0.006624	
		С	-7.622449	1.345625	2.721263	
		Н	-8.451887	0.799127	2.258920	
		Н	-7.530826	1.010703	3.759882	
		Н	-7.888949	2.409810	2.732717	
		N	-0.382948	-0.575595	1.869315	
		Н	-1.092779	-1.263104	1.627507	
		C	-5.161251	1.839390	2.584293	
		H	-5.360391	2.785540	3.089158	
		C	-6.313573	1.121305	1.945960	
		Н	-6.087/987	0.042859	1.956271	
		C	0.978035	-0.961664	1.510818	
		H	1.241329	-1.9/4444	1.836/06	
		H	1.680101	-0.258/91	1.957611	
		Г Г	0.97/2261	0.325292	-0.513/69	
		F F	2.386061	-1.32/21/	-0.344355	
	Γ	F	0.236238	-1./280/4	-0.626242	
40	F₃C∽	O O N ^S N H Boc	γ ð Me Me			
		Ator	n Co	ordinates (A	ngstroms)	
			Х	Y	Ζ	
		С	-5.476426	1.838953	0.001943	
		S	-7.425896	4.368807	1.609668	
		О	-8.507557	3.555986	2.163678	
		О	-6.177358	4.567403	2.335883	
		Ν	-8.164137	5.880087	1.287908	
		С	-7.490427	6.961382	0.697841	
		Ο	-8.042298	8.035903	0.532543	
		О	-6.238499	6.648340	0.358282	
		С	-5.295484	7.681878	-0.162325	
		С	-5.113173	8.782704	0.885346	
		Н	-4.323456	9.463924	0.552545	
		H	-6.028796	9.358303	1.026916	
		Н	-4.808449	8.351424	1.843874	

Η	-6.720282	8.790872	-1.386561	
Η	-5.035416	8.865069	-1.941174	
Н	-5.982979	7.391111	-2.201177	
С	-4.002173	6.886037	-0.343391	
Η	-4.136521	6.083728	-1.075064	
Η	-3.212642	7.549778	-0.707636	
Η	-3.677721	6.450228	0.605796	
С	-9.592820	6.075455	1.652943	
Η	-9.800106	5.452743	2.522748	
Η	-9.680833	7.121835	1.949691	
С	-10.557227	5.756029	0.508159	
Н	-10.289470	6.360370	-0.365807	
Η	-10.456132	4.702004	0.223971	
С	-13.012311	5.790969	-0.202605	
С	-13.149310	6.817678	-1.286015	
Н	-13.884697	7.597959	-1.013368	
Н	-12.205220	7.335902	-1.488477	
Н	-13.502232	6.375182	-2.225876	
С	-14.113602	4.793117	-0.016503	
Н	-14.506613	4.437848	-0.977066	
Η	-13.783414	3.921873	0.561326	
Η	-14.973149	5.225735	0.530176	
Ν	-7.036472	3.780533	0.090390	
Η	-7.806871	3.261712	-0.321133	
С	-12.025112	6.033272	0.907588	
Η	-12.093194	7.081229	1.248856	
Η	-12.277146	5.408721	1.774530	
F	-6.357522	1.093146	-0.718685	
F	-4.230168	1.481612	-0.392266	
F	-5.618905	1.478632	1.293627	
С	-5.695036	3.330628	-0.230269	
Η	-4.977511	3.883129	0.376170	
Η	-5.488881	3.529406	-1.286094	

## XVI. References.

¹ Mintz, M.J.; Walling, C. Org. Synth. 1969, 49, 9.

- ² Johnson, R. C. J. Chem. Ed. 1970, 47, 702.
- ³ Kanegusuku, A. L. G.; Castanheiro, T.; Ayer, S. K.; Roizen, J. L. unpublished results.

⁴ Zhao, R.; Lu, W. Org. Lett. 2017, 19, 1768–1771.

⁵ Govindarajan, S.R.; Xu, Y.; Swanson, J.P.; Jain, T.; Lu, Y.; Choi, J.-W.; Joy, A. *Macromolecules*. **2016**, *49*, 2429.

⁶ a) Quinn, R.K.; Könst, Z.A.; Michalak, S.E.; Schmidt, Y.; Szklarski, A.R.; Flores, A.R.; Nam, S.; Horne, D.A.; Vanderwal, C.D.; Alexanian, E.J. J. Am. Chem. Soc. **2016**, 138, 696.

b) Characterization data: Short, M. A.; Blackburn, J. M.; Roizen, J. L. Angew. Chem. Int. Ed. 2018, 57, 296.

⁷ Mustafa, D.; Ma, D.; Zhou, W.; Meisenheimer, P.; Cali, J. J. *Bioconjugate Chem.* **2016**, *27*, 87–101.

⁸ McCune, C. D.; Beio, M. L.; Sturdivant, J. M.; Salud-Bea, R. de la; Darnell, B. M.; Berkowitz, D. B. *J. Am. Chem. Soc.* **2017**, *139*, 14077–14089.

⁹ Carocci, A.; Catalano, A.; Corbo, F.; Duranti, A.; Amoroso, R.; Franchini, C.; Lentini, G.; Tortorella, V. *Tetrahedron: Asymmetry*, **2000**, *11*, 3619.

¹⁰ a) Koppenhoefer, B.; Schurig, V. Org. Synth. **1988**, 66, 151; b) Koppenhoefer, B.; Schurig, V. Org. Synth. **1988**, 66, 160.

¹¹ Blackburn, J. M.; Short, M. A.; Castanheiro, T.; Ayer, S. K.; Muellers, T. D.; Roizen, J. L. *Org. Lett.* **2017**, *19*, 6012.

¹² Skvorcova, M.; Jirgensons, A. Org. Lett. 2017, 10, 2478.

¹³ Thottumkara, A. P.; Bowsher, M. S.; Vinod, T. K. Org. Lett. 2005, 7, 2933.

¹⁴ Wong, M.-K.; Chung, N.-W.; He, L.; Yang, D. J. Am. Chem. Soc. 2003, 125, 158.

¹⁵ Mukherjee, S.; Maji, B.; Tlahuext-Aca, A.; Glorius, F. J. Am. Chem. Soc. 2016, 138, 16200.

¹⁶ Suthagar, K.; Watson, A. J. A.; Wilkinson, B. L.; Fairbanks, A. J. *Eur. J. Med. Chem.* **2015**, *102*, 153.

¹⁷ Masui, T.; Kabaki, M.; Watanabe, H.; Kobayashi, T. Masui, Y. Org. Process Res. Dev. 2004, 8, 408.

¹⁸ Kurokawa, T.; Kim, M.; Du Bois, J. Angew. Chem. Int. Ed. 2009, 48, 2777.

¹⁹ Shehata, M. F.; Short, M. A.; Sanders, M. A.; Roizen, J. L.; *Tetrahedron*, **2019**, *75*, 3186.

²⁰ Cismesia, M. A., Yoon, T. P. Chem. Sci. 2015, 6, 5426.

²¹ Hatchard, C.G.; Parker, C.A. Proc. R. Soc. Lond. A. 1956, 235, 518.

²² R. G. Parr, W. Yang, *Density-Functional Theory of Atoms and Molecules* 1989, Oxford University Press, Oxford U.K.

²³ M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Baron, E, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery Jr., J. E. Peralta, F. Ogliaor, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. CossI, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, D. J. Fox, Gaussian 09, revision D.01; Gaussian, Inc. Wallingford, CT, 2013.

²⁴ M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O.

Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian 16, revision B.01, Gaussian, Inc., Wallingford CT, 2016.

²⁵ R. Denningtom, T. Keith, J. Millam, GaussView 2009, version 5; Semichem Inc.: Shawnee Mission, KS, 2009.

²⁶ a) Stephens, P. J.; Devlin, F. J.; Chabalowski, C. F.; Frisch, M. J. J. Chem. Phys. 1994, 98, 11623; b) Becke, A. D. J. Chem. Phys. 1993, 98, 1372; c) Becke, A. D. J. Phys. Chem. 1993, 98, 5648; d) Lee, C.; Yang, W.; Parr, R. G. Phys. Rev. B 1988, 37, 785.

²⁷ Svejstrup, T. D.; Zawodny, W.; Douglas, J. J.; Bidgeli, D.; Sheikh, N. S.; Leonori, D.

Chem. Commun. 2016, 52, 12302.

²⁸ Morcillo, S. P.; Dauncey, E. M.; Kim, J. H.; Douglas, J. J.; Sheikh, N. S.; Leonori, D. *Angew. Chem. Int. Ed.* **2018**, *57*, 12945.

²⁹ Bootsma, A. N.; Wheeler, S. E. "Popular Integration Grids Can Result in Large Errors in DFT-Computed Free Energies," *ChemRxiv. Pre-print.* DOI:10.26434/chemrxiv.8864204.v5.

³⁰ Grimme, S. Chem. Eur. J. **2012**, 18, 999955.

³¹ Ribeiro, R. F.; Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. J. Phys. Chem. B, **2011**, *115*, 14556.









¹H NMR (400 MHz, CDCl₃) for 3,7-dimethyloctanoic acid (**S2h**)



¹H NMR (400 MHz, CDCl₃) for 2-cyclopentylacetamide (**S3d**)



¹³C NMR (126 MHz, CDCl₃) for 2-cyclopentylacetamide (S3d)



¹H NMR (400 MHz, CDCl₃) for 3,7-dimethyloctylamide (**S3h**)



¹H NMR (400 MHz, CDCl₃) for 3-(4-trifluoromethylphenyl)propamide (S3t)



¹³C NMR (126 MHz, CDCl₃, ¹H and ¹⁹F decoupled) for 3-(4-trifluoromethylphenyl)propamide (S3t)





¹H NMR (400 MHz, CDCl₃) for 3,7-dimethyloctylamine (**S4h**)



¹H NMR (400 MHz, CDCl₃) for 3-(4-(trifluoromethyl)phenyl)propylamine (S4t)



¹³C NMR (126 MHz, CDCl₃, ¹H and ¹⁹F decoupled) for 3-(4-(trifluoromethyl)phenyl)propylamine (S4t)



¹⁹F NMR (376 MHz, CDCl₃) for 3-(4-(trifluoromethyl)phenyl)propylamine (S4t)



¹H NMR (400 MHz, CD₃CN) for *N-tert*-butoxycarbonyl-*N'-tert*-butylsulfamide (S5a)





¹H NMR (400 MHz, CD₃CN) for *N-tert*-butoxycarbonyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**S5b**)





¹⁹F NMR (376 MHz, CD₃CN) for *N-tert*-butoxycarbonyl-*N'*-(2,2,2-trifluoroethyl)sulfamide (**S5b**)



¹H NMR (500 MHz, CD₃CN) for *N-tert*-butoxycarbonyl-*N*'-ethylsulfamide (**S5c**)




¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-hexyl sulfamide (**S5d**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-hexyl sulfamide (**S5d**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*'-isopentylsulfamide (**S6c**)





¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*'-(3,7-dimethyloct-1-yl)sulfamide (S6h)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N'*-(3,7-dimethyloct-1-yl)sulfamide (S6h)



¹H NMR (400 MHz, CDCl₃) for *N*-(*tert*-butyl butano-4-yl)-*N*'-*tert*-butylsulfamide (**S6t**)



¹³C NMR (126 MHz, CDCl₃) for *N*-(*tert*-butyl butano-4-yl)-*N*'-*tert*-butylsulfamide (**S6t**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N'*-(3-(4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (S6u)



¹³C NMR (126 MHz, CDCl₃, ¹H and ¹⁹F decoupled) for *N-tert*-butyl-*N'*-(3-(4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (S6u)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-N'-(3-(4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (S6u)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-ethyl-*N*'-hexylsulfamide (**S7a**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-ethyl-*N*'-hexylsulfamide (S7a)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-hexyl-*N*-(2,2,2-trifluoro)ethylsulfamide (**S7b**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-hexyl-*N*-(2,2,2-trifluoro)ethylsulfamide (**S7b**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-hexyl-*N*-(2,2,2-trifluoro)ethylsulfamide (**S7b**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-neopentylsulfamide (**S8a**)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-neopentylsulfamide (S8a)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-butyl-*N*'-tert-butylsulfamide (**S8b**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-butyl-*N'-tert*-butylsulfamide (S8b)



¹H NMR (400 MHz, C₆D₆) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-isopentylsulfamide (S8c)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-isopentylsulfamide (S8c)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(cyclopentyl)ethyl)sulfamide (**S8d**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(cyclopentyl)ethyl)sulfamide (**S8d**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(cyclohexyl)ethyl)sulfamide (S8e)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(cyclohexyl)ethyl)sulfamide (S8e)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N-((2R)*-methyl 4-methylpentano-2-yl)sulfamide (**S8f**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N-((2R)-methyl* 4-methylpentano-2-yl)sulfamide (S8f)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-*tert*-butyl-*N*-((*S*)-2-(1,3-dioxoisoindolin-2-yl)-3-methylbutyl)sulfamide (S8g)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-*tert*-butyl-*N*-((*S*)-2-(1,3-dioxoisoindolin-2-yl)-3-methylbutyl)sulfamide (S8g)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3,7-dimethyloct-1-yl)sulfamide (**S8h**)



S176



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-pentylsulfamide (S8i)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-pentylsulfamide (S8i)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-hexylsulfamide (S8j)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-hexylsulfamide (S8j)


¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyoxycarbonyl-*N'-tert*-butyl-*N*-(methyl hexano-6-yl)sulfamide (**S8k**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyoxycarbonyl-*N'-tert*-butyl-*N*-(methyl hexano-6-yl)sulfamide (S8k)



¹H NMR (400 MHz, CDCl₃) for *N*-acetyl-*N*'-*tert*-butyl-*N*-hexylsulfamide (**S8**I)



¹³C NMR (101 MHz, CDCl₃) for *N*-acetyl-*N*'-tert-butyl-*N*-hexylsulfamide (S8I)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*'-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (S8m)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N*'-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**S8m**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-*N*'-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (S8m)



¹H NMR (400 MHz, CDCl₃) for *N'-tert*-butyl-*N*-trifluoroacetyl-*N*-pentylsulfamide (**S8n**)



¹³C NMR (126 MHz, CDCl₃) for *N'-tert*-butyl-*N*-trifluoroacetyl-*N*-pentylsulfamide (**S8n**)



¹⁹F NMR (376 MHz, CDCl₃) for *N'-tert*-butyl-*N*-trifluoroacetyl-*N*-pentylsulfamide (**S8n**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (S80)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**S80**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**S80**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-Butyl-*N*'-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**S8p**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-Butyl-*N*'-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**S8p**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-Butyl-*N*'-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**S8p**)



¹H NMR (400 MHz, CDCl₃,) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-4-methylpentylsulfamide (**S8q**)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-4-methylpentylsulfamide (**S8q**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (S8r)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**S8r**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**S8r**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N-(tert*-butyl butano-4-yl)sulfamide (S8t)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N-(tert*-butyl butano-4-yl)sulfamide (S8t)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (**S8u**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (**S8u**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (**S8u**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-(2,2,2-trfiluoroethyl)-*N*-pentylsulfamide (S8v)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'*-(2,2,2-trfiluoroethyl)-*N*-pentylsulfamide (S8v)





¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-ethyl-*N*-pentylsulfamide (**S8u**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-ethyl-*N*-pentylsulfamide (S8u)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-ethyl-*N*'-chloro-*N*'-hexylsulfamide (5a)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-ethyl-*N*'-chloro-*N*'-hexylsulfamide (5a)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-chloro-*N*'-hexyl-*N*-(2,2,2-trifluoro)ethylsulfamide (**5b**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-chloro-*N*'-hexyl-*N*-(2,2,2-trifluoro)ethylsulfamide (**5b**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-chloro-*N*'-hexyl-*N*-(2,2,2-trifluoro)ethylsulfamide (**5b**)


¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-neopentylsulfamide (1a)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-neopentylsulfamide (1a)



¹H NMR (CDCl₃, 400 MHz) for *N-tert*-butoxycarbonyl-*N*-butyl-*N*'-tert-butyl-*N*'-chlorosulfamide (1b)



¹³C NMR (CDCl₃, 126 MHz) for *N-tert*-butoxycarbonyl-*N*-butyl-*N*'-tert-butyl-*N*'-chlorosulfamide (1b)



¹H NMR (C₆D₆, 400 MHz) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-isopentylsulfamide (1c)



¹³C NMR (CDCl₃, 126 MHz) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-isopentylsulfamide (1c)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(2-(cyclopentyl)ethyl)sulfamide (1d)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(2-(cyclopentyl)ethyl)sulfamide (1d)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(2-(cyclohexyl)ethyl)sulfamide (1e)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(2-(cyclohexyl)ethyl)sulfamide (1e)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-((2*R*)-methyl 4-methylpentano-2-yl)sulfamide (1f)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-((2*R*)-methyl 4-methylpentano-2-yl)sulfamide (1f)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-((*S*)-2-(1,3-dioxoisoindolin-2-yl)-3-methylbutyl)sulfamide (**1g**)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-*tert*-butyl-*N*'-chloro-*N*-((*S*)-2-(1,3-dioxoisoindolin-2-yl)-3methylbutyl)sulfamide (**1g**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(3,7-dimethyloct-1-yl)sulfamide (1h)





¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-pentylsulfamide (1i)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-pentylsulfamide (1i)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-hexylsulfamide (1j)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-hexylsulfamide (1j)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(methyl hexano-6-yl)sulfamide (1k)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(methyl hexano-6-yl)sulfamide (1k)



¹H NMR (400 MHz, CDCl₃) for *N*-acetyl-*N*'-tert-butyl-*N*'-chloro-*N*-hexylsulfamide (11)



¹³C NMR (126 MHz, C₆D₆) for *N*-acetyl-*N*'-tert-butyl-*N*'-chloro-*N*-hexylsulfamide (11)



¹³C NMR (101 MHz, CDCl₃) for *N*-acetyl-*N*'-*tert*-butyl-*N*'-chloro-*N*-hexylsulfamide (11)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*-chloro-*N*'-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (1m)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N*-chloro-*N*'-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (1m)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-*N*-chloro-*N*'-hexyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (1m)



¹H NMR (400 MHz, CDCl₃) for *N'-tert*-butyl-*N'*-chloro-*N*-trifluoroacetyl-*N*-pentylsulfamide (**1n**)



¹³C NMR (400 MHz, CDCl₃) for *N'-tert*-butyl-*N'*-chloro-*N*-trifluoroacetyl-*N*-pentylsulfamide (1n)



¹⁹F NMR (376 MHz, CDCl₃) for N'-tert-butyl-N'-chloro-N-trifluoroacetyl-N-pentylsulfamide (1n)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-hexyl-*N*'-chloro-*N*'-(2,2,2-trifluoroethyl)sulfamide (10)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-hexyl-*N*'-chloro-*N*'-(2,2,2-trifluoroethyl)sulfamide (10)



¹⁹F NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-hexyl-*N*'-chloro-*N*'-(2,2,2-trifluoroethyl)sulfamide (10)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*-chloro-*N*'-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**1p**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N*-chloro-*N*'-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (**1p**)


¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-*N*-chloro-*N*'-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (1p)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*'-chloro-*N*-4-methylpentylsulfamide (1q)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-4-methylpentylsulfamide (1q)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*²-chloro-*N*-4-methylpentyl-*N*²-(2,2,2-trifluoroethyl)sulfamide (1r)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*'-chloro-*N*-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (1r)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*'-chloro-*N*-4-methylpentyl-*N*'-(2,2,2-trifluoroethyl)sulfamide (1r)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-tert-butyl-*N*-(*tert*-butyl butano-4-yl)-*N*'-chlorosulfamide (**S9t**)





¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (S9u)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (**S9u**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N'*-chloro-*N*-(3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (**S9u**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-chloro-*N*'-(2,2,2-trifluoroethyl)-*N*-pentylsulfamide (**S9v**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-chloro-*N*'-(2,2,2-trifluoroethyl)-*N*-pentylsulfamide (**S9v**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-chloro-*N*'-(2,2,2-trifluoroethyl)-*N*-pentylsulfamide (**S9v**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-chloro-*N*'-ethyl -*N*-pentylsulfamide (**S9w**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-chloro-*N*'-ethyl -*N*-pentylsulfamide (**S9w**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-(4-chloro)hexyl-*N*-ethylsulfamide (6a)



S270



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-(4-chloro)hexyl-*N*-(2,2,2-trifluoro)ethylsulfamide (6b)







¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-2,2-dimethylprop-1-yl)sulfamide (4a)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-2,2-dimethylprop-1-yl)sulfamide (4a)



¹H NMR (400 MHz, C₆D₆) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chlorobut-1-yl)sulfamide (4b)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chlorobut-1-yl)sulfamide (4b)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chlorobut-1-yl)sulfamide (**4b**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3-methylbut-1-yl)sulfamide (4c)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3-methylbut-1-yl)sulfamide (4c)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(1-chlorocyclopent-1-yl)ethyl)sulfamide (4d)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(1-chlorocyclopent-1-yl)ethyl)sulfamide (4d)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(1-chlorocyclohex-1-yl)ethyl)sulfamide (4e)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(2-(1-chlorocyclohex-1-yl)ethyl)sulfamide (4e)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N-((2R)-methyl* 4-chloro-4-methylpentano-2-yl)sulfamide (4f)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N-((2R)*-methyl 4-chloro-4-methylpentano-2-yl)sulfamide (4f)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-*tert*-butyl-*N*-((*S*)-2-(1,3-dioxoisoindolin-2-yl)-3-chloro-3methylbutyl)sulfamide (**4g**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*'-*tert*-butyl-*N*-((*S*)-2-(1,3-dioxoisoindolin-2-yl)-3-chloro-3methylbutyl)sulfamide (**4g**)


¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3,7-dimethyloct-1-yl)sulfamide (4h)





Crude ¹H NMR (500 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of N-chlorosulfamide 1i



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloropent-1-yl)sulfamide (4i)





Crude ¹H NMR (500 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of N-chlorosulfamide 1j



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chlorohexyl)sulfamide (4j)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chlorohexyl)sulfamide (4j)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyoxycarbonyl-*N'-tert*-butyl-*N*-(methyl 4-chlorohexano-6-yl)sulfamide (4k)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyoxycarbonyl-*N'-tert*-butyl-*N*-(methyl 4-chlorohexano-6-yl)sulfamide (4k)



Crude ¹H NMR (500 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of N-chlorosulfamide 11



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chlorohex-1-yl)sulfamide (4I)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chlorohex-1-yl)sulfamide (41)



Crude ¹H NMR (500 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of N-chlorosulfamide 1m



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*'-(3-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (**4m**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N'*-(3-chlorohex-1-yl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (4m)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-*N'*-(3-chlorohex-1-yl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (**4m**)



¹H NMR (400 MHz, CDCl₃) for *N'-tert*-butyl-*N*-(3-chloropent-1-yl)-*N*-trifluoroacetylsulfamide (4n)





¹⁹F NMR (376 MHz, CDCl₃) for N'-tert-butyl-N-(3-chloropent-1-yl)-N-trifluoroacetylsulfamide (4n)



Crude ¹H NMR (500 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of N-chlorosulfamide 10



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(3-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (40)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(3-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (40)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(3-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (40)



Crude ¹⁹F NMR (471 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of N-chlorosulfamide 1p



¹H NMR (400 MHz, CDCl₃) for *N-tert*-Butyl-*N*'-(3-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (**4p**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-Butyl-*N'*-(3-chloro-4-methylpentyl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (4p)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-Butyl-*N'*-(3-chloro-4-methylpentyl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (4p)



Crude ¹H NMR (500 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of *N*-chlorosulfamide 1q



¹H NMR (400 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-4-methylpentyl)sulfamide (4q)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-4-methylpentyl)sulfamide (4q)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N'-tert*-butyl-*N*-(4-chloro-4-methylpentyl)sulfamide (7q)



¹³C NMR (101 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N'-tert*-butyl-*N*-(4-chloro-4-methylpentyl)sulfamide (7q)



Crude ¹H NMR (500 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of N-chlorosulfamide 1r



¹H NMR (400 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*-(3-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (4r)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*-(3-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (4r)


¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*-(3-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (4r)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*-(4-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (7r)



 13 C NMR (101 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*-(4-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (7r)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-Butoxycarbonyl-*N*-(4-chloro-4-methylpentyl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (7r)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N-(tert*-butyl 2-chlorobutano-4-yl)sulfamide (S10t)





¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (S10u)



¹³C NMR (126 MHz, CDCl₃, ¹H and ¹⁹F decoupled) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (**S10u**)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(3-chloro-3-((4-trifluoromethyl)phenyl)prop-1-yl)sulfamide (S10u)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(3-chloropent-1-yl)-*N*'-(2,2,2-trfiluoroethyl)sulfamide (S10v)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(3-chloropent-1-yl)-*N*'-(2,2,2-trfiluoroethyl)sulfamide (S10v)





¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(3-chloropent-1-yl)-*N*'-ethylsulfamide (S10w)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(3-chloropent-1-yl)-*N*'-ethylsulfamide (S10w)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(4-chloropent-1-yl)sulfamide (7i)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N'-tert*-butyl-*N*-(4-chloropent-1-yl)sulfamide (7i)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*'-(4-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (7m)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N'*-(4-chlorohex-1-yl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (7m)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-*N*'-(4-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (7m)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(4-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (70)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(4-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (70)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(4-chlorohex-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (70)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*'-(4-chloro-4-methylpent-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (**7p**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N'*-(4-chloro-4-methylpent-1-yl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (7p)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-*N'*-(4-chloro-4-methylpent-1-yl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (7p)



¹H NMR (500 MHz, CDCl₃) for *N-tert*-butyl-*N*'-(2-chloro-4-methylpent-1-yl)-*N*'-(2,2,2-trifluoroethyl)sulfamide (S11p)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N'*-(2-chloro-4-methylpent-1-yl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (S11p)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-*N'*-(2-chloro-4-methylpent-1-yl)-*N'*-(2,2,2-trifluoroethyl)sulfamide (S11p)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(4-chloropent-1-yl)-*N*'-(2,2,2-trfiluoroethyl)sulfamide (S12v)





¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(4-chloropent-1-yl)-*N*'-(2,2,2-trfiluoroethyl)sulfamide (S12v)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(4-chloropent-1-yl)-*N*'-ethylsulfamide (S12w)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butoxycarbonyl-*N*-(4-chloropent-1-yl)-*N*'-ethylsulfamide (S12w)



¹H NMR (400 MHz, CDCl₃) for 4-methylpentyl *tert*-butylsulfamate (**S13a**)



¹³C NMR (126 MHz, CDCl₃) for 4-methylpentyl *tert*-butylsulfamate (**S13a**)



¹H NMR (400 MHz, CDCl₃) for 4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (S13b)


¹³C NMR (126 MHz, CDCl₃) for 4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (**S13b**)



¹⁹F NMR (376 MHz, CDCl₃) for 4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (**S13b**)



¹H NMR (400 MHz, CDCl₃) for 4-methylpentyl *tert*-butylchlorosulfamate ester (9a)



¹³C NMR (126 MHz, CDCl₃) for 4-methylpentyl *tert*-butylchlorosulfamate ester (9a)



¹H NMR (400 MHz, CDCl₃) for 4-methylpentyl (2,2,2-trifluoroethyl)chlorosulfamate ester (9b)



¹³C NMR (126 MHz, CDCl₃) for 4-methylpentyl (2,2,2-trifluoroethyl)chlorosulfamate ester (9b)



¹⁹F NMR (376 MHz, CDCl₃) for 4-methylpentyl (2,2,2-trifluoroethyl)chlorosulfamate ester (9b)



Crude ¹H NMR (500 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of N-chlorosulfamate 9a



¹H NMR (400 MHz, CDCl₃) for 3-chloro-4-methylpentyl *tert*-butylsulfamate (10a)



¹³C NMR (126 MHz, CDCl₃) for 3-chloro-4-methylpentyl *tert*-butylsulfamate (**10a**)



¹H NMR (400 MHz, CDCl₃) for 4-chloro-4-methylpentyl *tert*-butylsulfamate (S14a)



¹³C NMR (126 MHz, CDCl₃) for 4-chloro-4-methylpentyl *tert*-butylsulfamate (**S14a**)



Crude ¹H NMR (500 MHz, CDCl₃, 25s relaxation delay) for chlorine-transfer reaction of N-chlorosulfamate 9b



¹H NMR (400 MHz, CDCl₃) for 3-chloro-4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (**10b**)



¹³C NMR (126 MHz, CDCl₃) for 3-chloro-4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (10b)



¹⁹F NMR (376 MHz, CDCl₃) for 3-chloro-4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (10b)



¹H NMR (400 MHz, CDCl₃) for 4-chloro-4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (**S14b**)



¹³C NMR (126 MHz, CDCl₃) for 4-chloro-4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (S14b)



¹⁹F NMR (376 MHz, CDCl₃) for 4-chloro-4-methylpentyl (2,2,2-trifluoroethyl)sulfamate (S14b)



¹H NMR (400 MHz, CDCl₃) for methyl 6-((*tert*-butoxycarbonyl)amino)-4-chlorohexanoate (S15k)





¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-N'-(3-(2,2-dimethylcyclopropyl)propan-1-yl)-N'-(2,2,2-trifluoro)ethyl sulfamide (S8s)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-N'-(3-(2,2-dimethylcyclopropyl)propan-1-yl)-N'-(2,2,2-trifluoro)ethyl sulfamide (S8s)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-N'-(3-(2,2-dimethylcyclopropyl)propan-1-yl)-N'-(2,2,2-trifluoro)ethyl sulfamide (S8s)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*-chloro-*N*'-(3-(2,2-dimethylcyclopropyl)propan-1-yl)-*N*'-(2,2,2-trifluoro)ethyl sulfamide (**1s**)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N*-chloro-*N*'-(3-(2,2-dimethylcyclopropyl)propan-1-yl)-*N*'-(2,2,2-trifluoro)ethyl sulfamide (1s)



¹⁹F NMR (376 MHz, CDCl₃) for *N-tert*-butyl-*N*-chloro-*N*'-(3-(2,2-dimethylcyclopropyl)propan-1-yl)-*N*'-(2,2,2-trifluoro)ethyl sulfamide (**1s**)



¹H NMR (400 MHz, CDCl₃) for *N-tert*-butyl-*N*'-(6-chloro-6-methylhept-3-en-1-yl)-*N*'-(2,2,2-trifluoro)ethyl sulfamide (12s)



¹³C NMR (126 MHz, CDCl₃) for *N-tert*-butyl-*N*'-(6-chloro-6-methylhept-3-en-1-yl)-*N*'-(2,2,2-trifluoro)ethyl sulfamide (12s)

